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The aim of this project is to further elucidate the pathways involved in the
intracellular signalling mechanisms of the 5-HT2A and related receptors. The G-
protein coupled receptors (GPCRs) are named after their ability to interact with and
signal through the trimeric G-proteins. The 5-hydroxytryptamine 2A receptor (5-
HT2AR) is a member of the group I family of rhodopsin-related GPCRs. The
receptor is known to activate phospholipase C (PLC) via the heterotrimeric G
proteins Gaq/n, but has been shown to also signal through the phospholipase D
(PLD) pathway in an ADP-ribosylation factor (ARF)-dependent manner, that appears
to be independent of Gq/n. The M3 muscarinic receptor, another member of the
group I GPCRs, has also been shown to signal through both PLC (via Got) and the
alternative pathway of PLD activation via ARF. In this thesis, it has been shown that
both these receptors interact directly with members of the ADP-ribosylation Factor
(ARF) family of small G-proteins. Not only is there evidence to show that these
receptors activate PLD signalling through the ARF family of proteins, as shown by
in vivo signalling assays, but it can also be shown that the receptors interact directly
with ARF. The 5-FIT2A receptor associates with ARF1, and the third intracellular
loop domain of the M3 muscarinic receptor associates with both ARF1 and ARF6, as
shown by in vitro GST interaction assays.
Experiments undertaken to elucidate the exact criteria for this interaction suggest that
a complex of proteins involving GPy for the M3 muscarinic receptor, and arrestin for
the 5-HT2A receptor. The GDP/GTP status of the ARF involved plays a role in the
ability of this interaction to take place. The conserved N/DPxxY motif in
transmembrane domain 7 (tm7) of the Group I GPCRs also seems to affect the ability
of the receptor to signal through ARF. Thus changing this motif altered the binding
of ARF isoforms to the 5-FIT2A receptor.
The binding of novel interaction partners to the 5-HT2A receptor was also
investigated, with the discovery of that the glial protein S100B bound to the carboxy
terminal domain of the 5-HT2A receptor in a calcium dependent manner.
These findings have implications for the investigation of the signalling pathways of
these and other related Group I type GPCRs
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Cell surface receptors play an essential physiological role in allowing cells to
recognise and react to external stimuli, allowing for cell-to-cell communication.
Receptor-encoding genes account for 1-5% of known genomes, and are split into
different families depending on their secondary structure and conserved domains.
The largest of these families is the heptahelical, G protein-coupled receptor (GPCR)
family, which accounts for >1% of the human genome, and contains over 1000
proteins. Members of this family of proteins are activated by many ligands (biogenic
amines, peptide and non-peptide neurotransmitters, hormones, growth factors,
odorant and taste molecules, light, ions, nucleotides, proteases), and act as the
biological target for >50% of the therapeutic agents on the market (Flower, 1999;
Marinissen and Gutkind, 2001). They share little sequence in common (although
several motifs are conserved) but they do have a great deal of structural similarity.
The GPCRs all follow a similar pattern of secondary structure, in that they all have
an amino terminal extracellular domain, 7 transmembrane a-helical domains (giving
rise to their alternative name, the 7TM receptors) which are connected by alternating
intracellular and extracellular loop domains, and end in an intracellular carboxy
terminal tail (Figure 1.1). These a-helical transmembrane domains have been
shown, in the case of the photoreceptor rhodopsin (Palczewski et al., 2000), to
cluster together in cell membranes to form an anticlockwise bundle of a-helices,
(viewed from the extracellular side) joined together by loops of various lengths. The




The GPCR super-family can be further divided into at least 6 families or types, and
several systems of classification have been used, the previously most used of these
systems uses classes A-F to identify the major groups (Kolakowski, 1994; Attwood
and Findlay, 1994), which is used to classify all GPCRs, vertebrate and invertebrate
(e.g. classes D and E represent fungal pheromone receptors)(Kolakowski, 1994). A
more recent, post-genome system of classification analyses the sequences of GPCRs,
and groups them on a phylogenetic basis. By comparison of the homology of the
transmembrane spanning domains of the GPCRs, a dendrogram was constructed of
the most related receptors (Fredriksson et al., 2003)(Fig 1.2). This gives rise to five
main families of GPCRs within the human genome. These are named for the best
known member of each family, giving rise to the GRAFS nomenclature (glutamate,
rhodopsin, adhesion, frizzled/taste2 and secretin) (Foord, 2002; Fredriksson et al.,
2003) (Figure 1.2).
Despite the shared structural topology of the seven transmembrane receptors, there is
very little sequence similarity shown between these families beyond the predicted
secondary structure (Probst et al., 1992; Kolakowski, 1994). Many of the receptors
within these families have been shown to couple to heterotrimeric G-proteins (Foord,
2002) but the rapidly increasing number of GPCR sequences being discovered by




The family R (rhodopsin-like/class A/type I) GPCRs are the most studied of the
groups, and includes receptors most like the photon receptor rhodopsin (Dixon et at,
1986). This, the largest of the GPCR families, contains over 700 (241 non-olfactory)
receptors in humans (Fredriksson et al., 2003). This family can be further divided
into 4 major subgroups, and comprise many different subfamilies, including: the a-
group, containing the amine receptors (which in turn includes the serotonin or 5-HT
receptors and the muscarinic receptors, as well as the adrenergic receptors, histamine
receptors and dopamine receptors amongst others), opsins, melatonin receptors,
prostaglandin receptors and MECA (melanocortin, endothelial differentiation,
cannabinoid and adenosine-binding) receptors; the P-group which includes
endothelin and neuropeptide Y receptors; the y-group of opioid and somatostatin
receptors and the 5-group of olfactory receptors (Dixon et at, 1986; Kubo et at,
1986; Strange, 1993; Drutel et at, 1995; Narumiya and Fitzgerald, 2001; Foord,
2002; Ronnett and Moon, 2002; Fredriksson et at, 2003). The first of these
receptors to be cloned was the bovine rhodopsin receptor in 1983 (Nathans and
Hogness, 1983)(Figure 1.3), with the sequence of the human rhodopsin receptor
following in the next year (Nathans and Hogness, 1984). The p-adrenergic receptor
followed shortly afterwards, and showed striking structural homology with the
rhodopsin receptor (Dixon et at, 1986). Since then a large number of GPCRs and
their splice variants have been characterised from their gene products. The most
studied of the members of the family R GPCRs include those for the biogenic
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amines, the adrenergic (a and p-adrenergic) receptors, muscarinic receptors,
dopamine receptors and 5-HT receptors (Lefkowitz et al., 1976; Dixon et al., 1986;
Kubo et al., 1986; Bonner et al., 1987; Strange, 1993; Hoyer et al., 1994;Hoyeret
al., 2002).
The classic family R GPCRs are those that bind "small molecule" transmitters
(adrenaline, noradrenaline, dopamine, 5-HT, histamine and acetylcholine). The
agonist binding sites for these molecules have been shown to be contained in a
binding crevice formed by the transmembrane helices. The residues involved are
buried deep within the receptor molecule as has been shown by spectroscopic
analysis of the P2-adrenergic receptor (Tota and Strader, 1990)(Figure 1.3). For the
larger peptide agonists of families R and S the extracellular domains have been
demonstrated to have a critical role, for example, the family R neurokinin receptors
(NK) have been shown to bind their tachykinin ligands through the amino-terminus,
a residue at the top of TM3 and residues at the top of TM7 (Fong et al., 1992a; Fong
et al., 1992b), and in the case of the agonist substance P, the extracellular loops
(Fong et al., 1992b; Huang et al., 1994). Other peptide agonists, for example
angiotensin (Hjorth et al., 1994; Feng et al., 1995; Heerding et al., 1997),
neuropeptide Y (Walker et al., 1994), GnRH (Davidson et al., 1997), opioids (Wang
et al., 1995; Xue et al., 1995; Valiquette et al., 1996; Varga et al., 1997; Pepin et al.,
1997), neurotensin (Labbejullie et al., 1995) and others all have major interactions
with the amino-terminal and predicted extracellular loop domains, and may to greater
or lesser extents have additional interactions with the transmembrane domains, and a
transmembrane binding crevice (Yamano et al., 1995; Ozenberger and Hadcock,
1995;Monnot et al., 1996).
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Homology between the receptors of this family is relatively low overall, however,
specific key regions or domains retain significant homology. The most conserved of
these regions is an Aspartate-Arginine-Tyrosine (DRY) motif at the cytosolic
interface at the end of transmembrane spanning domain 3 (TM3) (Probst et al., 1992;
Kolakowski, 1994). This motif has been implicated in the structural stability of the
receptors (Rasmussen et al., 1999), and has also been considered to be a
conformational switch, allowing coupling to heterotrimeric G proteins. Mutations in
these residues lead to constitutively active receptors in the case of the a i-adrenergic
receptor (Scheer et al., 1997), the A3 adenosine receptor (Chen et al., 2001) and the
GnRH receptor (Arora et al., 1997). However, there is some contrary evidence,
suggesting for example that mutation of the arginine of this motif in the P2-adenergic
receptor does not result in a constitutively active receptor (Seibold et al., 1998).
In nearly all GPCRs there is a highly conserved disulphide bridge, where cysteine
residues link the first extracellular loop (el) to the second extracellular loop (e2)
(Pedersen and Ross, 1985; Dixon et al., 1987; Karnik and Khorana, 1990; Schertler
et al., 1993b) again conferring stability of the barrel structure of the GPCR. The
majority of the family R GPCRs have a putative palmitoylation site on a cysteine in
the proximal carboxy-terminal tail, which causes the formation of a putative fourth
intracellular loop (i4) (fig 1.1). Another highly conserved motif in the family R
GPCRs is an Asparagine Proline xxTyrosine (NPxxY), that is found at the junction
of the a-helical transmembrane 7 (tm7) and carboxyl-terminal (ct) domains in a
number of rhodopsin family GPCRs, and has been implicated as a determinant of
ARF:receptor interactions and ARF-mediated signalling. Native receptors with an
alternative DPxxY motif, or N to D mutant receptor show selective defects in this
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pathway whereas native NPxxY containing receptors activate the PLD signalling
pathway in an ARF-dependent manner (Mitchell et al., 1998). However, it has not
been clear whether this motif might be accessible as a direct docking site or whether
instead it regulates access to a distinct site. What is known is that the proline (P)
induces a kink, by disrupting the H-bonds in the helix as it emerges from the plasma
membrane, however both NP and DP produce a perturbation of the helix that is
significantly different from the minimal Proline-kink. They also induce a high
degree of structural flexibility, making a large movement at the intracellular side of
the TM7 likely to be achieved by a small repositioning of the H-bond network,
especially the H-bond acceptors interacting with Asn (N) of the NPxxY motif
(Konvicka et al., 1998)
The first of these receptors, or in fact any of the GPCRs to have its crystal structure
defined was the rhodopsin receptor (Palczewski et al., 2000) showing the barrel
arrangement of the transmembrane a-helices (Fig. 1.2).
Secretin receptor-like GPCRs
The family S family of GPCRs, otherwise known as the type II, Class B or Secretin-
like receptors, is much smaller with around 25 members in total. Members of this
group all bind to large peptide agonists and includes the subfamilies of the
gastrointestinal peptide receptors (which includes the VPAC (vasoactive-intestinal
peptide, (VIP) and pituitary adenylate cyclase activating peptide (PACAP)
recognising receptors), as well as the receptors for secretin, glucagon, growth
hormone receptor hormone, calcitonin and parathyroid hormone (Christophe et al.,
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1988; Lutz et al., 1993; Spengler etal., 1993; Morrow etal., 1993;Foord etal.,
2002). The family S receptors are renowned for having large extracellular amino-
terminal domains, involved in recognition of their specific peptide agonists.
Furthermore the family S GPCRs do not have the DRY motif that is found in the
family R GPCRs, and neither the NPxxY motif, nor the putative fourth intracellular
loop. However they do contain a disulphide bridge between the i2 and i3 domains,
as is present in the family R receptors. One prominent characteristic of the family S
GPCRs is a large (-100 residue) extracellular amino terminus, that is rich in cysteine
residues, which presumably form a network of disulphide bridges (Ulrich et al.,
1998).
Receptors of the S family of GPCRs are thought to bind their peptide agonists
substantially through their characteristically large amino-terminus (Di Paolo et al.,
1999; Unson et al., 2002), however, there is additional evidence to suggest that the
extracellular loops of these receptors are also involved. Nevertheless, there is no
specific evidence at present to suggest a role of the transmembrane binding crevice in
ligand binding by this family of receptors (Gaudin et al., 1995; Unson et al., 2002).
Receptors within family S GPCRs all appear to couple to activation of adenylyl
cyclase through the G-protein Gs, although some members of this family can
additionally activate phospholipase C via Gq/n and some have been shown to activate
PLD in a heterotrimeric G-protein independent manner, through the small G-protein




The family G GPCRs are a small family of receptors with around 15 members, and
includes the metabotropic glutamate (mGlu) receptors, the metabotropic GABAb
receptors, as well as calcium-sensing receptors, pheromone and group-1 taste
receptors (Houamed et al., 1991; Masu et al., 1991; Conn and Pin, 1997; Kaupmann
et al., 1997; Couve et al., 2000; Pin et al., 2003).
Previously known as the class C GPCRs, members of this family have a large and
definitive extracellular amino terminal domain (-500-600 amino acids) (Desai et al.,
1995), which takes the form of a so-called Venus Flytrap Module (VFTM) and is
used for ligand recognition (Takahashi et al., 1993; Ohara et al., 1993). Additionally
in all but the GABAb receptor, there is a conserved cysteine-rich domain connecting
the VFTM to the seven transmembrane spanning part of the receptor (Pin et al.,
2003). The VFTM domain shares sequence similarity with a family of small
molecule-binding bacterial periplasmic transport proteins (Ohara et al., 1993), and it
has been proposed that the family G GPCRs may have evolved from the fusion of an
ancestral seven TM receptor with one of these periplasmic proteins (Felder et al.,
1999; Pin et al., 2003). The Venus Flytrap Module is so called because it is
composed of two regions (or lobes) each constructed of a P-sheet surrounded by two
a-helices, separated by three linkers, which form a cleft into which the ligand binds
(Sack et al., 1989; Galvez et al., 1999; Kunishima et al., 2000). These lobes exist in
either an open or closed conformation. The protein mostly exists in the open
conformation when not bound to ligand, and is stabilised in the closed state when
bound to ligand (Parmentier et al., 2002). It is thought that part of the mechanism of
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action of competitive antagonist ligands for this family of GPCR may be due to the
interference with efficient closure of the VTFM lobes (Costantino and Pellicciari,
1996).
The family G receptors were the first GPCRs to be shown to form functional dimers
in vivo. Subsequently, this has been shown to be the case for members of other
families of GPCRs (Romano et al., 1996; Robbins et al., 1999; Milligan et al., 2003).
Both homodimers (in the case of the mGluR and Ca2+ sensing receptors) and
heterodimers (e.g. the GABAb and taste receptors) can be formed and are required
for full agonist activation (Romano et al., 1996; Kuner et al., 1999; Kunishima et al.,
2000; Pin et al., 2003). Dimerisation of the receptors has been shown to involve the
VFTM domains (formed by a disulphide bridge and a hydrophobic interaction), a
putative transmembrane interaction and the carboxy terminal tail domains (Bai et al.,
1998; Robbins et al., 1999; Ray et al., 1999). It has been determined that the
receptors do not require the binding of two agonist molecules to elicit activation
(Galvez et al., 2000). However X-ray crystallography data of the N-terminal domain
suggests that the active state of the receptor may be more stable when the VFTM
lobes of both receptors in the dimer are closed (Kunishima et al., 2000; Pin et al.,
2003). Furthermore, the GPCR dimer appears to activate a single heterotrimeric G-
protein at any one time (although, the functional dimer is still required for G-protein
coupling) (Galvez et al., 2001; Pin et al., 2003). With regard to similarities with the
other families of GPCRs, the family G receptors maintain the disulphide bridge
structure between i2 and i3, but otherwise there are no other conserved residues
(Probst et al., 1992; Kolakowski, 1994).
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Families F and A
The last two groups are named after the frizzled like and adhesion receptors. The
family F, which includes the frizzled/smoothed receptors, the group-2 taste (TAS2)
receptors, and the cAMP receptors from Dictyostelium discoideum, of which there
are 4 currently known (Fredriksson et al., 2003). The frizzled receptors control cell
proliferation and polarity during metazoan development by mediating signals from
secreted glycoproteins known as Wnt. The frizzled family of receptors have a 200
amino acid N-terminus with conserved cysteines that are likely to participate in Wnt
binding (Fredriksson et al., 2003).
The family A receptors, of which there are 24 members, are made up of adhesion
receptors (or latrophilins), which are receptors that have the typical transmembrane
spanning domain coupled to an amino-terminal domain that contains a functional
adhesion motif, such as the EGF repeat or a mucin-like motif (Fredriksson et al.,
2003). The amino-terminal domains are vastly different in size, ranging from 200
residues up to 2800 residues in the case of the very large G protein coupled receptors
(VLGRs) (Foord, 2002). Functional activities associated with these receptors
include the definition of cell polarity, inhibition of angiogenesis and regulation of the
immune system.
Heterotrimeric G-protein signalling
G protein-coupled receptors, as the name suggests, signal classically through
activation of heterotrimeric guanine nucleotide-binding proteins, or G proteins.
These proteins exist as heterotrimers, each consisting of an a, p and y subunit.
Within this superfamily of proteins there is considerable diversity, with each subunit
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existing in several isoforms, with the Get subunit being the most diverse. There are
20 known Ga subunits (~41kDa), also 6 Gp subunits (~35kDa), and 12 Gy (~10kDa)
subunits. The Py subunits bind tightly together and are regarded as a single
functional unit in vivo. The number of possible combinations of G-protein subunits
is large, introducing a further level of variation within the heterotrimeric G-proteins,
and may yield part of the regulation that is necessary for the specificity of second
messenger coupling and activation.
Upon binding of ligand to the extracellular domains of the receptor, a conformational
change in the receptor causes the activation of the heterotrimeric G-proteins, and the
signal downstream thereof. Upon activation, guanosine diphosphate (GDP) bound to
the Ga subunit is exchanged for guanosine triphosphate (GTP), forcing the Ga
subunit to undergo a conformational change in the switch II region that binds to the
GPy subunit (Figure 1.5). This conformational change no longer allows for the
binding of the GPy subunit to the Ga subunit, and the subunits are dissociated from
each other. Both subunits are then free to interact with their respective effector
molecules to activate or modulate various signalling pathways (Limbird et al., 1980;
Stadel et al., 1981; Logothetis etal., 1987) (Figure 1.4).
The Ga subunits are divided into 4 families, categorised and named from the second
messenger pathways that the Ga subunits of the G-proteins couple to. These
groupings are as named Gas, Gai/o, Gaq and Gal2/13. The Gs heterotrimeric G
protein family includes Gas and Gaolf G proteins. The Gs G protein was the first
one characterised by Limbird and collegues, and has been shown to stimulate
adenylate cyclase, which catalyses the formation of the second messenger cAMP
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from ATP (Lefkowitz etal., 1976; Limbird et al., 1980; Sullivan et al., 1986). This
increase in cAMP levels subsequently activates protein kinase A to mediate other
intracellular effects (Robison et al., 1968; Walsh et al., 1968; Miyamoto et al.,
1968). The Gs family of G proteins have also been shown to close K+ channels
(probably via a cAMP-dependent mechanism) (Madison and Nicoll, 1986; Pedarzani
and Storm, 1995) and open cardiac L-type Ca2+ channels (mediated by a direct
coupling of GPy subunits to the channel) (Fisher and Johnston, 1990). The
hydrolysis of GTP to GDP by the dissociated Ga subunit can be specifically blocked
by ADP-ribosylation of the subunit by the bacterial cholera toxin from Vibrio
cholerae. Cholera toxin transfers the ADP-ribose group from nicotinamide adenine
dinucleotide (NAD+) to an arginine residue at position 178 in the Ga subunit (Hsia et
al., 1985). This permanently activates the G protein and it cannot then hydrolyse the
bound GTP.
The Gai/o family of G proteins consists of Gaii_3, Gaoa-t>, which are brain specific,
Gaz and the photoreceptor Gat (transducin) (Morris and Malbon, 1999). The Gai/o
subunits act to inhibit adenylate cyclase and thereby reduce the intracellular cAMP
levels (Sullivan et al., 1986; Yatani et al., 1988). The Gi/o family act to open the G
protein-coupled inwardly-rectifying K+ channels (GIRK), and close neuronal N-type
2+Ca channels by direct GPy coupling (Logothetis et al., 1987; Penington et al., 1993;
Krapivinsku etal., 1995; Oh etal., 1995; Herlitze etal., 1996; Ikeda, 1996).
Transducin (Gat) acts to activate cGMP phosphodiesterase, which is the main
effector mechanism in photoreceptor transduction (Morris and Malbon, 1999). With
the exception of Gz (of which very little is known), Gai/o subunits can be
specifically inhibited by the action of pertussis toxin from Bordatella pertussis,
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which transfers the ADP-ribose group from NAD+ to a cysteine residue at position
350 on the Ga subunit to prevent the GDP/GTP exchange upon receptor activation
(Hsia et al., 1985).
The pertussis toxin insensitive Gq/11 family consists of Gaq, Gal 1 and Gal4-16
proteins (Morris and Malbon, 1999). They can activate the beta isozymes of
phospholipase C (PLCpi-4), which hydrolyse PIP2 to form the second messenger
DAG and IP3. IP3 activates intracellular ionotropic IP3 receptors on the endoplasmic
reticulum to release the intracellular store of Ca2+ (Mak et al., 1998). DAG directly
activates protein kinase C, which phosphorylates many intracellular targets,
including phospholipase D (PLD) (Merritt et al., 1986b; Gierschikand Jakobs, 1987;
Taylor et al., 1991; Hammond etal., 1997). Members of the Gq/11 G protein family
have also been shown to modulate a novel K+ current (Shi et al., 2004) in addition to
inhibiting the established GIRK current (Hill and Peralta, 2001).
The Gal2/13 G proteins have been shown to couple with small G-proteins via GEF
pi 15RhoGEF, a GTPase activating protein (GAP) for the small G protein Rho (Jiang
et al., 1998; Kozasa et al., 1998). G12 G-proteins have also been shown to couple to
and activate PLD by a mechanism that may be Rho dependent (Hamm, 1998;
Rumenapp et al., 2001).
It was originally thought that the a-subunits of the G proteins could exclusively
regulate their downstream effectors, hence the families of trimeric G proteins being
named after the signalling cascade effected by the Ga subunit, but the Ga subunit is
not the only molecule that activates intracellular signalling upon receptor activation.
The GPy subunit has its own role in direct activation of at least three independent
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signalling pathways. It has been proposed that GPy has the ability to activate
phospholipase A2 (PLA2) based on reconstitution of purified retinal GPy with G
protein-depleted retinal membranes (Jelsema and Axelrod, 1987). Phospholipase A2
is an enzyme that hydrolyses the 2-acyl ester bond of membrane phospholipids to
generate free fatty acid and lysophospholipids, for example arachidonic acid.
The GPy subunit (Figure 1.5) has since been shown to have several crucial roles in
GPCR signalling. Firstly, it has been shown that the GPy subunit promotes the
association of GDP bound Ga with ligand-bound receptor, thereby appearing to
facilitate receptor dependent G-protein activation. Gat has been shown to be able to
bind directly to the rhodopsin receptor without GPy, however, the addition of GPy
appears to increase the affinity of Ga association with its target receptor
(Higashijima et al., 1987; Phillips and Cerione, 1992; Heithier et al., 1992). There is
also evidence to suggest that GPy remains bound to rhodopsin, even after the Gat
subunit dissociates (Phillips and Cerione, 1992; Jian et al., 2001). Gpy has also been
shown to interact directly with the p-adrenergic receptor (Heithier et al., 1992), the
a2-adrenoceptor (Richardson and Robishaw, 1999), the rhodopsin receptor (Phillips
and Cerione, 1992; Jian et al., 2001), and the muscarinic M2 (Azpiazu et al., 1999;
Hou et al., 2000)and M3 receptors (Wu et al., 1998; Wu et al., 2000).
PLCpi, PLCP2 and PLCp3 (but not PLCp4, PLCyl, or PLC81), have been shown to
be responsive to GPy (Lee et al., 1992; Park et al., 1993). Activation of PLCP by
purified GPy has shown that the interaction between PLCP and GPy is direct, that the
ability of the GPy subunit to bind to PLCP is via a separate binding site from that of
the Ga subunit (Park et al., 1993). Evidence exists to show that in Xenopus oocytes,
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the activation of PLCp by the M3 receptor was predominantly mediated by G|3y,
rather than Ga, since the PLC activation was inhibited by agents that specifically
bound free GPy (Ga-GDP, GRKct), concluding that although receptor coupling
specificity of the heterotrimer was determined by the Ga subunit, in this example,
the predominant signaling molecule was GPy (Stehno-Bittel et al., 1995).
G-protein and other interactions with intracellular receptor domains
Considerable insight has been gained into the specific domains and motifs of the
GPCRs that are involved in the activation of the trimeric G-proteins over the past
decade, and pivotal roles in this process have been established for the second (i2) and
third (i3) intracellular loops, with some receptors also utilising proximal regions of
the ct (Dohlman et al., 1991; Savarese and Fraser, 1992; Koblika, 1992; Strader et
al., 1994; Wess et al., 1997; Wess, 1997; Wess, 1998; Zhang et al., 1999; Du et al.,
2000; Xie et al., 2002). Mutagenesis studies of both the adrenergic and muscarinic
receptors have clearly shown the third intracellular loop (i3) as the major determinant
of coupling specificity among the different G protein a-subunits (Dohlman et al.,
1991; Savarese and Fraser, 1992; Koblika, 1992; Strader et al., 1994; Wess, 1997;
Wess, 1998). Point mutational analysis of various receptors has pinpointed this area
as the amino-terminal part of i3, adjacent to TM5 (Strader et al., 1994; Bluml et al.,
1994a; Bluml et al., 1994b; Burstein et al., 1996; Hill, Eubanks et al., 1996) and the
carboxy-terminal area next to TM6 (Liu et al., 1995; Burstein et al., 1995; Liu et al.,
1996). In the 5-HT2aR, the i3 domain has been shown to be important for coupling
to Gq/n and the carboxyl terminal segment of the i3 in particular, may play a key role
in the interaction (Roth et al., 1998). The i2 domain has also been implicated in G-
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protein specificity, but to a lesser extent than the i3 domain, although the i2 domain
seems to be important in G-protein activation (Dohlman et al., 1991; Savarese and
Fraser, 1992; Kobilka, 1992; Strader et al., 1994; Wu et al., 1997; Wess, 1997;
Wess, 1998; Oakley et al., 2001).
The i3 domains has also been shown to provide docking sites for heterotrimeric G
protein (3y subunits (Wu et al., 1998; Wu et al., 2000). It has been known for some
time that the arrestin family of proteins also interact directly with the GPCRs. These
arrestins bind specifically to GPCRs phosphorylated by G-protein receptor kinases
(GRK), an interaction which participates in the homologous desensitisation of the
receptor by disrupting their coupling to G-proteins (Gurevich et al., 1995). In these
cases, arrestin does bind to the receptor domains at a low level, but this binding is
considerably higher after GRK phosphorylation of the receptor domains (see
Gurevich and Gurevich, 2004 and Lefkowitz and Whalen, 2004 for reviews).
Arrestins also target the receptors for internalisation by virtue of their ability to
interact with clathrin (See Carman and Benovic, 1998 for a review). Arrestin
isoforms have been shown to bind to the i3 loop of the 5-HT2aR, as well as the M2
and M3 muscarinic and a2-adrenergic receptors. Arrestin bound to the 5-F1T2aR with
a broader specificity than is shown at i3 of the M2 and M3 muscarinic receptors,
where only non-visual arrestins are bound (Wu et al., 1997; Gelber et al., 1999).
The carboxy-terminal tail domains of various GPCRs have been shown to bind to a
large number of proteins with various functional roles, including chaperone proteins,
PDZ domain-containing proteins, as well as others that have no currently recognised
binding motif.
17
GPCR Signalling Pathways: Phospholipase C
32 •
In the 1950s a novel enzyme was discovered that incorporated [ P] into
phospholipids upon carbachol stimulation of pigeon pancreatic cells (Hokin and
Hokin, 1953). Later work by the Michell lab resulted in the characterisation of a
membrane-associated enzyme named phospholipase C (PLC). PLC was shown to
catalyse the formation of DAG and IP3 from the membrane lipid
phosphatidylinositol, which was coupled to an increase in intracellular Ca2+ levels.
(Miyamoto et al., 1968; Lapetina and Michell, 1972; Lapetina and Michell, 1973a;
Lapetina and Michell, 1973b; Jones and Michell, 1974; Allan and Michell, 1975;
Akhtar and Abdellatif, 1980).
Mammilian PLC isoforms are generally phosphatidylinositol specific (PI-PLC) and
preferentially hydrolyse the phospholipids phosphatidyl (4,5)-bisphosphate (PIP2)
into 1,2 diacylglycerol (DAG) and myo-inositol (l,4,5)-trisphosphate (IP3) (Griffin
and Hawthorne, 1978; Ryu et at, 1987; Berridge, 1993). DAG and IP3 then mediate
the activation of protein kinase C (PKC) and the release of Ca2+ from intracellular
stores respectively (Streb et at, 1983; Nishizuka, 1984b; Putney et al., 1986). There
are eleven mammalian isoforms of PLC, grouped into four main families. There are
four subtypes of PLCP (145-155 kDa), two subtypes of PLCy (145-155 kDa), four
PLCS (-85 kDa) and a novel PLCs isoform (-86 kDa) (Suh et at, 1988; Thomas et
at, 1991; Cockcroft and Thomas, 1992; Rhee and Choi, 1992; Berridge, 1993; Rhee
and Bae, 1997; Wing et at, 2003). PLC activation in response to agonist stimulated
GPCRs was determined to act via a heterotrimeric G protein mechanism (Merritt et
at, 1986a), and subsequent analysis revealed that the PLC activity was due to the
PLCP isoform (Taylor et at, 1991; Blank et at, 1991; Shaw and Exton, 1992;Exton,
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1993). PLCP isoforms are activated by the Gq/11 family of heterotrimeric G
proteins (Taylor et al., 1991; Blank et al., 1991; Lee et al., 1992; Wu et al., 1998).
Purified PLCpi is more potently activated than PLCP2 and PLCP3 (which showed
little difference in activation) by purified Gaq and Gal 1 subunits (Hepler et al.,
1993; Smrcka and Sternweis, 1993). It has been shown that both the Ga and GPy
subunits can activate members of the PLCP family with different potencies - the
activation of PLC by the GPy subunits of heterotrimeric G proteins is approximately
50-100 fold lower potency than that by the Ga subunits (Morris and Scarlata, 1997).
However, as the PLCp isoform has a GTPase-activating protein (GAP) effect for the
Ga subunit (Berstein et al., 1992; Paulssen et al., 1996), the use of the non-
hydrolysable GTP analogue (GTPyS) negates the GAP effect of PLC, and may
account for the higher potency of Ga activation in vitro (Morris and Scarlata, 1997).
The potency of PLCp activation by GPy subunits is also isoform dependent, with
PLCP2 and PLCP3 being more sensitive than PLCpl and PLCP4 (Smrcka and
Sternweis, 1993; Ueda et al., 1994).
PLCP is the only isoform subfamily that is directly activated by the Gq/11 family of
heterotrimeric G proteins (Rhee and Choi, 1992) and this is thought to be due to
PLCP having an extended carboxy-terminal domain when compared to PLCS and
PLCy (Lee et al., 1992; Park et al., 1993). Truncations of this tail portion abolished
the ability of this enzyme ability to be activated by Gaq, but not GPy (Wu et al.,
1992; Park et al., 1993). This suggests that this region contains a Gaq binding site.
The GPy binding site is thought to be in the N-terminal pleckstrin homology (PH)
domain, necessary for PIP2 binding (Kuang et al., 1996). There are recent reports
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that suggest PLCs can be activated in response to GPCR stimulation, possibly via the
Gal2/13 family of heterotrimeric G proteins (Wing et al., 2003; Kelley et al., 2004),
as well as PLCs activation which may be mediated by an elevated level of
intracellular cAMP (Evellin et al., 2002).
The PLC family have a common main structure (Figure 1.6) consisting of an amino
terminal pleckstrin homology (PH) domain, an EF-hand domain that acts as a
flexible linking domain to the conserved catalytic core of the enzyme (the X/Y box)
and a C2 region at the carboxy-terminal of the protein (Rhee and Choi, 1992). The
PH domain is approximately 120 amino acid residues long, and is necessary for the
association of PLC with phospholipids head groups in the membrane and specifically
with PIP2 (Paterson et al., 1995; Lomasney et al., 1994; Yagisawa et al., 1998). The
conserved catalytic core of the enzyme begins at approximately residue 300 and
consists of two parts - the X region is approximately 147 residues and is connected
to the Y region, which is approximately 118 residues in length. In PLC|3 and PLCS,
this X/Y box is separated by 50-70 amino acids, however PLCy has over 400
residues between the two regions, containing three src-homology (SH) domains (two
SH2 domains and one SH3 domain)(Rhee and Choi, 1992; Essen et al., 1996). The
catalytic domain contains residues that are important for phosphoinositol hydrolysis
(Lys-438, Lys-440, Ser-552 and Arg-549 in PLCS) and also other residues that are
important for catalysis (His-311 in PLC5)(Ellis et al., 1998). The C2 domain is
similar to that found in the protein kinases C superfamily (where it is necessary for
allosterically binding Ca2+ ions for activity), however it may primarily function as a
stabilising domain, a mutations to prevent Ca2+ binding do not significantly alter the
activity of the enzyme (James and Downes, 1997). The carboxy-terminal domain of
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the enzyme, in addition to binding the Gaq subunit, has an intrinsic GTPase
activating protein like (GAP-like) activity, which accelerates hydrolysis of the GTP
on the active Gaq subunit back to the inactive GDP form (Paulssen et al., 1996)
GPCR Signalling Pathways: Phospholipase D
Phospholipase D (PLD) activity was first described in plants (Hanahan and Chaikoff,
1948), and was originally thought to be present in eukaryotes only in simple forms
such as Dictyostelium discoideum (Ellingson and Dischinger, 1984; Cubitt et al.,
1993) and plants (Dawson, 1967; Long et al., 1967). PLD was characterised in
mammals only in the 1970s (Saito and Kanfer, 1973). It has since been shown that
PLD is widely present in mammalian cells, where it can be stimulated by a variety of
extracellular signals, to hydrolyse its main substrate, phosphatidylcholine (PtdCho)
to phosphatidic acid (PA) and choline. Phosphatidylcholine is the most abundant
phospholipid constituent of mammalian membranes, providing about 50% of the
total phospholipid content, and as much as 60% of the intracellular membrane
content (Owen et al., 1981; Lagarde et al., 1982; Patton et al., 1982).
The function of PLD activity has remained somewhat elusive. It was originally
thought that the release of the choline group from phosphatidylcholine was an
essential step in the synthesis of the neurotransmitter acetylcholine (Hattori and
Kanfer, 1984; Zhao et al., 2001) and whilst this may be the case in specific neuronal
cells, the role of phosphatidic acid (PA) released during this hydrolysis as a second
messenger in many peripheral tissues has also been established (Exton, 1990;
English, 1996). Phosphatidic acid has been implicated in a variety of cellular
functions, including a mode of Ca2+ mobilisation, apparently independent of that
21
caused by the action of IP3 (English, 1996), cellular proliferation (Knauss et al.,
1990) and as a substrate for downstream prostaglandin synthesis (Marshall et al.,
1981). It has also been implicated in the activation of certain kinases (Ohguchi et al.,
1997). Furthermore, PA is known to be an important regulator of the mitogen
activated protein kinase (MAPK) signalling mechanism (Ghosh et al., 1996; Rizzo et
al, 1999).
PLD isoforms
There have been 2 isoforms of PLD isolated from mammalian tissues, the 124 kDa
PLD1 and the 106 kDa PLD2 (Hammond etal., 1995; Colley et al., 1997;Kodaki and
Yamashita, 1997). PLD1 occurs as two splice variants, PLD la, and the shorter
variant PLD lb which lacks the amino acids 565-624, both of which have similar
regulatory properties (Rose et al., 1995; Hammond et al., 1997; Colley et al., 1997;
Park et al., 1997).
Subcellular localisation of PLD has been shown to be mainly in the plasma
membrane, as well as in the Golgi and nuclei. The localisation of PLD within the
cell seems to be isoform specific. Studies indicate that PLD2 localises
predominantly in the plasma membrane, whereas PLD1 is perinuclear (Golgi,
endoplasmic reticulum and late endosomes)(Colley et al., 1997; Park et al., 2000; Du
et al., 2004).
Domain structures of PLD
The cloning of tha mammalian phosphatidylcholine specific PLDs, PLD1 and PLD2
led to investigations into the domain structure of the isoforms and to comparisons
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with PLC to determine any regions of homology. It transpired that human PLD1 did
not contain any specific domain regions in common with PLC family members, such
as recognizable SH2 or SH3 domains and the PIP2 interacting domain was distinct
from that of PLCS (Hammond et al., 1995). The sequences of other PLD family
members, such as the phosphatidylinositol-glycan specific PLD isolated from bovine
sera (Scallon et al., 1991), indicated that there were conserved domains within the
PLD family group. One of these homologous domains is an invariant charged region
with residues HxKxxxxD, known as the HKD motif, present at residues 455-490 and
892-926 in the human PLD1 isoform, which is thought to be important for catalytic
activity (Hammond et al., 1995). Subsequent studies using mutagenesis of the lysine
(K) to an arginine (R) at position 898 have bourne out this hypothesis and the mutant
human PLD1 K898R has been shown to be catalytically inactive (Sung et al., 1997).
The same mutation at the equivalent residue in the PLD2 isoform, K758R, elicits the
same loss of catalytic activity (Sung et al., 1997). It is though that a loop region
within the enzyme allows PLD to fold, the amino- and carboxy-terminals are brought
into closer proximity and the two HKD motifs can associate together to form a
catalytic centre (Xie et al., 2000; Leiros et al., 2004). The two HKD motifs, along
with two other areas of high homology within the PLD family, the IYIENQFF
motifs, make up the conserved regions I, II, III and IV (Figure 1.6)(Morris et al.,
1996; Frohman et al., 1999)
Mammalian PLD1 and PLD2 both have Phox homology domains, which are
conserved regions found in many proteins, that facilitate protein-protein interactions
(Frohman et al., 1999). PLD1 has a Phox homology (PX) domain between residues
81-212 and PLD2 has a PX domain between residues 65-195 (Hammond et al., 1995;
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Lopez et al., 1998). The presence of the PX domain is critical for PLD activity
(Frohman et al., 1999; Sung et al., 1999) and it is regions of the PX domain that may
interact with the different PKC isoforms (Zhang et al., 1999). In addition, the PX
domains may be necessary for the modulation of the phospholipids-interacting PH
domains (Sugars et al., 2002; Ktistakis et al., 2003).
The ability of PLD to localize to cellular membranes is influenced by fatty acid
modifications of a POVinteracting PH domain, present in both mammalian PLD
isozymes (Sugars et al., 1999; Sung et al., 1999; Xie et al., 2001). The PH domain
of PLD1 is between residues 219-328 and within PLD2 is between residues 203-311;
plalmitoylation occurs on two adjacent cysteine residues in the PH domain of both
mammalian PLD isozymes to facilitate membrane association (Hammond et al.,
1995; Lopez et al., 1998; Sugars et al., 1999; Sung et al., 1999; Xie et al., 2001).
Furthermore, PIP2 has additionally been shown to be necessary as a cofactor for
PLD activity (Whatmore et al., 1996) and, although the PH domain is required for
PLD localization to membranes, the actual site of PIP2 that is involved in functional
activation has been contentious. It was originally proposed that the site of PIP2
activation of PLD was the PH domain (Hodgkin et al., 2000). However, experiments
performed more recently would suggest that although the PH domain facilitates PLD
localization with PIP2-containing lipid membranes, the site of PIP2 activation of PLD
is present in an arginine and lysine rich sequence in the region 691-712 on PLD I and
554-575 on PLD2 (Du et al., 2003). This region, in addition to the PH and PX
regions is also necessary for efficient PLD1 translocations to the plasma membrane
upon cellular stimulation (Du et al., 2003)
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Activation of PLD
Activation of GPCRs can lead to downstream signalling through PLD through many
routes. The most well defined regulation of PLD is through protein kinase C (PKC)
of which there are 12 isoforms, and this pathway may well occur to some degree in
most mammalian cells. However, another main route of PLD activation is through
the small G-proteins ARF and Rho.
The activation of PLD due to PLC activity upon agonist stimulation of GPCRs, and
the concomitant activation of PKC by DAG, a product of PLC activation, is well
known (Cockcroft, 1984; Martinson et al., 1989; Brown et al., 1990). It was first
shown in 1989 that the tumour-promoting phorbol esters, which activate PKC
(Castagna et al., 1982; Nishizuka, 1984a), led to the activation of PLD (Gelas et al.,
1989; Billah et al., 1989; Huang and Cabot, 1990). It was later shown that PKC could
indeed specifically activate PLD (Conricode et al., 1992). Recombinant PKCa, from
porcine brain has been shown to interact with and activate PLD1 synergistically with
ARF and in a kinase-independent manner (Singer et al., 1996). Moreover, the
conventional PKCp isoform, but not the PKCy isoform, was shown to stimulate PLD
activity, but with a lower potency than PKCa, whereas PKC8, PKCs and PKC^ were
ineffective (Conricode et al., 1994). However the use of PKC inhibitors, such as
staurosporine and bisindolylmaleimide has yielded information that agonist-
dependent GPCR-stimulated PLD activity is dependent on catalytic activation of PKC
in many cell types (Cook et al., 1991; Plevin et al., 1994; Meacci et al., 1995; Ahmed
et al., 1995; Martinson et al., 1995; Yeo and Exton, 1995; Rumenapp et al., 1997). It
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has been further demonstrated that both PLD1 and PLD2 are activated by PKC
isoforms with similar potencies (Xie et al., 2002; Chen and Exton, 2004).
The interaction of PKC with PLD has also been shown to lead to increased
phosphorylation of PLD, which may switch off PLD activity (Hu and Exton, 2003;
Chen and Exton, 2004). In addition to stimulation of PLD by PKCa, recently it has
been reported that the competitive association of PKC5 with PLD1 may have a
negative role in the activation of PLD. There is also evidence to suggest that PLD is
negatively regulated by PKC5 in vivo, as cells containing both PKCa and PKC5,
elicited a lower PLD response and attenuated PKCa and PLD association compared
to those containing PKCa alone (Hornia et al., 1999; Oka et al., 2003). However,
another group has reported that PKC8 can activate PLD as well as PKCa (Hodgkin et
al., 1999). These conflicting reports demonstrate that there may be a number of
distinct PKC isoform-dependent mechanisms for regulation of PLD activity and the
extent to which these operate is likely to depend upon cellular context.
A major breakthrough in the understanding of cellular PLD regulation was made
when a cytosolic factor of approximately 16 kDa was shown to reconstitute GTPyS
evoked PLD activity in permeabilised and isolated membranes from HL-60 cells
(Anthes et al., 1991; Geny and Cockcroft, 1992; Geny et al., 1993). This factor has
since been shown to be the small G protein ADP-ribosylation factor (ARF) (Brown
et al., 1993; Cockcroft et al., 1994). ARF has since been shown to activate PLD in a
GTP-dependent manner (Hammond et al., 1997). Recombinant ARF1 was shown to
be effective in activating PLD in the presence of GTPyS (Brown et al., 1993;
Cockcroft et al., 1994), as have ARF5 and ARF6 (Brown et al., 1995; Caumont et
26
al., 1998). In addition to ARF proteins, RhoA and other members of the Rho family
of GTPases have been shown to activate PLD in the presence of GTP (Bourgoin et
al., 1995; Ohguchi et al., 1995; Kanaho et al., 1996;Ohguchi et al., 1996; Kim et al.,
1998; Meacci et al., 1999; Genth et al., 2003) including cdc-42 (Kato et al., 1997)
and Ral (Jiang et al., 1995; Kim et al., 1998; Frankel et al., 1999). It was initially
shown that the Rho-guanine nucleotide dissociation inhibitor (GDI), inhibited the
GTP-dependent PLD activity in neutrophils (Bowman et al., 1993), and it has been
further shown that exogenously added RhoA reconstituted the GTP-stimulated PLD
activity in Rho-GDI-treated rat liver membranes and HL60 cell membranes
(Bowman et al., 1993; Malcolm et al., 1994). The ARF domain that is involved in
the stimulation of PLD differs from that required for activation of cholera toxin
(Zhang et al., 1995), and has been narrowed to residues 35-94 (Liang et al., 1997).
This is similar to the site required for recruitment of adapter protein 1 (API) to the
Golgi membranes by ARF. Adapter protein 1 is a subunit of clathrin-associated
adapter protein complex 1 that plays a role in protein sorting in the late-Golgi/trans-
Golgi network (TGN) and/or endosomes. The AP complex mediates both the
recruitment of clathrin to membranes and the recognition of sorting signals within
the cytosolic tails of transmembrane cargo molecules (see Robinson, 2004 for a
review).
It has also been shown that PLD can be activated via ARF upon agonist stimulation.
In human embryonic kidney cells stably expressing M2 muscarinic receptors, the
ARF-GEF-inhibitor brefeldin A (BFA) inhibited the stimulation of PLD by carbachol
in intact cells, but not that induced by GTPyS in permeabilised cells (Rumenapp et al.,
1995). It has also been shown that BFA has an inhibitory effect on the activation of
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PLD via receptors for platelet-derived growth factor (PDGF) and phorbol 12-
myristate 13-acetate (PMA) on HIRcB fibroblast cells, and that the combination of
GTPyS plus PDGF or PMA increased PLD activity, in permeabilised cells, in an
ARF-dependent manner (Shome et al., 1998). It has since been shown that activation
of PLD via many different GPCR agonists can occur via an ARF (or Rho) dependent
pathway. These include angiotensin II (ATi) and endothelin 1 (ET-1) receptors in
A10 smooth muscle cells (Shome et al., 2000), the M3 muscarinic and other receptors
in 1321N1 astrocytoma cells, angiotensin II (ATi) receptors in anterior pituitary gland
but not the wild type gonadotrophin-releasing hormone (GnRH) receptors.
Correspondingly ARF and RhoA could be co-immunoprecipitated with the
angiotensin AT] receptor and the M3 muscarinic receptor, but not the GnRH receptor
(Mitchell et al., 1998).
The isoform of PLD that is involved in the ARF-dependent responses was thought for
several years to be PLD1 because of its activation in vitro by ARF (and Rho and
PKC) (Hammond et al., 1997; Park et al., 1997). Nevertheless, recent evidence
suggests that PLD2, and especially an amino-terminally-truncated form of PLD2 can
also be activated by ARF (Lopez et al., 1998; Sung et al., 1999a). Both PLD1 and the
truncated form of PLD2 are activated in vitro by ARF1 more effectively than by
ARF6 (Sung et al., 1999a). In contrast, PLD2 heterologously expressed in cells can
be activated to a similar extent by constitutively active ARF1 and ARF6 (Du et al.,
2000). ARF-dependent PLD activity and GPCR-mediated PLD responses have been
described in the plasma membrane compartment (Provost et al., 1996; Morgan et al.,
1997), although the identity of the isoform responsible was not clear. PLD1 is largely
associated with Golgi and other intracellular membranes (Colley et al., 1997; Morgan
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etal., 1997; Ktistakis et al., 1999; Sung etal., 1999b), but some is also associated
with the plasma membrane, to a more predominant extent in some cell types, (Kim et
al., 1999; Freyberg et al., 2001; Humeau et al., 2001) and the enzyme can be recruited
to the plasma membrane during exocytosis (Morgan et al., 1997; Brown et al., 1998)
or in response to GPCR activation (Mitchell et al., 2003). In contrast, PLD2 is more
generally associated with the plasma membrane (Colley et al., 1997; Liscovitch et al.,
2000) although it too may be associated with Golgi structures (Freyberg et al., 2002).
It has since been suggested that both the small G proteins ARF and Rho, in
conjunction with PKC act in a synergistic fashion to activate PLD (Kanaho et al.,
1996). Mutation studies, where PKC non-responsive alleles of PLD were constructed
showed that the activation of PLD by PLD was synergistic with the activation of PLD
by Rho A, in that a much higher response by PLD was observed when both PKC and
Rho A were able to activate PLD than either PKC or RhoA acted individually (Zhang
et al., 1999). Furthermore, in studies with human neutrophils, where PLD activation
in response to fMLP receptor stimulation was studied, cell permeabilisation by
streptolysin O, which leads to the loss of cytosolic ARF, but not Rho proteins from
the neutrophil cells, leads to a progressive inability of these calls to activate PLD.
This ability is restored upon the re-addition of ARF, suggesting that Rho cannot act to
substantially activate PLD on its own (Fensome et al., 1998).
ADP Ribosylation Factor
ADP-ribosylation factors (ARFs) are 20 kDa GTPases of the Ras superfamily. ARF
was first identified during the 1980s as a factor that stimulated the ADP-
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ribosyltransferase activity of the cholera toxin A subunit (Kahn and Gilman, 1984).
The ARF proteins all have a consensus sequence for GTP binding and hydrolysis,
which are critical functions of ARF activity as a G protein (Moss and Vaughan,
1995), and this sequence is identical in all of the mammalian ARFs. It has been said
that it is in this GTP binding domain, as well as the fact that the ARF proteins are
myristoylated on an N-terminal glycine, that makes the ARF proteins more similar to
the heterotrimeric G proteins than to the other 20 kDa Ras-like proteins in terms of
secondary structure. ARF may indeed be an ancestor to both as it is present in the
primitive parasite Giardia lamlia that lacks Ga subunits (Moss and Vaughan, 1993).
Six ARF genes have been described, and the predicted protein sequences are highly
conserved (100% identity for human and murine ARF1) (Boman and Kahn, 1995).
There are 6 mammalian ARF proteins, which can be divided into 3 classes based on
size, amino acid sequence, gene structure and phylogenetic analysis. Class I contains
ARF1, ARF2 and ARF3; class II consists of ARF4 and ARF5; and class III consists
of ARF6 alone (Moss and Vaughan, 1998). All isoforms of ARF can activate
cholera toxin, and all isoforms of ARF can be shown also to activate PLD.
In man, there have been 5 ARF proteins identified (there is no ARF2 in humans).
The human Class I ARFs are 96% identical, in resting cells they are mostly cytosolic
in location, and they act to recruit coat proteins to the membranes of the Golgi
apparatus. The Class I ARFs are expressed at higher levels than the other three ARF
proteins in human tissues. The levels of ARF4-6 are often only about 10% of those
of ARF1 and/or ARF3 (D'Souza-Schorey et al., 1995; Peters et al., 1995; Cavenagh
et al., 1996).
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The two most abundant classes of cellular ARFs (Class I and III) are exemplified by
ARF1 and ARF6, hence these members of the ARF family of proteins have had the
most focus on them in studies of mammalian systems. GTP loading and GPCR
activation can cause translocation of ARFs to Golgi and other unspecified membrane
compartments, and marked translocation of ARF1 to the plasma membrane has been
shown following activation of the M3 muscarinic receptor (Mitchell et al., 2003) and
the 5-HT2A and other receptors (Park et al., 1997; Morgan et al., 1997; Fensome et
al., 1998; Sung et al., 1999b), thus both ARF1 and ARF6 are potentially available for
interaction with plasma membrane GPCRs following agonist stimulation.
Very little is known of the functions of the class II ARFs, though their interactions
with the effectors of other small GTPases suggest their potential role in co-ordinating
membrane traffic in conjunction with additional small G proteins (Deretic et al.,
2005). ARF4 has been shown to have a role in the post-Golgi trafficking of
rhodopsin, specifically recognising a C-terminal sorting sequence of rhodopsin and
regulating its incorporation into rhodopsin transport carriers, which are specialised
membrane carriers targeted to the rod cell outer segment (Deretic et al., 2005).
Most members of the ARF family of proteins are predominantly cytosolic, with
activation via GTP binding leading to increased membrane association. However,
ARF6 is largely associated with the plasma membrane, and also to endosomes, and
appears to modulate the assembly of actin cytoskeleton and endocytosis, as well as
having a role in recycling endosomes to the plasma membrane (D'Souza-Schorey et
al., 1995; Peters et al., 1995; Cavenagh etal., 1996; Park et al., 1997; Fensome et
al., 1998; Lopez et al., 1998; Sung et al., 1999a). ARF6 has been shown to interact
specifically with adapter protein complex-2 (AP-2) and promotes its membrane
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recruitment, thereby directly interacting with a route of endocytosis (Paleotti et al.,
2005). AP-2 plays a role in protein sorting in the late-Golgi/trans-Golgi network
(TGN) and/or endosomes. The AP-2 complexes mediate both the recruitment of
clathrin to membranes and the recognition of sorting signals within the cytosolic tails
of transmembrane cargo molecules. The AP-2 complex seems to play a role in the
recycling of synaptic vesicle membranes from the presynaptic surface (Laporte et al.,
1999; Laporte et al., 2000; Laporte et al., 2002 and see Robinson, 2004 for a review).
This association suggests that ARF6 may have a role in clathrin coating of vesicles
(Paleotti et al., 2005).
ARF myristoylation
There is a known myristoylation site with all isoforms of ARF, on glycine 2 at the
amino terminal end of the protein. Myristoylation allows for some GDP-GTP
2+
exchange at physiological Mg levels, in the presence of phospholipid vesicles
(Franco et al., 1995a). Both myristoylated and non-myristoylated forms of ARFoiPys
can bind to membrane phospholipids, but only myristoylated ARFgdp, and not the
non-myristoylated form has been shown to bind to the same membrane
phospholipids (Franco et al., 1996). ARF1 mutants with deletions of the first 13-17
residues of the N-terminus, and those with deletions of amino acids 3-7 (residues
shown to be important in recognition by N-myristoyltransferase), had a greater
affinity for GTPyS than for GDP|3S (Franco et al., 1995a). Therefore the N-terminus
of ARF1 is a GTP-sensitive effector domain. In the presence of phospholipids, the
myristoylated form of ARF1 has a higher affinity for GTPyS than for GDP. In the
absence of phospholipids, the reverse is true (Randazzo et al., 1995). It has been
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suggested that the GTP activation of ARF proteins is a multi-part process, with
myristoylation of the protein leading to membrane association. The myristoylated
amino-terminal takes the shape of an alpha helix that associates with a hydrophobic
cleft of the interswitch domain (amino acids 52-67 in ARF1) in the GDP bound form
of ARF, but this association is weakened by association of the myristoyl group with
the membrane, presumably allowing of the for greater access to the GTP binding site
by GTP. This leads to the formation of ARFgtp, which is more stable when
associated with the membrane (Randazzo et al., 1995; Franco et al., 1995a; Franco et
al., 1996).
Regulation of ARFs
ARF proteins exist as GTP-dependent switches, and, as in other Ras-like proteins,
the conformation of two regions of ARF, switch 1 (amino acids 40-51 of ARF 1) and
switch 2 (amino acids 68-81 of ARF1) differ between the GDP and GTP-bound state
(Amor et al., 1994; Greasley et al., 1995; Goldberg, 1998; Goldberg, 1999; Menetrey
et al., 2000; Amor et al., 2001; Pasqualato et al., 2001; Amor et al., 2002; Pasqualato
et al., 2002). Like all G-proteins, activation occurs when GDP is released from the
protein and exchanged for a molecule of GTP. This exchange is facilitated in cells
via a group of proteins known as guanine nucleotide exchange factors (GEFs),
however it is possible that conformational changes in GPCR structure could allow
the GPCR to act as a GEF for ARF, as is the case with the heterotrimeric G proteins,
although this theorem has not been proven. Transition from the GDP-bound to GTP-
bound form of ARF is achieved through the family of proteins known as ARF
guanine nucleotide exchange factors, or ARF-GEFs, which consist of 14 proteins in
5 subfamilies. All of these proteins contain a Sec7 domain that catalyses the
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exchange of nucleotide. Crystallographic studies reveal that the switch 1 and 2
regions of ARF form an interface with the Sec7 domain (Cherfils et al., 1998;
Beraud-Dufour et al., 1998; Mossessova et al, 1998; Goldberg, 1998; Cherfils and
Chardin, 1999; Peyroche et al., 1999). Nucleotide dissociation is favoured by
disrupting the binding site for Mg2+ and the introduction of a glutamate residue from
the Sec7 domain within 3 A of the P-phosphate of GDP. The GEFs seem to have
some specificity for the isoform of ARF they activate, which may lead to specificity
of ARF activation within the cell depending on isoforms of ARF and the particular
GEFs present. The GEF BIG 1/2 is known to activate ARF1 and ARF3
preferentially, whereas the GEFs ARNO and GRP seem to preferentially activate
ARF6 (Donaldson and Jackson, 2000; Jackson and Casanova, 2000) (Figure 1.7).
Deactivation of ARFqtp is facilitated by a family of 16 GTPase-activating proteins or
ARF GAPs. All of these proteins share a common GAP domain of 70 amino acids in
length, which includes a zinc finger motif (CxxCx(16-17)CxxC) that is critical for
GAP activity (Cukierman et al., 1995). In addition to the zinc finger, all GAPs have
a conserved arginine within the GAP domain. Mutation of this arginine to a lysine
results in a 103 fold decrease in GTPase activity (Mandiyan et al., 1999; Randazzo et
al., 2000) suggesting an arginine finger catalyst mechanism for GTP hydrolysis.
ARF GAPs also display some selectivity for ARF isoforms. ARF GAP1
preferentially deactivates ARF1, ARF3 and ARF5, whereas ASAP1 and PAP work
best on ARF1 and ARF5, and to a lesser extent deactivate ARF6. The ARF GAPs
GIT1 and GIT2 work on ARF1, ARF3, ARF5 and ARF6 with seemingly equal
effects (see Donaldson and Jackson, 2000 for a review). In the case of ARF and
Rho, a group of proteins known as GDP dissociation inhibitors (GDIs) which retain
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the G protein in an inactive state have also been discovered (Donaldson and Jackson,
2000; Nie et al., 2003).
Muscarinic Receptors.
Cholinergic transmission takes place in via two classes of receptor, the nicotinic
cholinergic family of ligand-gated ion channels, and the muscarinic family of
GPCRs. The physiological effects of the prototypical muscarinic agonist muscarine
(from the mushroom Amanita muscaria) and the antagonist atropine (from the plant
Atropa belladonna) have been known for many years (Ford 1909; Dale 1914). More
recent investigations have shown that there are 5 genes for the muscarinic receptors
(ml-m5), which encode for highly related, yet distinct Mi-Ms receptor subtypes.
(Bonner et al., 1987). Muscarinic receptors Mi, M3 and M5 have all been shown to
activate the phosphoinositide pathway via Gq/Gn activation of PLC leading to an
increase in the intracellular Ca2+ concentration, (Jones and Michell, 1974; Buckley et
al., 1989; Bonner, 1989) whereas M2 and M4 have been seen to couple through Gj/G0
G proteins, leading to the inhibition of adenylyl cyclase (Haga et al., 1985; Bonner,
1989). In 1321N1 astrocytoma cells and transfected COS7 cells, the M3 muscarinic
receptor has also been shown to activate PLD in a heterotrimeric G protein-
independent manner through the small G protein ARF (Mitchell et al., 1998).
However, in other cell types, protein kinase C (Martinson et al., 1990) and tyrosine
kinases have been shown to activate PLD, for example, in HEK293 cells, the
tyrosine kinase inhibitor genistein abolished the carbachol-induced activation of PLD
by the M3 receptor (Schmidt et al., 1994).
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Mb muscarinic receptor
The M3 muscarinic receptor was first cloned in 1987 (Bonner et al., 1987; Peralta et
al., 1987). It is distributed widely in neuronal cells and the CNS, as well as in the
peripheral ganglia, in visceral and vascular smooth muscle, exocrine glands and the
ciliary body of the eye. (Levey et al., 1994; Doods et al., 1994; de la Vega et al.,
1996; Zhang, 1996; Hoglund and Baghdoyan, 1997; Lau and Pennefather, 1998;
Masuda et al., 1998). The human M3 receptor is 590 amino acids in length
(approximately 66kDa in size) and like most of the family R GPCRs contains a
number of predicted N-linked glycosylation sites on asparagine residues at positions
5, 6, 15 and 41 in the extracellular amino-terminal domain. Cysteine residues at
positions 141 and 221 are presumed to form the extracellular disulphide bridge
present in nearly all GPCRs and the receptor contains consensus palmitoylation sites
on cysteine residues 561 and 563 in the intracellular carboxy-terminal tail domain
(Peralta et al., 1987; Bonner, 1989). Mutagenesis and modelling studies have
demonstrated that the acetylcholine binding site is probably formed by multiple
tyrosine and threonine residues within the transmembrane domain a-helices, which
co-ordinate to provide a binding pocket on the internal face of the a-helix barrel.
This ligand binding domain involves a conserved Asp-148, which co-ordinates the
protonated nitrogen of acetylcholine, Tyr-149 in TM3, Thr-232 and Thr-235 in TM5,
Tyr-507 in TM6 and Tyr-530 and Tyr-534 in TM7, mutations of which were shown
to not appreciably affect receptor expression or G-protein coupling, but caused
reduced agonist binding affinity (Wess et al., 1991; Wess, 1993). A proline residue
(201) in TM4, which does not appear to interact with the ligand, is also thought to be
necessary for binding (Wess et al., 1991; Wess, 1993).
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The M3 receptor is unusual in the fact it has a particularly large third intracellular
loop (i3) domain (239 amino acids in length) R2;>3-Q491, which has been previously
mooted as a candidate area for binding of signalling proteins. The heterotrimeric G
protein GPy subunit has been shown to bind to this M3i3 domain at residues 331-333,
and it has been put forward that the G protein coupled receptor kinase GRK2
phosphorylates the M3i3 somewhere on residues 331-333 and 348-352 (Wu et al.,
2000), although this phosphorylation may not be necessary for receptor
internalisation (Shockley et al., 1999; Budd et al., 2000). Another kinase has been
shown to phosphorylate the M3 receptor on the i3 domain. Casein Kinase 1 a
(CKla) has been shown to phosphorylate the M3i3 in an agonist-dependent manner,
however, this phosphorylation event does not lead to a desensitisation of the
receptor, phosphorylation of the M3i3 by CK1 a instead seems to dramatically
potentiate the inositol phosphate response of the M3 receptor, possibly playing a role
in the control of the magnitude of the PLC response of the M3 and other PLC-
coupled GPCRs (Tobin etal., 1993;Tobin et al., 1997; Budd et al., 2000).
5-HT receptors.
Serotonin, or 5-hydroxytryptamine (5-HT) is a biogenic amine whose multiple
actions are mediated by a diverse group of receptors. Receptors for 5-HT are found
in both the central nervous system and the peripheral nervous system, as well as in a
number of non-neuronal tissues in the gut, cardiovascular system and blood. In
evolutionary terms, 5-HT is one of the oldest neurotransmitters (first chemically
characterised in 1948), and was identified as one of the major vasoconstricting
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substances in defibrinated blood (Rapport et al., 1947). In 1954, striking structural
similarities were noticed between LSD and 5-HT (Woolley and Shaw, 1954). Based
on this observation, and the fact that schizophrenia is characterised partially by
hallucinosis, 5-HT was proposed as possibly being involved in the pathogenesis of
schizophrenia (Woolley and Shaw, 1954). 5-HT has since been implicated in the
aetiology of a much wider range of disease states including depression (Amamoto
and Sarai, 1976), anxiety (Lesch, 1991a; Coplan et al., 1992), social phobia
(Denboer et al., 1994), schizophrenia and obsessive-compulsive and panic disorders
(Bender, 1978; Rammsayer and Netter, 1990; Lesch, 1991b; Coplan et al., 1992); in
addition to migraine, hypertension (Chemerinski et al., 1980), pulmonary
hypertension (Kanai et al., 1993), eating disorders (Cooper, 1989), vomiting (Miller
and Nonaka, 1992) and irritable bowel disorder (Talley, 1992).
The family of 5-HT receptors encompasses seven major subclasses, consisting of 14
different subtypes of receptors in total. All but one of these subtypes (5-HT3, which
is in fact a ligand-gated ion channel) signal through G protein-linked pathways
(reviewed in (Raymond et al., 2001; Hoyer et al., 2002)). The classification of the 5-
HT receptors began in 1957, when it was demonstrated that the functional responses
of the guinea pig ileum, but not other tissues, to 5-HT could be blocked by morphine
(Gaddum and Picarelli, 1957). Originally a nomenclature of M and D receptors was
proposed, however, due to the non-specific effects of the ligands on other
neurotransmitter systems, this system was not fully accepted (Lewis, 1960; Day and
Vane, 1963). In 1976, a radioligand binding study of rat cortical membranes gave
rise to the postulation that specific binding sites for 5-HT reflected the previously
reported pharmacological receptors (Bennett and Snyder, 1976). The presence of
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two distinct membrane binding sites for 5-HT was demonstrated in 1979, and these
were named 5-HTi and 5-HT2 (Pertouka and Snyder, 1979). The previously named
M receptor was found to be distinct from these 5-HT] and 5-HT2 receptors, and was
subsequently renamed the 5-HT3 receptor (Bradley et al., 1986). The 5-HT4 receptor
was discovered shortly afterwards in the gastrointestinal tract and brain tissue. The
cloning of the 5-HTia receptor was completed in 1988 (Fargin et al., 1988) with the *
others following on in rapid succession. This cloning process led to the
identification of a number of new receptors, initially named 5-HTie, 5-HTif, 5-HTsa,
5-HT5B, 5-HT6 and 5-HT7 (reviewed in Hoyer et al., 1994; Hoyer et al., 2002). In
the post genomic era, hundreds of receptors have been identified either by functional
studies, or by cloning, so to ensure a clear and comprehensive nomenclature for the
existing 5-HT receptors, and any orphan receptors that may join this class, a new
classification system has been proposed (Humphrey et al., 1993; Hoyer et al., 1994;
Hartig et al., 1996; Hoyer and Martin, 1997), which has lead to the currently
recognised seven families of 5-HT receptor. The diversity of this group of GPCRs is
further increased by the fact that some members of the 5-HT family (5-HT4 and 5-
HT7) can exist as different splice variants, leading to further different isoforms of
these receptors (Kilpatrick et al., 1999).
The different subclasses of receptors for 5-HT transduce their signals via different
heterotrimeric G proteins, with the 5-HTi group (and 5-HTs) linking preferentially, to
Gj/0„ and thereby inhibiting cyclic AMP (cAMP) production. 5-HT2 receptors have
been shown to preferentially signal through Gq/i 1 to increase inositol trisphosphate
levels and intracellular Ca2+ levels via PLC. 5-HT4, 5-HTg and 5-HT7 all signal
through Gs to increase production of cyclic AMP, however they are categorised as
39
separate receptor classes due to their limited (<35%) overall sequence identities
(reviewed in Hoyer et al., 2002 and Raymond et al., 2001). The 5-HT3 receptor
differs entirely from the other members of this family in that it is not a 7
transmembrane domain receptor, but a ligand-gated ion channel.
5-HT2 receptors
The 5-HT2 subclass consists of the 5-HT2A, 5-HT2b and 5-HT2C (originally 5-HTiC)
receptors. The 5-HT2 receptors are all of a similar size, 451-479 amino acids, (-52
kDa) and display -70% sequence homology in their transmembrane regions, and an
overall sequence identity of 46-50%. The 5-HT2 receptors share many
characteristics, including some regions of sequence similarity, and considerable
overlap in ligand recognition sites. Like most of the family R GPCRs, they display
predicted glycosylation sites on asparagine residues in their extracellular domains
(Asn 8, 38, 44, 51 and 54 for the 5-HT2a receptor; Asn 203 in the 5-HT2b receptor;
Asn 39 and 204 in the 5-HT2c receptor), as well as predicted palmitoylation on a
cysteine residue in the proximal part of the carboxy-terminal tail. All three receptors
have the cysteine residues required for putative disulphide bridges linking the
extracellular loop 1 and 2 (el and e2) domains (Cys 95-Cysl72 for the 5-HT2a,
Cysl28-Cys207 for the 5-HT2b and Cysl27-Cys207 for the 5-HT2c). The members
of the 5-HT2 subfamily all have highly conserved NPxxY motifs at the proximal
region of the carboxy-terminal tail (Saltzman et al., 1991; Cook et al., 1994;
Schmuck et al., 1994; Xie et al., 1996).
Residues thought to contribute to the ligand binding site of the 5-HT2a receptor were
first hypothesised through the use of 3D molecular modelling techniques, where two
aspartic acid residues in the central core of the receptor (Asp 120 and Asp 155) were
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postulated to interact with the protonated ligands 5-HT and ritanserin. During the
simulations 5-HT had only a weak interaction with Aspl55, but a strong interaction
with Asp 120, where the amino group on 5-HT bound tightly to the carboxylic side
chain of the Asp residue (Edvardsen et al., 1992). These findings were backed up
the next year by functional studies following mutagenesis studies that showed not
only these two residues, but a further aspartic acid at position 172 may be involved.
This study showed that the Asp 120 was important for allosteric activation of the
guanine nucleotide-binding protein, Aspl55 is necessary for high affinity ligand
binding, and mutation of Aspl72 lead to an approximately 5 fold decrease in the
affinity of the receptor for 5-HT (Wang et al., 1993).
Both the 5-HT2A and the 5-HT2C receptors are widespread in the central nervous
system, whereas the 5-HT2B receptor has a much more restricted distribution. 5-
HT2A receptors occur in high levels in the limbic forebrain, in particular in the frontal
cortex and nucleus accumbens. 5-HT2C receptors occur in moderate density
throughout the forebrain and in the hindbrain and are particularly concentrated in the
choroid plexus. 5-HT2B receptors are scarce in the brain, and are found mostly in the
stomach and other peripheral tissues (though their levels there are also low)
(VanOekelen et al., 2003; Hoyer et al., 1994; Hoyer et al., 2002, reviewed in Roth et
al., 1998).
The 5-HT2A receptor in particular has been implicated as an important site of actions
for drugs used in a variety of major psychiatric disorders, including: antipsychotics;
antidepressants; anxiolytics; and antihistamines (which have 5-HT2 antagonistic
action), as well as in hallucinogenic drug actions such as that of rf-lysergic acid
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diethylamide (LSD) and similar compounds, which have an antagonistic effect on the
5-HT2 receptors (Van Oekelen et al., 2003).
The 5-HT2 receptors signal through coupling to Gq/n to activate PLC, leading to an
increased accumulation of inositol phosphates and intracellular Ca'+. In addition to
Gq/n-mediated phospholipase C (PLC) activation, the 5-HT2A receptor can activate
other signalling pathways that may involve alternative direct coupling to the
receptor. These include activation of phospholipase A2 (PLA2) (which may be
mediated by a transduction mechanism other than Gq/n (Berg et al., 1998) and
activation of tyrosine phosphorylation (correlating with evidence for direct
association of the tyrosine kinase Jak2 with the carboxy-terminal tail domain of the
receptor (Guillet-Deniau et al., 1997) and ARF-dependent activation of
phospholipase D (PLD) (which may involve direct GPCR:ARF interactions (Mitchell
etal., 1998)).
Despite their general structural and functional similarities, there may be differences
in the mechanisms desensitisation of 5-HT2A and 5-HT2C receptors. In rat NIFI 3T3
cells, receptor activation led to a decrease in surface levels of 5-HT2C, but not 5-
HT2A, but both exhibited a decrease in inositol phosphate production over time,
therefore they undergo differential desensitisation in the same cell type (Oekelen et
al., 2001). The 5-HT2A receptor seems to be regulated by uncoupling from G
proteins (Oekelen et al., 2001). Receptor levels were actually increased during the
key time frame, due to synthesis of new receptors. Newly synthesised receptors
appear not to couple readily to G-proteins. These findings taken together seem to
suggest that rat 5-HT2A and 5-HT2C receptors differ markedly in their ability to
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couple to G-proteins to form a functionally active receptor (Oekelen et al., 2001; Van
Oekelen et al., 2003).
All three of the 5-HT2 receptors contain PDZ target motifs at the extreme end of their
carboxy-terminal tail. In the case of the 5-HT2A receptor, this PDZ target motif has
been shown to bind to a PDZ domain protein named PSD-95, which can link to
additional signalling pathways and regulate receptor trafficking (in HEK-293 cells)
(Xia et al., 2003). PSD-95 augmented the signalling of the 5-HT2A receptor through
Gaq to activate phosphoinositide hydrolysis, without altering the kinetics of the
receptor desensitisation, but did however inhibit the agonist-induced internalisation
(Xia et al., 2003). PSD-95 has also been shown to bind to the ct of the 5-HT2C
receptor (in complex with several other synaptic structural proteins: Veli3, CASK
and Mintl) (Becamel et al., 2002) as well as to some extent to the 5-HT2A receptor
(Becamel et al., 2004). The 5-HT2C receptor also been shown to bind to MUPP1, a
multi PDZ domain protein with unknown function (Marinissen and Gutkind, 2001;
Bockaert et al., 2003; Bockaert et al., 2004).
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General aims of the present study
This study will investigate members of separate sub-families of the family R GPCRs,
focusing particularly on the M3 muscarinic receptor, the 5-HT2A receptor and the
closely related 5-HT2C receptor. Both the M3 and 5-HT2A receptors have previously
been shown to be able to activate PLD via an ARF-dependent pathway (Mitchell et
al., 1998). Experiments with wild type and negative mutant ARF constructs will be
used to discern the involvement of ARF1 and ARF6 in receptor-mediated activation
of PLD, determining if this role is isoform specific, and indeed if there is any
variation in specificity between receptor subtypes.
Using the in vitro technique of GST-fusion protein pull-down assays, the interactions
of ARF isoforms with individual intracellular domains of the M3 muscarinic and 5-
HT2 receptors will be analysed. This will determine the specificity of each isoform
for the receptor domains, and also allow investigation into the mechanisms of this
interaction as well as any modulation influences over these interactions of ARF with
receptor domains. Experiments will be carried out to address the roles of GPy, which
has been shown to bind to the third intracellular loop of the M3 receptor, and
arrestins, which are known to interact with both third intracellular loop, and carboxy-
terminal tail domains of family R GPCRs.
Finally this study will use a targeted proteomic approach in an attempt to discover
novel interaction partners for the intracellular domains of the 5-HT2A receptor, and
begin to characterise any interactions discovered to elucidate the role of novel
binding partners in 5-HT2A receptor signalling.
These studies will develop the understanding of GPCR:ARF interactions, and will





The topology ofa typical Gprotein-coupled receptor
A two dimensional representation of the topology of a generic 7-transmembrane
GPCR embedded in the plasma membrane. The figure shows the extracellular N-
terminal domain, the 7 transmembrane spanning a-helices, linked by intracellular
(il-3) and extracellular (el-3) loops, and the intracellular C-terminal (ct). The
conserved cysteine bridge between el and e2 is shown in red. Palmitoylation of a
conserved cysteine residue in the proximal part of the carboxy terminal tail, is
present in most of the rhodopsin family GPCRs, and gives rise to a putative fourth
intracellular loop (i4). In the folded protein, the 7 transmembrane domains form a
barrel like structure, into which the agonist can bind from the extracellular surface.
Furthermore, a short section of amphipathic a-helix, apparently running in the
cytosolic compartment, parallel to the plane of the membrane has been identified
distal to the seventh transmembrane spanning a-helix. This region which ends near a
palmitoylated cysteine residue (occurring in most, but not all, of the family R
GPCRs) is sometimes referred to as the fourth intracellular loop (i4 loop) or helix 8,
and may be important for G protein coupling (Bourne, 1997; Wess, 1998; Palczewski
et al., 2000). The extracellular domains and in some cases parts of the TM regions
are mostly involved in agonist recognition, and the intracellular domains seem to be








Phylogenetic relationship between the GPCRs in the human genome
The above dendrographs were calculated using the maximum parsimony method on
1000 replicas of the data set terminally truncated GPCR as described in Fredriksson
et al., 2003. The position of the rhodopsin family was established by including
twenty random receptors from the rhodopsin family. These branches were removed






The crystal structure ofrhodopsin, a templatefor the G-protein coupled receptor
Figure 1.2 shows a diagram of the solved crystal structure of the seven
transmembrane spanning helices of rhodopsin as seen from the sude, and from the
extracellular views (Palczewski et al., 2000). The helices are organised sequentially
in an anticlockwise fashion with helix 3 being almost in the centre of the molecule.
The seven transmembrane anticlockwise a-helix bundle is apparent (with helices
labelled I-VII), as is the extracellular amino- and intracellular carboxy-terminal
domains, the left hand image shows the extracellular view, containing the site of




The activation/deactivation cycle ofheterotrimeric G-proteins
Heterotrimeric G protein activity is regulated by the binding and hydrolysis of GTP
by the a subunit. Only the GTP-bound a subunit is active, and contributes to the
intracellular signalling of the GPCR by acting on the various effector proteins with
the specificities described above. A GDP-bound a subunit is inactive. This figure
shows the cycle of activation of trimeric G-proteins by GAPs (including ligand
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3D structure of the G(3yheterodimer
Structure of the GPy heterodimer bound to the peptide SIGK (a small GPy binding
peptide) (Davis et al., 2005). Two views of the Gpy-SIGK complex, shown in
ribbon representation. The two representations are related by -90°. Gp, blue,
Gy purple and SIGK is colored pink. The N- and C-termini of GP, and Gy are
labeled. The G protein beta subunit contains a distinctive 7 WD-40 repeat
(tryptophan-aspartate repeat) structure. Each of the 7 repeats folds into a small
antiparallel beta-sheet. These sheets are arranged around a central pseudosymmetry
axis into a beta propeller. On the left panel, the seven blades of GP are labeled
following the convention of Wall et al. (Wall et al., 1995; Wall et al., 1998). The
SIGK peptide binds to two surfaces on GPi, and the contact surface for SIGK on






The domain structures ofthe phospholipase C and D, andprotein kinase C
The domain structures of the major GPCR pathway-coupled isozymes of PLC, PKC
and PLD. The catalytic domains in each are indicated in red. The pleckstrin
homology (PH) domains in PLC and PLD (blue) are important for associating with
lipid membranes. The EF-hand and C2 regions in PLC and C2 region in PKC are
important for Ca2+ ion binding. The P-box in PLCp is important for interaction with
the heterotrimeric G proteins. PKC contains and additional conserved CI domain,
where diacylglycerol and phorbol esters bind. PLD contains a phox homology (PX)
domain and the conserved regions I-IV include the catalytic HKD domains. PLD
contains an additional loop region, and allosteric PIP2 site and the carboxy-terminal
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Figure 1.7
Crystal structure ofARF1 bound to the Sec7-domain exchange factor
The mechanism by which ARF-family GTPases are activated to the GTP-bound state
by exchange factors was revealed by the crystal structure of ARF1 complexed with a
cognate exchange factor of the Sec7 family. The crystal structure shows how the
exchange factor inserts amino-acid side chains directly into the ARF1 GTPase active









All chemicals and reagents were from Sigma Chemical Company, (Poole, Dorset,
UK) unless otherwise indicated. All restriction enzymes and appropriate buffers
were from New England Biolabs, (NEB (UK) Ltd. Hitchin, Herts. UK), unless
otherwise stated.
Plasmids
ARF1-HA, ARF6-HA, ARF1-HA G2A, ARF6-HA G2A, ARF1-HA Q71L and
ARF6-HA Q67L, in plasmid pXS, were a kind gift from (Julie Donaldson, NIH).
PLD1/2-HA (Mike Frohman, State University ofNew York). Arrestin 2 and arrestin
3 in pCMV5 and GRKct were a kind gifts from the Lefkowitz lab (Duke Medical
Center). Gaq-HA and hM3 muscarinic receptor clones were obtained from ATCC
(Manassas, Virginia, USA). Signal FLAG construct of the M3 muscarinic receptor
was made by Dr Eve Lutz (Dept of Biochemistry, University of Strathclyde,
Glasgow). 5-HT2a receptor clone SCS93 was a kind gift from Stuart Sealfon (Mount
Sinai School of Medicine, New York).
Oligonucleotide Primers
Oligonucleotide primers were designed with the aid of GeneJockey (Biosoft









Preparation of competent cells
Escherichia coli (E. coli) cells strains JM109 and BL21-RIL, were grown overnight
at 37°C on M9 minimal media plates (5% glucose (w/v), 5mg/ml vitamin Bl).
Colonies were selected and grown up in 8ml of Luria Bertani (LB)-broth (10g/l
tryptone, 5g/l yeast extract, 5g/l NaCl) for 8 hours. From this starter culture, 2.5ml
was added to 250ml of LB-broth (+ 0.02M MgSOzj), and grown until the Optical
Density (OD) of the culture was between 400 and 600. Cultures were centrifuged to
pellet cells (3000g, 10 min, 4 °C) and the pellet resuspended gently in 0.4 volumes of
ice cold sterile TFB1 (1M KOAc, 0.1M CaCl2, 1M MnCI2, 2M RbCl2, 15% glycerol
(v/v) in UHP FI2O, pH 5.8) before being incubated on ice for 5 minutes. Cells were
again pelleted by centrifugation (3000g, 10 min, 4 °C), before being gently
resuspended in l/25th original culture volume in ice-cold sterile TFB2 (0.1M MOPS,
0.1M CaCl2, 2M RbCl2, 15% glycerol (v/v) in ultra high purity (UHP) H20 pH 6.5).
Cells were then incubated on ice for 15-60 minutes, before being aliquoted into
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200jal lots into ice-cold 1.5ml Eppendorf tubes (Eppendorf) and snap frozen in a dry
ice/ethanol bath. Cells were stored at -70 °C.
Transformation of competent cells
Approximately lOOng of cDNA was added to a 50pl aliquot of competent JM109 E.
coli cells, mixed gently and incubated on ice for 30 minutes. The cells were then
heat shocked for 45 seconds at 42°C, before being placed on ice for 2 minutes. 900pl
of LB-broth was added, and the culture placed in a shaking incubator (Model G25
Incubator Shaker, New Brunswick Scientific Co. Inc. NJ, USA.) at 37°C for 45
minutes. 200pl of this suspension was plated out onto LB-agar plates (LB-broth +
1.2% bactoagar (w/v)) supplemented with ampicillin at 12.5pg/ml and/or tetracycline
at 7.5pg/ml to select for plasmid-containing cells, and grown at 37°C in an incubator
overnight.
Plasmid purification
Plasmid purification was carried out using the Qiagen QIAfilter Maxi kit (Qiagen
Ltd. West Sussex, UK). Competent cells were transformed with cDNA as described
above. A distinct colony was picked from the plates, and grown up for 8 hours in
3ml LB-broth (+ 12.5pg/ml ampicillin) at 37°C. 1 ml of this starter culture was
transferred to 100ml of LB-broth (+ 12.5 pg/ml ampicillin) and grown overnight in a
shaking incubator at 37°C. The culture was then centrifuged to pellet the bacterial
cells (20 min, 7700g, 4°C) (Sorvall R.C-5B Refrigerated Superspeed Centrifuge, Du
Pont Instruments; Sorvall GSA rotor). The supernatant was removed, and the cells
were resuspended in 10ml of Buffer PI (Qiagen resuspension buffer; 50mM
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Tris.HCl, pH 8.0; lOmM EDTA; lOOpg/ml RNase), then 10 ml of Buffer P2 (Qiagen
lysis buffer; 200mM NaOH, 1% SDS (w/v)) was added, and mixed gently, before
incubating at room temperature for 5 minutes. 10 ml of ice-cold Buffer P3 (Qiagen
neutralisation buffer; 3.0 M potassium acetate pH 5.5) was then added and the lysate
mixed gently. The lysate was poured into the barrel of a QIAfilter Maxi Cartridge,
and left to stand for 10 minutes, before being filtered into a QIAGEN-tip 500
column, which had been pre-equilibrated with 10 ml of Buffer QBT (Equilibration
buffer; 750 mM NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol(v/v); 0.15%
Triton® X-100 (v/v)). After the lysate had flowed though the column, the column
was washed through with 2 x 30ml Buffer QC (Wash buffer; 1.0 M NaCl; 50 mM
MOPS, pH 7.0; 15% isopropanol (v/v)), and eluted by 15 ml Buffer QF (Elution
buffer; 1.25 M NaCl; 50 mM Tris.HCl, pH 8.5; 15% isopropanol (v/v)). The cDNA
was precipitated by the addition of 0.7 volumes (10.5 ml) of isopropanol, and then
centrifuged (16000g, 30 min, 4°C) (Sorvall SS-34 rotor). The supernatant was
removed, and the pellet washed in 5 ml of 70% ethanol (v/v), and recentrifuged
(16000g, 30 min, 4°C). This step was repeated, and the pellet then allowed to air dry,
before resuspension in an appropriate volume of TE buffer (10 mM Tris.HCl, pH
7.4; ImM EDTA, pH 8.0; pH to 7.4).
Miniprep of cDNA
Small (3-5 ml) bacterial cultures, pre-transformed with cDNA were grown overnight
at 37°C in LB broth (+ 12.5pg/ml ampicillin), before being centrifuged (5 min,
!2000g) in 2ml tubes, to pellet bacteria, in an benchtop centrifuge (Eppendorf),
resuspended in 300 pi resuspension buffer PI (15 mM Tris.HCl, pH 8, 10 mM
EDTA, which was sterilised and to which was added 100 pg/ml RNase A), and 300
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pi lysis buffer P2 (0.2 N NaOH, 1% SDS (w/v)) was added, the tubes were then
mixed carefully by inversion, and left at room temperature for 5 minutes to lyse
fully. After this, 300 pi of ice-cold neutralisation buffer P3 (3 M KOAc, pH 5.5,
autoclaved) was added, and the tubes inverted to mix. Tubes were centrifuged (20
min, 12000g) in a benchtop centrifuge, and the supernatant retained. To the
supernatant, 800 pi isopropanol was added. The tubes were incubated on ice for 1
hour, and again centrifuged (20 min, 12000g, 4°C) and the resulting pellet washed in
1 ml 70% ethanol (v/v), centrifuged (5 min, 12000g, 4°C), and then air-dried. The
pellet was finally resuspended in 40 pi TE buffer.
Cell culture
Cell lines were grown and maintained in a humidified atmosphere of 5% CO2 (v/v) at
37°C at all times unless otherwise indicated. Culture medium was refreshed every 3-
4 days, all flasks and 12 well plates for culturing and plastics were obtained from
Greiner Bio-One (Gloucestershire, UK).
The cells were harvested by a brief incubation with 10 ml/175 cm2 Hank's Buffered
Saline Solution (HBSS) containing 10% (v/v) lOx trypsin-EDTA (Gibco), which was
applied to the cell layer, agitated and aspirated after 20 seconds. After a further 10
minutes, the cells were washed off the flask surface with the appropriate medium and
resuspended. The cells were then reseeded into flasks at a ratio of 1:3 or onto 12
well plates for assay purposes.
This method is added for the sake of completeness, all cell culture was performed by
Pamela Holland.
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Transient transfection of cDNA into mammalian cells
C0S7 cells were trypsinised as described earlier and seeded into 75 cm2 or 175 cm2
flasks, or into 12 well plates at approximately 50% confluency for transfection the
following day. Fugene-6 transfection reagent (Roche Diagnostics, East Sussex, UK)
or genejuice (Novagen, Merck Biosciences, Nottingham, UK) was added to DMEM
(with 4500 mg/1 glucose, with 1-glutamine, without pyruvate) according to
manufacturers instructions and incubated for 5 minutes. cDNAs encoding proteins
of choice or empty vector pcDNA3 (as a control) were added to the Fugene-
6/DMEM or Genejuice/DMEM according to the manufacturers instructions and
swirled gently to mix, then incubated for a further 15 minutes. The transfection
mixture was added to the cell layer, swirled gently and the cells incubated at 37°C for
48 hours. Cells were made quiescent by replacing culture media with serum free
media.
This method is added for the sake of completeness, all transient transfections of
cDNA into mammalian cells were performed by Pamela Holland.
Construction of 5-HT2a receptor carboxy terminal tail GST-fusion
proteins
The human 5-HT2aR carboxy-terminal tail constructs were PCR amplified using the
proofreading KOD Polymerase (Novagen) from SCS93 (5-HT2A receptor clone) with
the following primer pairs: GST-5-HT2AGINPLVYct (amino acids GIN376-V471)
with primer pair h2ARGINPLVY.fp and h2ARCT.rp (see above for primer
sequences); GST-5-HT2AL406ct (GIN376-L406) with primer pair
h2ARGINPLVY.fp and h2ARL406.rp; GST-5-HT2AQ396ct (GIN376-Q396) with
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primer pair h2ARGINPLVY.fp and h2ARQ396.rp, using Taq polymerase
(Promega). The following temperature cycles were used: (94°C, 2 min) xl cycle;
(94°C; 1 min, 55°C; 1 min, 68°C ; 2.5 min) x40 cycles; (68°C, 10 min) xl cycle, and
then held at 4°C. The resulting PCR products were purified by Wizard cDNA clean¬
up resin (Promega), and subcloned into the pCR4Blunt TOPO vector using the
ZeroBlunt® TOPO® PCR cloning kit for sequencing (Invitrogen). The resulting
plasmids were transformed into competent JM109 E. coli strain, and plated out onto
LB plates (+ 12.5pg/ml ampicillin), and incubated overnight at 37°C. Resulting
colonies were grown overnight at 37°C in 5 ml LB broth (+ 12.5p.g/ml ampicillin).
Minipreps were performed on the cultures as described previously. Plasmids were
checked by digests using the appropriate restriction enzyme pairs, and also by
sequence analysis. Individual clones were isolated and the inserts checked by
restriction digest with EcoRl and sequence analysis. Clones with the appropriate
sequence were digested with the following restriction enzymes in order to subclone
the inserts into the BamHl/EcoRl site of the GST vector pGEX3x
(Amersham/Pharmacia): Bcl\ and Mfe 1 (GST-5-HT2AGINPLVYct) in buffer 4; Bcl\
and EcoR\ (GST-5-HT2AL406ct and GST-5-HT2AQ396ct) in buffer 3; BamUl and
Mfel, for 1 hour at 50°C where Bel] was used, followed by 1 hour at 37°C. Plasmid
constructs that were to be digested with the Bell enzyme had to be transformed into
the methylase free E. coli strain JM110 (Stratagene) before isolation because this
restriction enzyme is sensitive to DNA methylation. Plasmid digests were run on a
2% (w/v) low melting point agarose gel and the band of interest was cut out, and the
DNA extracted from the gel by using the Qiaex II gel extraction kit (Qiagen).
Purification of DNA from gels
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Each gel slice was weighed and 3x volume of solubilisation solution (Qiagen) added
along with the Qiaex II resin. The mixture was incubated at 50°C for 10 mins with
intermittent mixing to ensure the resin stayed in suspension. This was then
microfuged for 30 sees and the resin/captured DNA pellet washed once in 500 pi of
solubilisation solution (Qiagen), then twice in 500 pi wash buffer. The pellets were
briefly air-dried and the DNA eluted by incubation for 10 minutes with sterile UHP
water at 50°C. Extracted DNA was subcloned into the BamYiVEcoBA site of pGEX-
3X plasmid, and again cloned inserts were checked by sequence analysis.
Expression of GST proteins
GST-5-HT2Ai3 (pGEX-3X), GST-5-HT2Act (pGEX-2T), GST-5-HT2A103ct, GST-5-
HT2AK385ct, GST-5-HT2Cct, GST-5-HT2Ci3, GST-M3ct (All kindly provided by Eve
Lutz, University of Strathclyde), the GST-5-HT2AL406ct and GST-5-HT2AQ396ct
(pGEX-3X) described above, GST-M3i3 (kindly provided by Stephen M. Lanier,
Louisiana State University Health Sciences Center, New Orleans) constructs, as well
as a control GST fusion protein of the STREX insert of the large conductance Ca2+-
and voltage-activated K+ (BK) channel, in the pGEX-5Xl vector (kindly supplied by
Mike Shipston, University of Edinburgh) and GST (PGEX-3X) alone were
transformed into the BL21-RIL strain of is. coli bacterial cells, as detailed above. A
single colony was selected from the plate, and grown overnight at 37°C in 20 ml of
2xYT medium (16 g/1 tryptone, 10 g/1 yeast extract, 5 g/1 NaCl) with 2% (w/v)
glucose and 12.5 mg/ml ampicillin. From this starter culture, 4 ml was taken and
added to 400 ml of 2xYT medium (+ 2% glucose (w/v); 12.5 pg/ml ampicillin) and
grown until the culture had reached an OD600 of 0.6-0.8, expression of the fusion
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proteins was then induced by the addition of 0.1 mM isopropyI-(3-D-thiogalactoside
(IPTG) and the culture left for a further 3 hours at 37 °C. Cells were harvested by
centrifugation (10 min, 7700g, 4°C; Sorvall GSA rotor), the supernatant removed and
the cells resuspended in 10 ml BugBuster reagent (Novagen, CN-Biosciences,
Nottingham, UK) and left for 10 min to lyse. The culture was again centrifuged (20
mins, 16000g, 4°C; Sorvall SS-34 rotor) and the supernatant, containing the GST
fusion proteins, was added to glutathione-Sepharose beads which had been
prewashed in 1 ml PBS, to give a final bed volume of beads of 200p.l (Amersham-
Pharmacia Biotech AB). The beads were incubated with an amount of bacterial
supernatant that would ensure equal amounts of protein for each construct, for 20
minutes at room temperature to allow binding of the GST fusion proteins to the
beads. The matrix formed was then washed three times with 2 ml each PBS and used
immediately in the protein interaction assay.
Preparation of protein enriched extracts
COS7 cells were transfected with various constructs (ARF1/6-HA; "AARF1/6-HA;
HA-PLDlb/2; arrestin 2/3; GRK2495.689; Gaq) through the use of genejuice ®
transfection reagent (Novagen) according to manufacturers instructions, in 175 cm2
flasks. Cells were washed with 10 ml Earle's Balanced Salt Solution (EBSS; Life
Technologies) before being scraped into 2 ml ice-cold extraction buffer (2 |a.g/ml
aprotinin, 1 mM 4-(2-aminoethyl)-benzenesulphonylfluoride (AEBSF) (Alexis
Biochemicals, San Diego, CA, USA), 1 mM dithiothreitol (DTT), 1 mM pepstatin, 1
mM Na orthovanadate, 1 mM NaF, 50 p.g/ml soyabean trypsin inhibitor (SBTI) in
PBS). In the case of the extracts containing overexpression of either of the PLD-F1A
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isoforms, to allow the PLD-HA to become soluble, 1% (w/v) CHAPS, 1% (w/v)
deoxycholate and 20% (v/v) glycerol (for stability) were added to the above buffer.
The cells were then homogenised (Ystral polytron, (Scientific Industries Intl. UK
Ltd, Loughborough, UK) setting 3, 15 sec) before being centrifuged, (12000 g, 20
min, 4 °C). The supernatant was aliquoted and stored at -40 °C until required.
In vitro protein interaction assays
COS7 cellular extracts enriched in the various constructs made as described above
(Preparation ofprotein enriched extracts), and/or pure protein (G(3y subunit from
bovine brain) (Calbiochem) were incubated with GST-fusion proteins bound to
glutathione-Sepharose beads, as described in the Expression ofGST Proteins section
above (Amersham Pharmacia Biotech), in 250 pi Buffer A (20 mM Tris HC1 pH 7.5,
0.6 mM EDTA, 1 mM DTT, 70 mM NaCl, 0.05% Tween 80 (v/v)) for 90 min at 4°C,
with rolling. In some experiments, GTPyS (100 pM) was added to the incubations.
The beads were washed 4 times in 1 ml Buffer A and the retained proteins removed
from the beads with x2 Laemmli buffer (2% SDS (w/v), 715 mM mercaptoethanol
20 mM Tris HC1, pH 7.4)(Laemmli, 1970) before SDS-PAGE and immunoblotting
(see below). Input levels of both putative interacting proteins and fusion proteins
(monitored by GST immunoreactivity) were carefully balanced by use of the
ScanAnalysis densitometric imaging program (Biosofit, Cambridge, UK), to ensure
comparability between samples.
In the case of the rat brain homogenate, loosely-bound proteins were eluted from the
column with a high salt elution buffer (50mM Tris, 1M NaCl, ImM EDTA, ImM
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EGTA, 5% glycerol (v/v)) before any proteins remaining were removed with x2
Laemmli buffer as above.
The quality of wild type and mutant receptor GSTs was routinely monitored by anti-
GST blots/protein staining.
Preparation of rat brain homogenate
Male rat brains were kindly provided frozen by Susan Fleetwood-Walker (Royal
Dick Vet School, University of Edinburgh). Each brain was homogenised in 8ml of
homogenisation buffer (2 pg/ml aprotinin, 1 mM 4-(2-aminoethyl)-
benzenesulphonylfluoride (AEBSF) (Alexis Biochemicals, San Diego, CA, USA), 1
mM dithiothreitol (DTT), 1 mM pepstatin, 1 mM Na orthovanadate, 1 mM NaF, 50
pg/ml soyabean trypsin inhibitor (SBTI) in PBS). The brains were homogenised
(Ystral polytron (Scientific Industries Intl.) setting 3, 1 min) before being centrifuged
(12000g, 30 mins, 4°C). The cytosol was then incubated for 90 min with 1ml
glutathione-Sepharose beads that had been preincubated with GST protein alone, to
remove any proteins that may bind non-specifically to the GST part of the construct
of interest, before the brain lysate was introduced to each of the target GST-
constructs. See Expression ofGST Proteins above.
Protein interaction assays with homogenised rat brain extracts
2 ml of homogenised and solubilised rat brain as described above (Preparation of
Rat Brain Homogenate) was added to each of columns that contained 500 ml of
glutathione-Sepharose beads that had been bound to the GST constructs of interest
{Expression of GST Proteins) to give a final reaction volume of 2.5 ml and incubated
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at 4°C for 16 hours. Columns were washed twice in homogenisation buffer detailed
above, and then proteins were eluted from the column with 1ml of a high salt elution
buffer (50mM Tris, 1M NaCl, ImM EDTA, ImM EGTA, 5% glycerol (v/v) pH 7.5)
before any proteins remaining were removed with x2 Laemmli buffer as above, and
the eluates run on SDS-PAGE gells as described below (Western Blots).
Western blots
Western blots were carried out on samples from immunoprecipitation and GST-
fusion protein interaction assays. Either 20% or 12.5% precast homogeneous
Phastgels (Amersham Pharmacia Biotech) were used. SDS-PAGE and
electroblotting onto polyvinylidene difluoride membranes (Immobilon-P;
Immobilon-PSQ; Millipore, Watford, UK) were performed on a Phastsystem
apparatus (Amersham Pharmacia Biotech). Membranes were blocked overnight at
4°C in 5% Marvel (Premier Brands UK Ltd, Spalding, Lines UK)/PBS (w/v). The
detection antibodies used were rabbit polyclonal anti-HA (Santa Cruz
Biotechnology; Autogen Bioclear, Calne, Wilts, UK, catalogue number sc-805) at a 1
in 500 dilution, goat polyclonal anti-GST (Amersham Pharmacia Biotech, catalogue
number 27-4577-01) at a 1 in 300 dilution and mouse monoclonal anti-PrC (Roche,
clone HPCA, catalogue number 1814508) at 1 in 1000 dilution. Primary antibodies
were incubated with the membranes for 90 minutes in 0.1% TWEEN®-20/PBS (v/v)
at room temperature with agitation, washed 5x5 minutes in 0.1% TWEEN®-20/PBS
(v/v) followed by incubation for 2 hours with preabsorbed secondary antibodies
conjugated to HRP (Chemicon Intl. Ltd., Harrow, UK) in secondary antibody buffer
(0.25% BSA (w/v) / 0.1% TWEEN®-20 (v/v) in PBS), followed by a further 5 x 5
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minute washes in 0.1% TWEEN® 20/PBS (v/v). Visualisation of antibody bands
was achieved using Luminol (New England Biolabs (NEB) Hitchin, UK) as per
manufacturers instruction, and blots were exposed to ECL film (Amersham
Pharmacia Biotech).
Some Western blots were also run on the larger NuPAGE Surelock™ Mini-cell
(Invitrogen). Samples were prepared by the addition of 4pl loading buffer (0.04%
(w/v) bromophenol blue in glycerol), and samples were centrifuged to mix, and then
20pl of each sample loaded onto gels and run under reducing conditions using either
10% or 4-12% gradient Bis-Tris precast gels (Invitrogen) and either NuPAGE® lx
MES or lx MOPS running buffer (Invitrogen) at 200V for 1 hour. Transfer of
proteins was to PSQ transfer membranes (Immobilon), which were previously
washed, 1 x 1 minute in 100% (v/v) methanol, 2x5 minutes in UHP H2O, to remove
residual methanol, and then immersed in lx NuPAGE transfer buffer (Invitrogen)
containing 10% (v/v) methanol. Following separation, the gel was placed on the
membrane and transfer of proteins carried out using X Cell II blot module
(Invitrogen) at 30V for up to 2 hours. Gels were stained using Colloidal Coomassie
Blue stain (Invitrogen).
Densitometric analysis of ECL images from Western blots was carried out using a
flat bed scanner and the ScanAnalysis program (Biosoft, Cambridge, UK).
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MALDI-TOF mass spectrophotometry
Bands visualised by Colloidal Coomassie Blue were cut from these gels and sent for
MALDI-TOF mass spectrometry "fingerprinting", carried out by the Edinburgh
Protein Interaction Centre (EPIC) centre (University of Edinburgh, Swann Building,
Kings Buildings, Edinburgh, UK.).
Protein searches were made in both Swissprot and NCBI protein databases for
candidate proteins. Likely matches were identified on the following criteria: the
number of peptides matched; extent (%) of sequence coverage; the molecular weight
search (MOWSE) score (Pappin et al., 1993); and the molecular mass of the protein
identified. "Matched peptides" is a measure of the number of peptides from the
digest that are matched to database listings of peptides known to result from
digestion of the particular protein. The percentage coverage is the "matched
peptides" expressed as a percentage of the total protein sequence. For proteins under
lOOkDa, a minimum of 20% is generally required. The MOWSE score is a number
providing a probability value for a potential hit, as first described by Pappin (Pappin
et al., 1993). The higher this number, the greater is the likelihood of a correct
identification. Although MOWSE score does not take account of relative peak
abundance, it does provide reliability weightings for the results based on variability




Cells were plated out into 12 well plates (1x10s cells/well), and 24 hours later
transfected with plasmids containing the cDNA for proteins or peptides of interest.
18 hours prior to experiment, cells were labelled with [3H]palmitate (specific activity
47.5 Ci/mmol) (Perkin Elmer Biosciences, Hounslow, UK) (1.5 pCi/well) and
deprived of Ultra Ser-G (USG), synthetic serum, or normal calf serum by
transferring to DMEM (1 ml per well). After washing once in 0.75 ml MEM
containing HEPES (25 mM, pH 7.5) (Gibco Life Technologies) with 1% (w/v) fatty
acid-free bovine serum albumin, cells were preincubated for 20 min in 1 ml MEM
containing HEPES (25 mM, pH 7.5) with 0.5% fatty acid-free bovine serum
albumin. Various inhibitors or antagonists were added up to 20 minutes before the
addition of butan-l-ol (30 mM). The butanol was added immediately prior to the
cells being incubated for the appropriate time period in various concentrations of
appropriate agonist (5-hydroxytryptamine or carbachol). Reactions were terminated
by removal of MEM medium and cells being scraped into 0.5 ml ice-cold methanol.
Phospholipids were extracted by placing the contents of each well into 2 ml vials
(Chromacol, BDH), and adding to each vial 500 pi chloroform and 400 pi distilled
water to give a final ratio of methanol/chloroform/water of 1:1:0.8 by volume. Vials
were thoroughly mixed by vortex, and centrifuged (5000g, 20 min, RT) (Jouan RC
10.22 centrifugal evaporator; Jouan) to allow the sample to separate into aqueous and
organic layers. The upper aqueous layer was removed, and 250 pi of the non¬
aqueous layer was transferred into a separate Chromacol vial, and centrifuged
(5000g, 30 min, 30°C) under vacuum conditions, to ensure the evaporation of the
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sample carrier. The sample was dissolved in 50 p.1 in a mix of chloroform and
methanol (19 parts CHCI3: 1 part CH3OH).
The samples were separated on Whatman LK5D thin layer chromatography silica
plates (Whatman, Maidstone, Kent, UK) with the solvent being the organic phase of
a mixture of ethyl acetate/ 2,2,4-trimethylpentane/acetic acid/water in the ratios of
110:50:20:100. The area corresponding to the [3H]phosphatidyl butanol
([3H]PtdBut), which had been previously identified using iodine staining of
phosphatidyl butanol standard (Avanti Polar Lipids, USA), was scraped from the
plates in 6 x 0.5 cm bands. Each band was placed into a miniature 6 ml polyethylene
vial (Packard Bioscience) and 4 ml of Emulsifier-Safe LSC cocktail (Packard
Bioscience) added. Samples were thoroughly mixed, and counted (4 min count per
sample) on a Beckman LS 5801 Series scintillation counter (Beckman).
Phospholipase C assays
Cells were plated out into 12 well plates (lxl05 cells/well), and 24 hours later
transfected with plasmids containing the cDNA for proteins or peptides of interest.
18 hours before the experiment, cells were deprived ofUSG by transferring to
Earle's Balanced Salt Solution (EBSS) containing 10 mM HEPES (pH 7.5) and
0.18% glucose (w/v) (37°C, in an 5% CC>2/95% O2 environment), and labelled with
[3H]inositol (specific activity 25 Ci/mmol) (Perkin Elmer Biosciences) (0.75
pCi/well). The medium was changed for EBSS containing 10 mM HEPES, 0.18%
(w/v) glucose and 0.2% (w/v) bovine serum albumin and washed once in the same
medium. Cells were preincubated for 20 min with 10 mM LiCl, before being
incubated for 30 min with various concentrations of 5-HT. Reactions were
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terminated by the removal of medium and the addition of 1 ml ice cold 10 mM
formic acid (Almaula et al., 1996; Bohm et al., 1997) and the cells were left on ice
for at least an hour to ensure lysis. [3H]Inositol phosphates ([3H]InsP) were separated
following addition to a 1 ml Dowex anion exchange resin (1x8 resin, formate form,
200-400 mesh) (Bio-Rad). A stepwise gradient of ammonium formate/formic acid
was used to separate and then elute the [3H]InsPs as previously described (Berridge
et al., 1983). The samples in the columns were washed with 15 ml UHP water, then
by 5 ml of 50 mM ammonium formate. The [3H]InsPs were eluted by addition of 10
ml of 1 M ammonium formate/0.1 M formic acid to the column, and collected in
scintillation vials (Zinsser Analytic GmbH). The columns were regenerated by the
addition of 5ml 2 M ammonium formate/0.1 M formic acid, and washed through
with 15 ml UHP water.
500 p.1 of collected eluates were distributed into miniature 6 ml polyethylene vials
(Packard Bioscience), two for each sample, and 4 ml of Emulsifier-Safe LSC
cocktail for aqueous samples (Packard Bioscience) added. The samples were shaken
briefly, and left overnight, before being counted (4 min count per sample) on the
Beckman LS 5801 Series scintillation counter (Beckman).
Data Analysis
All values were expressed as mean ± standard error of mean (SEM) from data
obtained from a number (n) of individual experiments. Statistical analyses were
carried out using the Wilcoxon test unless otherwise stated. The concentration of
drug which could produce 50% of the maximum response (EC50 value) and the
concentration of inhibitors which inhibit 50% of a stimulus-evoked response (IC50)
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were assessed by fitting the data with a non-linear, error weighted, iterative curve
fitting programme, Fig.P (Biosoft, Cambridge, UK), using the logistic Hill equation.
In the case of signalling experiments, when an experiment has been said to have been
repeated n times, each experiment has been repeated from the stage of transfection of
cells with appropriate plasmids onwards. In the case of pull down assays, each
repeat of an experiment was repeated from the stage of plasmid transduction
onwards.
In Glutathione Sepharose pull-down assays for the GST-5-HT2 constructs,
normalisation of data was achieved by taking a ratio of the GST-construct present in
each blot to the amount of protein binding (e.g. ARF-HA or PLD-HA) present, both
being measured by chemoluminescence. This gave a figure, which would take into
account small fluctuations in GST-construct levels across the different columns of
each experiment. Within each experiment, the binding to the wild type GST-5-
HT2Act construct was taken to be 1, and the binding of proteins to the other
constructs compared to this value, this allowed for direct correlations to be made
between different experiments. The extent of proteolytic cleavage of the GST
constructs following isolation was shown to have no effect on the interpretation of
the results gleaned by this comparison.
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Chapter 3:
The interaction of the small G protein ARF with domains of
the M3 muscarinic receptor
Introduction
It has been previously shown that a number of the family R (group I) GPCRs can
signal through non-trimeric G protein pathways to stimulate downstream effectors, in
particular PLD. PLD activation has also been shown upon G-protein mediated
responses after agonist stimulation of muscarinic receptors (Martinson et al., 1990;
Sandmann et al., 1991; Nieto et al., 1994; Schmidt et al., 1994). PLD can be
activated via PKC, protein tyrosine kinase, PI 3-kinases, and possibly by the
elevation of intracellular Ca2+ levels (reviewed in Exton, 1999). The activation of
PLD by tyrosine kinases has been shown in many studies as a product of the
activation of growth factor receptors which have an intrinsic tyrosine kinase activity
(Rydzewska and Morisett, 1995; Natarajan et al., 1997). For example PLD2 (but not
PLD1) was seen to form a complex with the EGF receptor, and was tyrosine
phosphorylated upon receptor activation (Slaaby et al., 1998). Tyrosine kinase
activation of PLD has also been shown following activation of insulin receptors
(Shome et al., 2000; Slaaby et al., 2000) and receptors for the T-cell antigen of mast
cells (Exton, 1997) as well as in several other cell systems (e.g. PLD activation by
thrombin in human platelets, by vasopressin or TPA in rat fibroblasts, PGDF in A10
smooth muscle cells. Reviewed in Natarajan et al., 1996).
The best established signalling pathway for the M3 muscarinic receptor is via the
heterotrimeric G protein Gq/n leading to activation of PLC. Almost every GPCR that
is known to activate PLC also activates PLD, and indeed 4 muscarinic receptor
isoforms have been shown to activate PLD in HEK cells (Mm). However in the case
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of both the Mi and M3 receptor-mediated stimulation of PLD, this activation may be
independent of PLC activation, as inhibition of PLC activation by neomycin does not
drastically change the PLD response in the same cells (Sandmann et al., 1991).
When activation of PLD does occur via PLC, this may be due to several signalling
events caused by these receptors. The cellular signals generated by PLC activation
are expected to lead to activation of protein kinase C (PKC), which is known to
activate PLD. Diacylglycerol will directly activate PKC isoforms, and inositol 1,4,5-
triphosphate will cause Ca2+ mobilisation and therefore further stimulate the Ca2+-
dependent PKC isoforms a, (3 and y (Exton, 1997; Rumenapp et al., 2001). The
possibility of PLD being activated directly by Gq cannot be ignored, however there
is no evidence to suggest this might be the case. The small G proteins ARF and
RhoA have been implicated in PLD activation by the M3 receptor in HEK cells
(Rumenapp et al., 1995; Schmidt et al., 1997), and indeed stimulation of the M3
receptor in 1321N1 cells and in transfected COS7 cells has been suggested to
activate PLD through the more direct pathway of activation of the small G proteins
of the ARF and Rho families, in a trimeric G protein-independent manner (Mitchell
et al., 1998). Furthermore, PLD responses elicited by U46619 (an agonist of the
native thromboxane A2 (TP) receptor which is present in to 1321N1 cells) and PMTx
(Pasturella multocida toxin, which was been shown to cause a concentration-
dependent and Gq/n-mediated activation of PLC) have been shown to be inhibited by
the PLC inhibitor U73122 in 132IN 1 cells, suggesting an indirect PLC-dependent
route of activation. In contrast carbachol-induced activation of the M3 receptor in
these cells (and in COS7 cells transfected with the M3 receptor) is unaffected by
U73122, suggesting that the route of activation here is not reliant on the classical
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Gq/i i coupling to PLC (Mitchell et al., 2003). Alternative pathways of PLD
activation by the M3 receptor may play a greater role in other cell types, depending
on the relative expression of different components
ARF and Rho have each been implicated in M3 receptor-mediated PLD activation in
particular cell types. However the exact role of the ARF family of small G proteins
has not been fully investigated. To further investigate the activation pathway of PLD
activation via ARF, a variety of approaches were taken, including the use of assays
of phospholipase D (PLD) and phospholipase C (PLC) activity for the M3 muscarinic
receptor expressed endogenously in 132 IN 1 human astrocytoma cells, and
heterologously in COS7 cells. It has been previously shown that the py subunit of
trimeric G proteins, but not the Ga (Wu et al., 1998) and the G protein receptor
kinase GRK2 (Wu et al., 1998) can both bind to the 3rd intracellular loop of the M3
and M2 muscarinic receptors. Therefore to investigate the ability of the ARF protein
to bind to the M3 receptor in vitro glutathione S-transferase pull-down assays using
specific domains of the M3 muscarinic receptor were carried out. Further
experiments then explored the possibility that the additional presence of GPy might
influence the efficiency of ARF binding to domains of the M3 receptor.
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Results
The role of ARF1 and ARF6 in PLD activation by the sFM3 receptor
expressed in COS7 cells
In order to elucidate which ARF isoforms were mediating the M3 receptor response,
experiments using both native M3 receptors in 1321N1 cells and the signal sequence
FLG-tagged M3 receptor construct (sFM3) transfected into COS7 cells were carried
out. To elicit a response from the M3 receptor, the muscarinic agonist carbachol was
used. Carbachol is not selective for the M3 subtype of muscarinic receptor, however,
no PLD or PLC response to carbachol by COS7 cells was elicited in the absence of
the transfected SFM3 receptor, and there are no other known muscarinic receptors in
the 1321N1 cell line (Wall et al., 1991). In 132IN 1 cells, carbachol caused
concentration-dependent increases in both [3H]PtdBut and [3H]InsP production
(Figure 3.1). The EC50 values for these PLD and PLC responses were similar (10.2 ±
2.0 and 8.1 ± 1.7 pM respectively). In the COS7 cells transfected with SFM3
receptor, carbachol caused concentration-dependent activation of PLD and PLC with
EC50 values of 9.4 ± 2.2 and 1.2 ± 0.1 pM respectively (Figure 3.2). Brefeldin A
(BFA) is an inhibitor of one subclass of ARF-GEFs (BIG1/2), and has been shown to
have relative selectivity to inhibit the activation of ARF1 over ARF6 (Morinaga et
al., 1999). BFA caused a significant inhibition of the carbachol-induced PLD
response in 132IN 1 cells, at both lOpM and 200pM carbachol (showing that ARF-
dependent PLD activation does not only occur at high occupancy of the receptor, and
the linkage to signalling via ARF makes an important contribution at all
concentrations, not only at high doses of agonist). However BFA had no effect on
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the ability of the M3 receptor to activate PLC upon exposure to carbachol (Fig 3.3).
Co-transfection of negative mutant ARF1 or ARF6 constructs, where the site of
GDP-GTP exchange has been mutated to ensure the construct remains in the GDP-
bound form (making the constructs functionally negative for all known functions of
ARFs) caused inhibition of carbachol-induced activation of PLD, but not PLC (Fig
3.2). Both T31N-ARF1 and T27N-ARF6 caused significant inhibition of carbachol-
induced PLD activation throughout the concentration-response curve (Fig. 3.2b).
The co-transfection of wild type ARF1 or ARF6 had no significant effect on the
activation of PLD by carbachol stimulation of the SFM3 receptor (Figure 3.2b). None
of the ARF constructs significantly modified basal PLD activity (Figure 3.2b and
data not shown). In cells transfected with the SFM3 receptor alone, 200 pM
carbachol caused 5.18 ± 0.50 fold of basal [3H]PtdBut production, whereas co-
transfection with T31N-ARF1 gave a 2.80 ± 0.21 fold response, co-transfection with
T27N-ARF6 gave a 3.26 ± 0.48 fold response and co-transfection with a
combination of the ARF 1/6 mutant constructs resulted in a 1.68 ± 0.28 fold response
(n=8) (Fig. 3.4). Where various constructs were omitted from the transfections,
empty vector was used in substitution. The negative mutant ARF values were
significantly less than responses to carbachol alone and the combination showed a
further significant reduction due to the interruption of activation of PLD by each of
the individual isoforms of ARF. A small residual component of SFM3 receptor-
-5
mediated [ HJPtdBut production remained in the presence of both T31N-ARF1 and
T27N-ARF6 (Fig 3.4).
Figure 3.4 also illustrates the BFA-sensitivity of carbachol-induced [3H]PtdBut
production with or without the negative mutant ARF 1/6 constructs present. Controls
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showed inhibition of responses by BFA with an IC50 of 64.1 ± 16.3 pM. The
remaining PLD activation in the presence of T27N-ARF6 remained sensitive to BFA
with an IC50 of 29.8 ±17.1 pM. In contrast, the residual responses in the presence of
T31N-ARF1, or both T31N-ARF1 and T27N-ARF6, were no longer reduced by
BFA. This suggests that the SFM3 receptor can utilise both ARF1 and ARF6 for
activation of PLD, but the BFA-sensitivity of the response reflects predominantly a
role of ARF1 (Fig 3.4).
Physical association ofARF1/ARF6 with GST fusion proteins ofsFM3
receptor domains
The question of whether ARF1 or ARF6 could participate in some form of direct
complex with the receptor was investigated by looking for in vitro interactions with
GST-fusion proteins of the M3 receptor i3 and ct domains. These domains were
selected as the most likely candidates because the i3 region is thought to be the site
of key interactions with subunits of heterotrimeric G proteins and the ct region
contains the NPxxY motif that is critical in determining linkage to ARF-dependent
PLD responses (Mitchell et al., 1998). GST constructs of these two domains, the
M3B (G308-L497) and the M3Ct (N540-L590) were attached to glutathione Sepharose
beads, and exposed to cytosolic extracts from COS7 cells enriched with ARF1-HA or
ARF6-HA under conditions that were optimised in previous studies (Wu et al.,
1998). Proteins captured by the fusion protein constructs were removed from this
affinity matrix and separated by SDS-PAGE.
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Figure 3.5 shows the relative sizes of the M3 receptor i3 and ct domain constructs
used in these glutathione S-transferase pull-down experiments, and shows the levels
present in a typical assay. As a positive control, G(3y purified from bovine brain
(Calbiochem) was used, as G(3y has been previously shown to bind specifically to the
third intracellular loop of the M3 muscarinic receptor (Wu et al., 1998; Wu et al.,
2000, Fig 3.6). Figure 3.6 shows that indeed GPy did bind specifically to the GST-
M3G construct, but not to the control GST-BKstrex exon or GST alone. Cytosolic
extracts containing equivalent amounts of ARF1-HA and ARF6-HA were introduced
to assays containing GST constructs of the M3B, M3Ct, BKstrex and GST alone.
ARF1-HA bound specifically to the GST constructs of the 3rd intracellular loop, and
the carboxy-terminal tail domain of the M3 muscarinic receptor (Fig. 3.7a). Both M3
receptor constructs also bound ARF6-HA. ARF6-HA bound well to the GST-M3i3
construct, but bound to the GST-Nfjct with a lower affinity, when compared to a
similar input of ARF1-F1A (Fig. 3.7b). The levels of each GST construct were
shown to be similar by Coomassie Blue staining and by GST-immunoreactivity and
any adjustments needed to ensure fully balanced construct inputs were made on the
basis of comparing the levels of the specific construct bands of interest. These data
are representative of at least 4 separate experiments.
Potential interaction ofARFs and heterotrimeric G protein subunits in
their association with GST-fusion proteins of M3 receptor domains
The question of whether of GPy might have an effect on ARF binding to the M3
muscarinic receptor was investigated because two reports in the literature have
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suggested that ARF can bind directly to GPy subunits, although probably with lower
affinity than to Got subunits (Colombo et al., 1995; Franco et al., 1995b). To
investigate firstly whether any functional evidence could be found to implicate a role
of GPy in ARF-dependent PLD responses, experiments were conducted on cell
signalling responses. The peptide encoding the C-terminal domain of GRK2
(GRK.2495.689) has previously been shown to sequester GPy (Koch et al., 1994) and
has been used effectively to suppress Gpy-mediated signalling responses in cells.
The plasmid encoding the GRK2495-689 peptide was transfected into COS7 cells in the
presence of the sFM3 receptor, and assays of PLC and PLD activity were used to
determine the effect of the GRKct peptide on carbachol-induced activation of PLD.
The peptide had no effect on the ability of the SFM3 receptor to activate PLC (Fig.
3.8a). The ability of the sFM3 receptor to activate PLD in the presence of the
GRK2495.689 peptide was inhibited to give a reduced maximal response, and the
extent of the reduction was similar to the inhibition caused by lOOpM BFA (Fig.
3.8b). The PLD activity remaining in the presence of the GRK2495.689 peptide was
shown to be BFA insensitive (Fig 3.8c), suggesting that the GRK2495.689 peptide may
be blocking the activation of PLD via ARF1.
The ability of G(3y to directly contribute to the mechanism of ARF activation of PLD
was further investigated in vitro by comparing binding of ARF (with or without G(3y
present) to GST-fusion protein constructs of the 3rd intracellular loop and the
carboxyl terminal tail domains of the M3 receptor. GST constructs were incubated
with equivalent amounts of ARF1-HA and ARF6-HA in either the presence or
absence of GPy. The HA-tagged ARFs were supplied as cytosolic extracts from
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C0S7 cells transfected with these constructs and the G(3y was purified from bovine
brain (Calbiochem) and used at a concentration of 30nM. Figure 3.9a shows the
effects of GPy on the binding of ARF1 to the M3 receptor constructs. In the case of
both control constructs, GST-BKstrex and GST alone, there was no apparent
difference in the basal binding of ARF1-HA due to the addition of Gpy. In the case
of both the GST-M3i3 and GST-lVbct construct, the addition of 30nM GPy clearly
increased the ability of ARF1-HA to interact with both receptor domains. In the case
of ARF6-FIA, the addition of GPy had no apparent effect on the ability of ARF6-HA
to bind to the control constructs, and only a slight increase of ARF6-HA binding to
the GST-M3Ct construct was seen (however, the basal level of binding of ARF6-HA,
in the absence of GPy, to the ct construct was lower than that to the M3B). The
ability of ARF6-HA to bind to the M3B construct was however clearly increased in
the presence of GPy. The data shown in figure 3.9 are representative of 3 separate
experiments.
It has previously been shown that Gotq/i 1 does not bind directly to either the M2B or
M3i3 receptor domains in a manner that shows lasting association (Wu et al., 1998).
However, the effect of addition of Gaq/n on the binding of ARF1-HA and its
facilitation by GPy was investigated here by addition of cytosolic extracts from
COS7 cells over-expressing ARF1-HA to glutathione S-transferase pull-down assays
containing the M3 receptor i3 in the presence of either GPy, Gaq/n or both. No
binding of Gaq/i |-HA was seen to the M3B receptor domain construct (data not
shown). The introduction of Gaq/n led to a decrease in the basal level of binding of
ARF1-HA to the M3G (Fig. 3.10), this may well be due to the Gaq/n binding to free
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cytosolic G(3y, and therefore diminishing the ability of this free cytosolic G(3y to aid
ARF1-HA binding to the GST-M3i3. The addition of Gaq/n and GPy together had an
intermediate effect, between that of ARF1-HA alone and that of GPy alone (Fig.
3.10). The ability of Gaq/n to modulate the binding of ARF1-HA in the presence of
GPy cannot be defined in more exact terms here because the experimental setup
makes it not possible to add Gaq/n, which was in cytosolic extract, and therefore of
an undefinable amount, in stoichiometric levels to GPy, which was purified and
added amounts could be calculated exactly (30 nM was added to each column in
these experiments). Figure 3.10 is representative of 3 individual experiments.
The role of GPy was further investigated by examining the participation of GRK2 in
the M3i3:ARFl :GPy complex. It has been shown previously that GPy can interact
with GRK2 to mediate the binding of the kinase to the M3 receptor (Koch et al.,
1993). To investigate whether this interaction might inhibit or aid the binding of
ARF1 to the M3B domain, pilot glutathione S-transferase experiments were carried
out where ARF1-HA binding was attempted in the presence of GRK2, and GRK2
and GPy. It was observed that the ability of ARF1-HA to bind to the 3rd intracellular
loop of the M3 receptor was increased in the presence of GRK2, and a further
increase was seen in the presence of GRK2 and GPy (Fig 3.11). These observations
suggested that the presence of GRK2 could further augment ARF1-HA binding to
the MpB-GST-fusion protein but were not pursued further because of the difficulty in
achieving precisely balanced inputs of a range of different reagents which would be
necessary to make formal comparisons using this approach.
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Discussion:
A brefeldin A-sensitive route of PLD activation for the M3 receptor and
some, but not all other family R GPCRs:
The M3 muscarinic receptor shows BFA-sensitive activation of PLD when expressed
as a native receptor in 132IN 1 cells (Mitchell et al., 2003) or heterologously in
COS7 cells. Time-course experiments have shown a rapid desensitisation of M3
receptor PLD and PLC responses in 132IN 1 cells (Nieto et al., 1994; Mitchell et al.,
2003). The addition of BFA led to no change in the activation of PLC by carbachol,
but in the presence of BFA, the initial rate and maximal extent of the PLD response
was diminished although the profile of desensitisation remained the same, therefore
the mechanism of activation of PLD is not involved with the mechanism for
desensitisation of the receptor (Mitchell et al., 2003). In contrast, it has been shown
that the PLD responses of several other family R GPCRs, for example the TP
receptor in 132IN 1 cells, as well as the P2U receptor and N376D-mutant 5-HT2A
receptor in COS7 cells, are BFA-insensitive (Mitchell et al., 2003). These receptors
differ from the M3 receptor in that they contain a DPxxY sequence in the carboxy-
terminal tail, whereas the M3 receptor contains an NPxxY motif. BFA inhibited M3
receptor PLD responses in 1321N1 and COS7 cells with IC50 values around 50 pM.
BFA-sensitivity of M3 receptor PLD responses in HEK 293 cells has been reported
previously, but with some 2-3 fold lower potency (Rumenapp et al., 1995) as we
confirmed in transiently transfected HEK 293 cells (IC50 of 157 ± 23 pM, n=4). The
lower potency in HEK 293 cells may reflect greater involvement of an alternative
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tyrosine kinase-dependent pathway (Schmidt et al., 1994). The PLD responses of
angiotensin II type 1A and ET-1 receptors were strongly inhibited by BFA in A10
smooth muscle cells, (Shome et al., 2000), whereas fMLP and ATP receptor
responses in differentiated HL60 cells, and bradykinin and sphingosine 1-phosphate
receptor responses in A549 adenocarcinoma cells, were not (Guillemain and Exton,
1997; Meacci et al., 1999). The extent to which a GPCR demonstrates BFA-sensitive
PLD responses in different cell types may well be influenced by the cellular
expression of the various pathway components. The concentrations of BFA that
selectively inhibit M3 receptor PLD responses here exceed those needed to disrupt
the integrity of Golgi membranes (Donaldson et al., 1990; Guillemain and Exton,
1997; Meacci et al., 1999), but are similar to those that inhibit the ARP-GEFs, BIG1
and BIG2 (Morinaga et al., 1999). However, the cell surface expression of the M3
receptor has been shown to be unaffected at this concentration of BFA (Mitchell et
al., 2003), as has the ability of the receptor to signal through PLC. Furthermore, the
subcellular location of carbachol-induced [3H]PtdBut production in SFM3 receptor-
containing COS7 cells has been shown to be predominantly in the plasma membrane
fraction and furthermore, while the response involved a movement of both PLD1 and
ARF1 to this site, the translocation of these proteins was not prevented by BFA
(Mitchell et al., 2003). Therefore the effects of BFA on PLD responses of particular
receptors appear to be the result of a specific inhibition of the signal transduction
pathway rather than a general disruption of protein trafficking.
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ARF1 and ARF6 involvement in PLD activation by the sFM3 receptor,
but not other GPCRs:
There are 3 subtypes of the ARF family. The two main classes of cellular ARFs are
exemplified by ARF1 and ARF6, which are thought to have characteristically
distinct subcellular distributions. The Group II ARF subtype is exemplified by
ARF5, however very little is known of the functions of ARF5, and no link has been
made to the activation of PLD by ARF5 in vivo. This being said, recent evidence has
suggested that another of the group II ARF isoforms, ARF4, can bind to the ct
domain of the rhodopsin receptor (Deretic et al., 2005). The role of different
subtypes of ARF in SFM3 receptor PLD activation was investigated by co-
transfection with the SFM3 receptor of either wild type ARF1 or ARF6, or their
dominant-negative constructs, T31N-ARF1 and T27N-ARF6 (Peters et al., 1995).
Neither wild type ARF construct had a significant effect on PLD activation by
carbachol, suggesting that the cellular levels of endogenous ARFs are probably not a
limiting factor. However, dominant-negative ARF1 and ARF6 constructs each
inhibited PLD responses without modifying PLC responses. Effects of negative
mutant ARF1 and ARF6 in combination were cumulative, suggesting that the two
ARF isoforms might each play a distinct role. Although negative or positive mutants
of ARFs can disrupt Golgi and other vesicular trafficking (Peters et al., 1995;
D'Souza-Schorey et al., 1998; Beraud-Dufour and Balch, 2001; Donaldson and
Radhakrishna, 2001; Kuai and Kahn, 2002) it has been shown that neither the levels
of specific cell surface binding sites for [3H]oxotremorine-M (an M3 receptor ligand)
(Mitchell et al., 2003) nor sFM3 receptor PLC responses were affected by the ARF
constructs. Similarly, the abilities of the angiotensin II and ET-1 receptors to
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stimulate PLD responses in A10 cells were inhibited by both T31N-ARF1 and
T27N-ARF6 constructs (Shome et al., 2000). In contrast, the responses of two
DPxxY-containing receptors, the P2U receptor and the N376D-mutant 5-HT2A
receptor were unaffected by T31N-ARF1, but were clearly inhibited by T27N-ARF6
and PKC inhibitors (P2U receptor) or by PKC inhibitors (N376D-mutant 5-FIT2A
receptor)(Mitchell et al., 2003). This suggests that ARF6 and PKC may be important
in alternative pathways that underlie the BFA-insensitive [3H]PtdBut production seen
with some GPCRs. The presence of dominant-negative ARF1 significantly decreased
the BFA-sensitive activation of PLD upon carbachol stimulation. However, the
addition of dominant-negative ARF6 did not affect the ability of BFA to inhibit the
remaining PLD response after carbachol stimulation. This suggests that an ARF1-
dependent pathway from the receptor, probably involving the BFA targets, BIG 1/2,
is responsible for the BFA-sensitivity. Correspondingly, it has been shown that
BIG1/2 can act as effective, BFA-sensitive, ARF-GEFs for ARF1 but not ARF6
(Morinaga et al., 1999) and that in vivo functional effects of ARF6 are often BFA-
insensitive (Frank et al., 1998; Franco et al., 1999). In the case of the SFM3 receptor
in COS7 cells, the PLD response seems to be mediated by ARF1 through a BFA-
sensitive pathway, and by ARF6 in a BFA-insensitive manner.
Physical association of both ARF1 and ARF6 with the M3 receptor
through the i3 and ct domains:
Immunoprecipitation experiments carried out in the lab to determine the ability of
wild type ARFl-HA and ARF6-HA to bind to the SFM3 muscarinic receptor in COS7
cells showed that low levels of ARFl-HA and ARF6-HA were associated with the
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sFM3 receptor under basal conditions, while the amount of associated ARF1-HA but
not ARF6-HA clearly increased when cells were incubated with carbachol (Mitchell
et al., 2003). In an alternative immunoprecipitation procedure where sFM3 receptor
association with ARF1-HA/ARF6-HA was measured as ['H]NMe-QNB binding, low
levels of basal co-immunoprecipitated binding sites were observed, but increased
association of the sFM3 receptor with ARF1-HA and to a lesser extent ARF6-HA
was revealed following carbachol stimulation (Mitchell et al., 2003).
Based on this evidence, GST-fusion proteins were used here to further investigate the
interaction of ARF1 and ARF6 with the M3i3 and M3ct receptor domains. The
carboxy-terminal tail of the receptor contains the NPxxY motif which has been
shown to influence the ability of the family R GPCRs to activate PLD through an
ARF1-dependent pathway (Mitchell et al., 1998), making the ct domain a candidate
for direct ARF interaction. However, the ct of the M3 receptor is relatively short, at
only 43 amino acids. The third intracellular loop of the M3 receptor is much longer
in comparison (239 aa), and is known to contain sites for interaction with
heterotrimeric G proteins, arrestins, GPy and the kinases GRK2 and CKl-a (Wu et
al., 1997; Budd et al., 2000; Wu et al., 2000). It has been shown previously that i3
domain splice variants of the PAQ receptor show marked differences in their BFA-
sensitive activation of PLD but not other signalling responses (McCulloch et al.,
2001) suggesting that M3i3 may potentially contribute part of the binding interface
for ARF docking to the receptor, along with the M3ct. Indeed specific binding of
each ARF was demonstrated to the M3i3 GST-fusion protein, and also to the M3ct
GST-fusion protein, with ARF6-HA binding to a lesser extent than the ARF 1-HA to
the M3ct. No binding of either ARF was observed to the control constructs.
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Role of G(3y modularity in the binding ofARF1 and ARF6 to M3 receptor
domains:
It has been previously shown that there is a direct interaction between the third
intracellular loop of the M3 receptor and purified G-protein [3y subunits (GPy), but
not with the Ga subunit (Wu et al., 1998; Wu et al., 2000), and that Gpy acts as an
apparent docking module for the kinase GRK.2 through the PH domain within the
GRK2ct domain (Wu et al., 1998). There is also evidence for a direct interaction
between the small G protein ARF1 and the Gtpy subunit (Franco et al., 1995b),
where ARF1 is recruited to retinal membranes, and to isolated phospholipid
membranes (in its GDP-bound form) by Gpy in the absence of the Gcigdp subunit.
GPy interacts with ARF1 through a sequence in the "switch II" domain of ARF1.
The switch II domain was first described in Ga as an a-helical domain on the
effector binding surface of Ga that may provide a GDP-dependent binding site for
GPy (Conklin and Bourne, 1993). This domain consists of 2 flexible loops, and
undergoes a dramatic conformational change between GDP and GTP-bound states,
where in the GTP bound form, the a2 helix binds tightly to the a3 helix of the same
domain of Ga (Lambright et al., 1994). It has been shown that there is some
sequence homology between the ARF1 switch II domain and that of the Ga subunit,
particularly in the a2 helix, which has a conserved RxxWxxxF sequence
(RxxWxxxF211 in Ga; RxxWxxxF81 in ARF1 and ARF5; RxxWxxxY76 in ARF6).
The RxxWxxxF motif does not exist in the small G-protein Ras, and indeed it has
been shown that Ras does not bind GPy under similar conditions (Franco et al.,
1995b). This sequence may be an analogue of the PH (Pleckstrin homology) domain
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which also contains the RxxWxxxI sequence, and has been shown to be present in
many signalling proteins, some of which bind GPy (Touhara et al., 1994; Franco et
al., 1995b). With this in mind, the question of whether GPy may affect the binding
of ARF1 and ARF6 to the M3 receptor domain constructs was investigated.
Assays of cellular PLD and PLC activity showed that the GPy-sequestering agent
GRK.2495-689 (Eichmann et al., 2003) had no effect on the M3 muscarinic receptor's
ability to activate PLC. Flowever, the same agent decreased the ability of the M3
muscarinic receptor to activate PLD to an extent similar to that caused by the ARF-
GEF inhibitor, BFA. It has also been shown that in the presence of the GRK2495.689
construct, BFA did not reduce the residual PLD response, revealing the presence of a
BFA-insensitive (possibly ARF6-mediated) component to carbachol-induced PLD
activation. These data show that GPy increases the ability of ARF1 to bind to both
the M3i3 and PvLct GST constructs, and also increases the binding of ARF6 to the M3
receptor domain constructs, although the effect on the binding of ARF6 to the IVLct
did not appear to be as marked.
Several reports indicate that the G-protein receptor kinase GRK2 interacts with the
3rd intracellular loop of the muscarinic receptors (Kameyama et al., 1993; Nakata et
al., 1994; Haga et al., 1996) including the M3 receptor (Debburman et al., 1995; Wu
et al., 1998), and binds to the Py subunits of trimeric G proteins, through the PH
domain at the carboxy-terminal end of GRK2 (Koch et al., 1993; Carman et al.,
2000). It has been shown here that the GRK2495-689 peptide, which codes for the
carboxy-terminal domain of GRK2 can be used to block the activation of PLD
through ARF1 upon stimulation of the M3 receptor. However, it is unclear whether
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this is due to any direct blocking of the ability of Gpy to bind to ARF1, or if it was
due to the inability, following G0y sequestration, of the cells to form the correct
complex of proteins to ensure ARF1 activation of PLD. Figure 3.11 shows that both
GPy and GRK2 act in a distinct facilitatory fashion to increase the ability of ARF1-
HA to bind to the GST-M3B construct. This suggests that an active complex of GPy,
GRK2 and ARF1 may be formed upon agonist activation of the M3 receptor, through
which the activation of PLD is achieved. The variety of binding sites on GPy for
ARF/Ga.q/n, GRK2 and other partners (for example the adenylyl cyclases AC1 and
AC2 (Chen et al., 1997)) suggest that GPy may be a vital partner in this complex,
and may act to recruit ARF1 and GRK2. However, the activation of PLD via ARF
upon M3 muscarinic receptor activation by carbachol appears to be independent of
activation of the trimeric G proteins, at least in 132 IN 1 and COS7 cells. The
detailed mechanisms of how this complex is brought about, in what order the
proteins are recruited, and indeed, if they are all necessary for activation of the PLD
pathway in vivo, will therefore be targets for future study.
In conclusion, the present experiments describe an ARF-dependent activation of PLD
by the M3 muscarinic receptor that appears to be essentially independent of
conventional routes of GPCR signalling. Instead, both ARF1 and ARF6 can associate
physically with the receptor, as shown by GST-fusion protein experiments, and both
may have a role in the carbachol-induced activation of PLD by the M3 receptor, as
shown by the use of dominant negative constructs of ARF 1/6. The range of GPCR
motifs and cellular factors that determine receptor selectivity for these different
pathways of PLD activation remain to be determined, however the G(3y subunit (and
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possibly also the docking of GRK2) has been shown to increase the ability of




Carbachol-induced PLC and PLD responses mediated by native M3 receptors in
1321N1 cells
The data show the concentration-dependence of [3H]PtdBut (PLD) responses (•) and
[3H]InsP (PLC) responses (■) elicited by the cholinergic receptor agonist carbachol
in 132IN 1 human astrocytoma cells which natively express the M3 muscarinic
receptor, but not any other muscarinic or nicotinic subtype of cholinergic receptor.
Carbachol elicited concentration-dependent responses of PLC and PLD with similar
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Figure 3.2
PLD and PLC responses of the sFM3 receptor transfected into COS7 cells and
the effects on these of wild type and dominant negative constructs of ARF1 and
ARF6
COS7 cells were co-transfected with sFM3R and a range of ARF constructs,
including the wild type ARF1-HA, wild type ARF6-HA, and the dominant negative
forms T31N-ARF1-HA and T27N-ARF6-HA. The control (•) dose response curves
showed EC50 values for PLC and PLD activation to be 1.2 ± 0.1 and 9.4 ± 2.2 pM
respectively. In the case of the [3H]InsP (PLC) responses (3.2a), none of the ARF
constructs (ARF 1-HA (■), ARF6-HA (A), T31N-ARF1-HA (A) or T27N-ARF6-
HA(A)) showed any consistent deviation from the response of the control (•)
experiments (sFM3R plus empty pcDNA3 plasmid). In the [3H]PtdBut production
(PLD) response experiments, (3.2b), wild type ARF 1-HA (■) and wild type ARF6-
HA (A) did not cause any apparent difference from responses in the presence of the
control vector (•). However, in the presence of the negative mutant forms of both
ARF 1-HA (□) and ARF6-FLA (A), the ability of the sFM3R to activate PLD was




Dominant negative constructs of ARF1 and ARF6
inhibit PLD but not PLC responses of the sFM3R






























EC50 and Emax values for PLC and PLD responses of the SFM3R in transfected
COS7 cells
Table 3.1 a shows the EC50 and Emax values for the PLC response of the SFM3
receptor in COS7 cells, as shown in figure 3.2a. The table also shows the same
values in the presence of the negative mutant forms of ARF1 and ARF6. There is no
significant difference in these values in the presence of the mutant ARF isoforms
when compared with the control. The results shown on this table are from a total of
6 separate experiments.
Table 3.2 b shows the same values for PLD activation, as shown in figure 3.2b. The
table shows values for control (•) experiments, as well as with additional wild type
ARF1 (■) and ARF6 (A), and mutant forms of ARF1 (□) and ARF6 (A). Values
could not be obtained for EC50 and Emax for PLD responses in the presence of mutant
ARF1 (□) due to the fact that a sigmoid curve fit could not be determined as no clear
maximum was reached with the concentrations of carbachol used, however, the Emax
value for PLD response in the presence of ARF6 (A) was significantly less than the




ECso and Emax values for PLC and PLD responses of the sFM3R in transfected
COS7 cells
a PLC response
ECso (nM) Emax (fold of basal)
control (•)
1.21 ±0/11 3.60 ±0.33
A' ARF 1 (□) 0.90 ±0.23 3.74 ±0.42
A ARF6 (A) 0.77 ±0.28 3.35 ±0.40
b PLD response
ECso (nM) Emax (fold of basal)
control (•)
9.2 ±2.2 4.890± 0.45
wild type ARF 1 (■) 5.1 ±3.2 5.46 ±0.60
wild type ARF6 (A) 5.7 ±3.6
4.98 ±0.49
A" ARF 1 (□) nd nd
A" ARF6 (A) 10.8 ±2.9 3.04 ±0.29*
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Figure 3.3
Effects of brefeldin A (BFA) on carbachol-induced PLD and PLC responses in
1321N1 cells
This figure shows the concentration-dependence of BFA effects on PLD responses to
200 pM carbachol (•) and 10 pM carbachol (A) as well as PLC responses to 200
pM carbachol (O) in 132IN 1 cells. BFA caused statistically significant inhibition of




Effects of brefeldin A on carbachol-induced PLD
and PLC responses in 1321N1 cells
Figure 3.4
Effects of dominant negative ARF1 and ARF6 constructs on the brefeldin A
(BFA) inhibition of carbachol-induced PLD responses of the SFM3 receptor
transfected into COS7 cells
Shows the concentration-dependence of BFA effects on PLD responses to 200 pM
carbachol in the presence of control vector (•), T31N-ARF1 (■), T27N-ARF6 (A)
and T31N-ARF1 plus T27N-ARF6 (Y). (O) Shows the effects of BFA on PLD
responses of cells transfected with SFM3 receptor, but no ARF constructs, in the
absence of carbachol stimulation. All controls for transfections contained equivalent
levels of empty vector. The carbachol-evoked PLC responses of SFM3 receptor-
transfected cells were unaffected by BFA (data not shown). BFA (50-200 pM)
caused significant inhibition of the PLD responses to carbachol only in the presence
of control vector or of the negative mutant form of ARF6 (p<0.05, Wilcoxon test).
The fact that the presence of T31N-ARF1 but not T27N-ARF6 pre-empts any
inhibitory effect of BFA suggests that BFA inhibition may reflect a contribution of
ARF1 rather than ARF6 in these M3 receptor-mediated PLD responses.
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Figure 3.4
Effects of dominant negative ARF1 and ARF6 constructs on the brefeldin A inhibition of















Brefeldin A concentration (pM)
Figure 3.5
The relative sizes and input levels of GST, GST-BK and GST-M3B fusion
proteins used for pull-down assays with ARF1/6
GST alone, GST-BKstrex and GST-M3i3 constructs were separated on 20%
homogeneous gels, blotted onto PVDF membrane, and incubated with anti-GST IgG,
then HRP linked secondary antibody, before being visualised via enhanced-
chemiluminescence (ECL). Lane 1 is GST protein, lane 2 is GST-BK fusion protein
and lane 3 is GST-M3i3 fusion protein. This shows that GST has a MW of ~29kDa
and that, as would be predicted from the sequences of the inserts in the constructs,
GST-BK has a MW of ~35kDa and GST-M3i3 has a MW of ~49kDa.
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Figure 3.5
The relative sizes and input levels of GST, GST-BK




Purified GPy binds to the GST-M3i3 construct but not GST alone
Purified GPy isolated from heterotrimeric brain G-protein (Calbiochem) (30nM) was
incubated with the control GST or GST-M3i3 constructs. Lane 1 shows GPy as a
positive control, lane 2 shows GST-M3i3 incubated with GPy and lane 3 shows GST
incubated with GPy protein. This illustrates that GPy binds strongly to the M3i3
construct and does not bind to GST protein alone.
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Figure 3.6










ARF1-HA and ARF6-HA bind specifically to both the M3B and M3ct GST-
fusion proteins but not to control constructs
GST-M3i3, GST-M3ct, GST-BKstrex or GST alone constructs were incubated with
equal amounts of ARF1-HA and ARF6-HA. Figure 3.7a shows the ability of ARF1-
FIA to bind to both the GST-M3i3 and the GST-M3ct, but not to the GST-BKstrex or
GST alone. Figure 3.7b shows that ARF6-HA binds to the GST-M3i3, and to a lesser
extent to the GST-M3ct, but not to either the GST-BKstrex or to GST alone.
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Figure 3.7
ARFl-HA and ARF6-HA bind specifically to both the M3i3 and M3ct GST-
fusion proteins but not to control constructs













Effects of the Gpy-sequestering GRK2495.689 construct and brefeldin A (BFA) on
PLD and PLC responses of the SFM3 receptor transfected into COS7 cells
Figure 3.8 also shows the effects of the carboxy-terminal domain of GRK2 on the
ability of the SFM3R to activate PLC and PLD. In these experiments, the addition of
GRK2495-689 had no effect on the ability of the SFM3R to activate PLC (3.8aA).
However, the PLD activation by SFM3R in these COS7 cells was reduced in the
presence of the GRK2495_689 construct (3.8b A).
In these experiments, lOOpJVI BFA had no effect on the ability of the SFM3R to
activate PLC when the receptor was transfected into COS7 cells (3.8a ■) when
compared to control experiments (•), however, the ability of the SFM3R to activate
PLD in COS7 cells in the presence of BFA (3.8b ■) was reduced when compared to
the control experiments (•).
Figure 3.8c shows the effect of BFA on the carbachol-induced PLD response of cells
co-transfected with the SFM3 receptor and the GPy-sequestering agent GRK.2495.689-
Under the control conditions (•), BFA inhibited the carbachol-elicited PLD response
at carbachol concentrations of 50-200|uM (p<0.05 Mann-Whitney U-test). The
response in the presence of the GRK2495.689 (■) was reduced overall, but the
remaining response was then no longer affected by the presence of BFA (O).
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Figure 3.8
Effects of brefeldin A (BFA) and the GPy-sequestering GRK2495_689 construct on
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Table 3.2
ECsoand Emax values for PLD and PLC responses of the SFM3 receptor in
transfected COS7 cells in the presence of BFA and GRK2495.689
Table 3.1a shows the EC50 and Emax values for the PLC response of the SFM3
receptor in COS7 cells, as shown in figure 3.8a. The table also shows the same
values in the presence the GPy sequestering agent GRK.2495.689 (A) and the ARF-
GEF inhibitor BFA (lOOpM) (■). There is no significant difference in these values
in the presence of these agents when compared with the control response. The
results shown on this table are from a total of 6 separate experiments.
Table 3.2b shows the same values for PLD activation, as shown in figure 3.8b. The
table shows values for control (•) experiments, as well as with the addition of
GRK2495.689 (A) and BFA (lOOpM) (■). The Emax value for PLD response in the
presence of both GRK2495.689 (A) and BFA (lOOpM) (■) was significantly less than




EC50 and Emax values for PLD and PLC responses of the SFM3 receptor in
transfected COS7 cells in the presence of BFA and GRK2495.689
a PLC response
EC50 (nM) Emax (fold of basal)
control (•)
0.59 ±0.31 5.40 ±0.58
GRK2495-689 (A) 0.63 ± 0.28 5.22 ±0.27
BFA 100pM(B) 0.98 ±0.33 4.71 ±0.49
b PLD response
EC50 (nM) Emax (fold of basal)
control (•)
2.13 ±0.42 4.76 ±0.55
GRK2495-689 (A) 1.82 ± 0.56 3.01 ±0.40 *
BFA lOOpM (■) 5.76 ±2.91 2.48 ±0.35 *
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Figure 3.9
Effect of Gpy on ARF1-HA and ARF6-HA binding to the Mai3 and Mbct GST-
fusion proteins
Equal amounts of ARF1-HA and ARF6-HA were added to glutathione-Sepharose
columns loaded with GST-BKstrex, GST alone, GST-M3Ct or GST-MhO, in the
presence or absence of Gpy (30nM). In the presence of GPy, the binding of ARF1-
HA to both the GST-M3Ct and the GST-M3i3 constructs was clearly increased, but
not to the GST-BKstrex construct or to GST alone. ARF6-HA showed a similar
increase in binding to the GST-M3i3 construct in the presence of GPy, however the
binding of ARF6-HA to the GST-lVbct construct was not as robust, and any increase
in binding in the presence of GPy is therefore less obvious.
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Figure 3.9
Effect of Gpy on ARF1-HA and ARF6-HA binding to the M3i3 and M3ct GST-
fusion proteins
ARF1-HA association
Bait: BK BK GST GST M3ct M3ct M3ic3 M3ic3
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Figure 3.10
Effect of G(Xq on ARF1-HA binding to the Mji3 GST-fusion proteins with or
without GPy
Figure 3.10 shows a representative image (n= 4) of the extent of ARF1-HA binding
(HA immunoreactivity) to the GST-M3i3 in the presence of purified GPy, Gaq-
enriched COS7 extracts or GPy and Gaq together. Equivalent amounts of transfected
COS7 cytosolic extracts were included to ensure balanced amounts of cytosol were
present in all samples. The lower panel shows the grey-scale density of each band in
this experiment (representing associated ARF1-HA) as measured by Scan-Analysis
(Elsevier software E1K), with the value for ARF1-HA alone taken to equal 1, and the
other bands compared to this.
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Figure 3.10
Effect of Gaq on ARF1-HA binding to the M3i3 GST-fusion protein
Figure 3.11
Effect of GRK2 and GPy on ARF1-HA binding to the M3O GST-fusion protein
This figure shows the effect of the addition of COS7 cells extracts overexpressing
GRK2 as well as the additional influence of purified Gpy (30nM) on the binding of a
submaximal amount of ARF1-HA (from COS7 cell cytosolic lysate) to the M3B
GST-fusion proteins. Input amounts of GRK2-enriched extract were balanced with
COS7 cell extracts from cells containing empty pcDNA3 vector. Figure 3.1 la shows
the binding of ARF1-HA under these conditions to the GST-M3i3 constructs, and
3.1 lb shows binding to the control construct, GST-BKstrex-
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Figure 3.11
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Chapter 4:
The association of ARF and other signalling proteins with
domains of the 5-HT2a receptor.
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Introduction
The 5-hydroxytryptamine 2A receptor (5-HT2aR) is known to activate phospholipase
C (PLC) via the heterotrimeric G proteins Gq/n (Hoyer et al., 1994), and has also
been shown to be able to couple to phospholipase A2 (PLA2)-mediated arachidonic
acid release (Berg et al., 1994; Berg et al., 1996). Since the 5-HT2A receptor (and 5-
HT2C) can activate both PLC and PLA2 in an agonist-dependent manner but with
different profiles of efficacies for different agonists (Berg et al., 1998) it is
hypothesised that this differential coupling is mediated via receptor coupling to
different trimeric G-proteins. It has been further suggested that the mechanism of
PLA2 activation may be through a complex signalling mechanism involving both
Gcxj/o associated GPy-mediated ERK1,2 activation and Gai2/n-coupled, Rho-
mediated p38 activation (Berg et al., 1998; Kurrasch-Orbaugh et al., 2003a;
Kurrasch-Orbaugh et al., 2003b). The 5-HT2a receptor has also been shown to
activate tyrosine phosphorylation (correlating with evidence for association of the
tyrosine kinase JAK2 with the ct domain (Guillet-Deniau et al., 1997)). Another
important signalling cascade activated by the 5-HT2a receptor is the activation of the
phospholipase D (PLD) pathway in an ADP-ribosylation factor (ARF)-dependent
manner, that appears to be independent of Gq/n or Gj/0(Mitchell et al., 1998; Mitchell
et al., 2003).
GPCR interactions with heterotrimeric G proteins often (but not exclusively) appear
to involve the third intracellular loop (i3) (Wess et al., 1997). The i3 domains of
various GPCRs have been shown to provide docking sites for heterotrimeric G
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protein Py subunits (Wu et al., 1998) as well as arrestins (Wu et al., 1997; Mukherjee
et al., 1999; Gelber et al., 1999), GPCR-kinases (GRKs) (Wu et al., 1998) and
indeed ARFs (McCulloch et al., 2001; Ronaldson et al., 2002). In a number of
GPCRs, other intracellular loops and ct domains have also been implicated in
interactions with heterotrimeric G proteins, and indeed it seems likely that there are
multiple sites of interaction, suggesting that the interaction of G proteins and GPCRs
may involve motifs on both the i3 and the ct domains (Taylor et al., 1994; Hamm,
2001). In the 5-HT2aR, the i3 domain has been shown to be important for coupling
to Gq/n and the carboxyl terminal segment of the i3 in particular, may play a key role
in this interaction (Roth et al., 1998). The carboxyl terminal tail of the rhodopsin
receptor has been shown to interact with the a and y subunits of transducin (Ernst et
al., 2000; Marin et al., 2000), and the NPxxY motif and the seven residues
downstream have been shown to influence the heterotrimeric G protein activation of
both rhodopsin and the 5-HT2C receptor (Prioleau et al., 2002; Fritze et al., 2003).
It has previously been shown that members of the arrestin family can bind to various
intracellular domains of the family R GPCRs, and this may also involve multiple
interaction sites (Oakley et al., 2000). High affinity binding of arrestins to GPCRs
generally requires both receptor activation and phosphorylation by GRKs or other
kinases (Gurevich et al., 1995). However, arrestins can also bind to non-
phosphorylated sites (Wu et al., 1997; DeGraff et al., 2002; Mukherjee et al., 2002).
The binding of arrestins has been documented to non-phosphorylated forms of the i3
loops of the M3 and M2 muscarinic receptors, and the 0C2A/D adrenoreceptor (Wu et
al., 1997) and indeed arrestin isoforms have been shown to bind to the i3 loop of the
5-HT2aR, with a broader specificity than is shown at i3 of the M2 and M3 muscarinic
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receptors, where only non-visual arrestins are bound (Wu et al., 1997; Gelber et al.,
1999). Additionally, a range of the family R GPCRs (P2 adrenergic receptor, mu
opioid receptor, endothelin type A receptor, dopamine D1A receptor, and alb
adrenergic receptor) have been shown to bind arrestin 3 with a higher affinity than
arrestin 2 through the carboxy-terminal tail, whereas no interaction was observed
with arrestin 1 (visual arrestin) (Oakley et al., 2000), however, the third intracellular
loop of these receptors was not investigated in depth in this study.
The specific conserved NPxxY motif that is found at the junction of the tm7 and ct
domains in a number of rhodopsin family GPCRs, has been implicated as a
determinant of ARF:receptor interactions and ARF-mediated signalling since native
receptors with an alternative DPxxY motif, or N to D mutation (for example in the 5-
HT2A receptor) display selective reduction in this pathway (Mitchell et al., 1998; Xu
et al., 1999). Flowever, it has not been clear whether this motif might be accessible
as a direct docking site or whether instead it regulates access to a distinct site.
There is evidence to suggest that PLD may be able to bind directly to some of the
family R GPCRs. The amino terminal domain of PLD2 has been found to interact
with the carboxy-terminal tail domain of the p-opioid receptor by yeast two-hybrid
screening and co-immunoprecipitation experiments, whereas PLD lb did not
associate with the receptor in this investigation (Koch et al., 2003). This association
of PLD2 and the p-opioid receptor was also suggested to be necessary for ARF1 to
bind to the p-opioid receptor. The proposed arrangement involved ARF1 binding to
the PLD2 which in turn associated with the receptor, however agonist stimulation
increased the association of ARF1 with the p-opioid receptor, suggesting a
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conformational change of the receptor may facilitate binding of ARF (Koch et al.,
2003). The physical association of both PLD1 and PLD2 with the muscarinic M3
receptor has also been shown by co-immunoprecipitation assays in other work in this
laboratory (Collins, D. and Johnson, M.S. unpublished), although signalling may be
preferentially through PLD1 (Mitchell et al., 2003).
In the case of the M3 muscarinic receptor, both ARF1 and ARF6 play a role in the
activation of PLD upon receptor activation (Chapter 3). The aim of this investigation
was to assess the role of ARF in the PLD signalling of the 5-HT2A receptor,
elucidating the relative involvement of ARF1 and ARF6 isoforms, including the
location and mechanism of their potential interaction with the receptor. The
influence of interactions with some other possible binding partners for ARF and the
5-HT2A receptor was also examined, as well as the ability of PLD itself to bind to the
5-HT2A receptor.
Results
The role of ARF1 and ARF6 in PLD activation by the 5-HT2a receptor.
The role of ARFl and ARF6 in the activation of PLD by the 5-HT2A receptor was
investigated. Figure 4.1 illustrates functional signalling responses of the sPrC-5-
HT2AR expressed in COS7 cells. [3H]Ketanserin binding experiments indicated that
the sPrC-5-HT2AR was expressed in COS7 cell membranes at a mean level of 0.84 ±
0.04 pmol/mg total protein with an Kj value of l .96 ± 0.08 nM (with Kd data from
GPCR database, as calculated by the Cheng-Prussoff equation)(Robertson et al.,
128
2003). The receptor produced robust PLC and PLD activation responses to 5-HT
stimulation, similar to the untagged receptor (Bohm et al., 1997; Mitchell et al.,
1998) but with slightly greater potency, the EC50 values for PLC and PLD responses
being 5.0 ± 2.2 and 6.8 ± 1.9 nM respectively (Fig. 4.1 a,b). The EC50 value for PLC
activation by the untagged receptor in similar experiments was found to be 28 ± 2
nM (unpublished observations) and 22 ± 5 nM (Bohm et al., 1997). The effects of
co-transfection of ARF mutants were investigated on 5-HT-induced signalling events
mediated by the sPrC-5-HT2AR expressed in COS7 cells. PLC activation was
unaffected by co-transfection of either T31N-ARF1-HA or T27N-ARF6-HA;
(mutant constructs of the ARF isoforms that have a dysfunctional GTP binding
domain (Peters et al., 1995)), (Fig. 4.1a). However T31N-ARF1-HA, but not T27N-
ARF6-HA, significantly inhibited 5-ht2ar-mediated PLD activation (Fig. 4.1b).
Figure 4.1c shows the inhibitory effect of BFA (a blocker of the BIG 1/2 class of
ARF GTP-exchange factor (GEF) (Morinaga et al., 1999)) on the PLD response of
the 5-HT2A receptor. When only the receptor was expressed, BFA caused a
concentration-dependent inhibition of 5-HT-induced PLD activation, with significant
inhibition at 50 pM and above. In cells additionally expressing T27N-ARF6-HA,
BFA was also inhibitory throughout a similar concentration range. However, in cells
expressing T31N-ARF1-HA, the residual 5-HT-induced PLD response became
insensitive to BFA. The PLC response of the 5-HT2aR was unaffected by BFA (data
not shown).
These findings demonstrate that a negative mutant construct of ARF1, but not
ARF6, inhibits the activation of PLD, but not PLC, by the 5-HT2aR- This indicates a
selective functional role for the ARF1 isoform in the PLD signalling pathway of the
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5-HT2aR- PLD, but not PLC responses of the 5-HT2aR were correspondingly
reduced in a concentration-dependent manner by BFA. Further evidence consistent
with a functional role for ARF1 in BFA-sensitive PLD responses can be taken from
the experiments assessing the BFA-sensitivity of 5-FIT2aR PLD responses in cells
co-expressing negative mutant ARFs, T31N-ARF1-HA or T27N-ARF6-HA. The
inhibitory effect of the negative mutant ARF1 construct pre-empted any further
inhibition by BFA, suggesting that they both acted within the same pathway, whereas
negative mutant ARF6 was without effect. Other GPCRs may show different
selectivity for ARF isoforms. In COS7 cells expressing the M3 muscarinic receptor
and in A10 smooth muscle cells, PLD responses to carbachol and to angiotensin II or
ET-1 respectively were attenuated by T31N-ARF1 and by T27N-ARF6 (Xu et al.,
1999; Shome et al., 2000), whereas some other GPCRs such as P2U and PACi-hopi
receptors may show partial selectivity for ARF6 over ARF1 (Xu et al., 1999;
Ronaldson et al., 2002).
To investigate whether a physical interaction of either ARF1 or ARF6 with the
receptor occurs upon activation, co-immunoprecipitation of HA-tagged ARF
isoforms with the sPrC-5-HT2AR was carried out. Significant levels of ARF1-HA
(and to a much lesser extent, ARF6-HA) appeared to be specifically associated with
the PrC-tag antibody pulldowns of the sPrC-5-HT2AR, even without agonist.
Densitometric analysis indicated that basal levels of ARF 1-HA co-
immunoprecipitated were increased on average 3.32 ± 1.58 fold over non-specific, as
determined with NI IgG. The corresponding value for ARF6-HA was lower, at 0.32
± 0.05 fold increase over non-specific. Although co-immunoprecipitation of both
isoforms of ARF with the receptor appeared to be increased by addition of 5-HT
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(mean increase to 1.61 fold and 1.26 fold of control with ARF1-HA and ARF6-HA
respectively), only the effect on ARF1-HA was statistically significant(Robertson et
al„ 2003).
ARF binding to 5-HT2A receptor domains.
To examine the receptor-ARF interaction in more detail, we generated GST fusion
protein constructs of the intracellular loop 3 (i3; I258-G326) and carboxy-terminal tail
(ct; N376-V471) of the 5-HT2aR, and investigated their ability to bind ARF1-HA and
ARF6-HA in vitro. Figure 4.2 is a schematic representation of the 5-HT2aR showing
the amino acid sequences used for these GST constructs. GST-fusion protein
constructs of the i3 and ct domains of the 5-HT2aR, or the STREX exon of the BK
channel as a control, were attached to glutathione Sepharose beads and used in in
vitro interaction assays at equivalent input levels (as estimated by GST
immunoreactivity or Coomassie staining (Fig. 4.3a)). The STREX exon is a peptide
of unrelated sequence to the 5-HT2a receptor, from the BK (Big Potassium) channel
which is a membrane associated protein with an entirely different function, and was
used as a negative control. The input levels of ARF 1-HA and ARF6-HA or the
negative mutant constructs, deficient in GTP binding; T31N-ARF1-HA and T27N-
ARF6-HA were also balanced for HA-immunoreactivity (Fig. 4.3a). Figure 4.3b
compares ARF1-HA and ARF6-HA interaction with the constructs. ARF1-HA
displayed much greater relative binding to the ct domain of the 5-HT2aR than to the
BK channel construct or the i3 domain of the 5-HT2aR. ARF6-HA showed a much
lower level of binding to the 5-HT2ACt construct and little interaction with the 5-
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HT2Ai3 or BK constructs. Figure 4.3c shows the binding profiles for the functionally
negative mutants of ARF1 and ARF6; T31N-ARF1-HA and T27N-ARF6-HA. The
binding of T31N-ARF1-HA to the 5-HT2Act construct was greatly reduced compared
to that of the ARF1-HA wild type, and the low background levels of T31N-ARF1-
HA binding to 5-HT2Ai3 and BK channel constructs were similar to those seen with
wild type ARF1-HA. T27N-ARF6-HA showed a low level of binding to the 5-
HT2ACt construct that appeared to be similar to that of the ARF6-HA wild type. The
apparently slightly higher levels of T27N-ARF6-HA binding compared to the wild
type in the experiment displayed correspond to its somewhat higher input level.
GTPyS facilitated the interaction of submaximal levels of ARF1-HA (cytosolic
extract additions were reduced to a level where ARF1-HA binding was seen to be
less than previous experiments, and a difference could be seen by visualisation of the
ARF1-HA by western blot procedures) with the 5-HT2ACt construct and also
appeared to strengthen a weak interaction with the 5-HT2Ai3 construct, which had
been minimal in the absence of added nucleotide (Fig. 4.3d). GTPyS did not
facilitate T31N-ARF1-FIA binding to the receptor constructs. (Similar results were
obtained in 3 different experiments).
Further to this work, a range of concentrations of both ARF1 and ARF6 were added
to the GST-5-FlT2Ai3 and GST-5-HT2ACt constructs to assess the concentration-
dependence of binding. Figure 4.4 shows the relative proportion of ARF isoform
bound to the constructs at increasing ARF concentrations, expressed as a ratio of
densitometric values for HA-immunoreactivity of the bound ARF versus GST
immunoreactivity in the construct. Increasing the concentration of ARF 1-HA
present with each construct caused corresponding increases in the amount of ARF
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bound. ARF1-HA bound to the GST-5-HT2ACt construct to a much greater extent
than to the GST-5-HT2Ai3 construct. ARF6-HA also bound to both the GST-5-
HT2Act and the GST-5-HT2a13 constructs, but to a much lesser extent than the ARF1-
HA bound to either construct, requiring higher levels of added ARF6-HA to obtain
detectable binding. It must be noted, however, that there is a major limitation in the
GST-fusion protein experiments mentioned above. What has not been measured in
these experiments is the accumulation of active GTP-ARF in vitro, and the possible
effects of endogenous ARF GEFs in the COS7 cell cytosolic preps to the observed
effects.
The GST-fusion protein experiments suggested that the ct domain of the 5-HT2aR
provides a binding site for ARFs at which ARF1 shows a higher affinity than ARF6.
To address the question of whether the binding of ARF1 to the 5-HT2A receptor
constructs was direct, and to try to ascertain the affinity of this binding, a variation of
the standard technique had to be implemented, since the COS7 cytosolic extracts
containing transfected ARF-F1A isoforms introduced other unknown cytosolic
proteins into the equation. To ensure a higher purity of ARF was being introduced to
columns, an alternative approach using ARF1-V5-His6 was used (Robertson et al.,
2003). The use of the His6 tag allows for purification of the ARF isoform via the
tag's ability to bind to cobalt-derivatised columns. Comparison of the
immunoreactivity for ARF1-V5-His6 bound to the GST-5-HT2ACt construct with
known amounts of purified ARF1-V5-His6, the percentage purity of the purified
protein was assessed by staining with high sensitivity Colloidal Coomassie on an
SDS-PAGE gel and identifying the correct band by Western blot. A standard curve
was then produced from the purified ARF1-V5-His6, which when co-processed with
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experimental cytosolic inputs allowed an estimate of the affinity of interaction of
ARF1-V5-His6 with the GST-5-HT2a receptor domains (Robertson et al., 2003).
These experiments showed not only that the ARF1-V5-His6 bound directly to the 5-
HT2a receptor domains, but nonlinear curve fitting of the saturation curve gave a
value for affinity (50% saturation) of (1.7 ± 0.4 nM), with 90% occupany of
available sites by 4 to 5 nM. This shows ARF-V%-His6 to be of lower affinity than
that for arrestin interaction with the M3R i3 domain (Wu et al., 1997), but higher
than the corresponding interaction of Gpy (Wu et al., 1998). The 5-HT2A receptor i3
domain shows only low affinity for ARF in vitro but may still represent an auxiliary
binding site in vivo. The interaction of ARF 1-HA with the ct or i3 domain of the 5-
HT2aR appeared to be facilitated by GTPyS, suggesting that occupancy of its
nucleotide recognition site by GTP rather than GDP promotes the interaction.
Correspondingly, the GTP-binding-defective mutant ARF1 construct (T31N-ARF1-
HA) showed an almost complete lack of specific binding to the ct or i3 domain GST
fusion proteins, that was unmodified by GTPyS. The lower level of ARF6-HA
binding appeared to be little affected by T27N mutation of ARF6-HA, but this was
not investigated further. The means by which agonist may induce increased (BFA-
sensitive and GTP status-sensitive) binding of ARF1 to the 5-HT2AR is not clear.
Involvement of BIG1/2 is implicated by the BFA sensitivity, but it is not known
whether agonist activation of the receptor might facilitate GTP loading of ARF1 by
direct proteimprotein interaction, by regulation of BIG1/2 or by other means.
However, GTP binding operates a conformational switch in ARFs that might
contribute to additional protein:protein interactions (Goldberg, 1998). In
experiments carried out with BIG1 on the GST constructs of the 5-HT2a receptor
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domains to assess the binding capability of BIG1, or if BIG1 had an effect on the
ability of ARF1-HA to bind to the receptor domains, insufficient expression of
BIG 1-HA in COS7 cells meant that neither binding of BIG 1-HA to any of the GST-
5-HT2A constructs, nor any effects of BIG1-HA on the binding of ARF to the
constructs could be detected (data not shown).
The role of the NPxxY motif in ARF1 association with the 5-HT2a
receptor.
The differential signalling properties of the wild type 5-HT2aR and the Nj76D mutant
5-HT2aR (Mitchell et al., 1998; Mitchell et al., 2003) suggest that the NPxxY motif,
at the junction of the ct and the 7th transmembrane domain, may participate in some
way in the binding of ARFl to the receptor. To test this theory, signalling
experiments and co-immunoprecipitation studies with both the wild type and Nj76D
mutant form of the receptor were carried out in the lab. 5-HT (l pM) -induced PLD
activation by the wild type sPrC-5-HT2AR was significantly reduced by BFA (100
pM) or by co-expression ofT31N-ARFl-HA but not T27N-ARF6-HA (Robertson et
al., 2003). Corresponding responses of the N376D-sPrC-5-HT2AR examined in the
same experiments showed no significant inhibition by either BFA or T31N-ARF1-
HA. Co-immunoprecipitation experiments were carried out in COS7 cells co-
transfected with ARFl-HA and either the wild type sPrC-5-HT2AR or its N376D
mutant form. After stimulation with 5-HT (1 pM, 5 min) or under control
conditions, solubilised extracts were immunoprecipitated with the HA-tag antibody.
The 5-HT2aRs associated with the immunoprecipitate was assayed as specific
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[3H]ketanserin binding. Low levels of non-specific [3H]ketanserin binding were
present in each case and these showed no discernable differences between samples
(Robertson et al., 2003). In cells transfected with the wild type sPrC-5-HT2AR, but
not those expressing the N376D mutant, significant levels of specific [3H]ketanserin
binding became associated with the HA tag-directed immunoprecipitate following 5-
HT stimulation. Thus 5-HT stimulation appeared to cause an increased interaction
between the sPrC-5-HT2AR and ARF1-HA (Robertson et al., 2003).
Although the tm7 NPxxY motif has been implicated as a critical determinant of ARF
co-immunoprecipitation and ARF-dependent signalling in rhodopsin family GPCRs,
the precise site of ARF binding to the ct of the 5-HT2aR remains to be elucidated.
Mutation of this motif to DPxxY strongly inhibits BFA-sensitive, ARF-mediated
activation of PLD (Mitchell et al., 1998) and sPrC-5-HT2AR co-immunoprecipitation
with ARF 1-HA (Robertson et al., 2003).
Figure 4.5 shows results from GST-fusion protein experiments investigating whether
the N376PLVY motif in the 5-HT2A R ct domain may directly form part of the binding
site for ARF1-HA. GST-fusion protein constructs of the wild type (N376-V471) 5-
HT2Act, the mutant (N376D-V471) 5-HT2Act and the truncated (K385-V471) 5-HT2Act
were prepared. Equal inputs of these constructs (and GST alone) were determined
by Coomassie Blue staining and by GST immunoreactivity at the predicted
molecular mass before interaction assays with ARF1-HA. The ratios of the
densitometric values for bound ARF 1-HA immunoreactivity to fusion protein input
were then calculated on an arbitrary scale relative to that for the wild type construct.
Densitometric values for fusion protein input levels and HA-immunoreactivity were
calculated utilising ScanAnalysis® software. Conditions were selected so that
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densities of both ECL (enhanced chemiluminescence) and colloidal Coomassie
staining were in the lower part of the range since the scales of density against
concentration tend to become non-linear at higher values. Therefore measurements
at low densities tend to give a more accurate representation of protein concentration.
Both individual images and the mean densitometry ratios for band ARF1-HA:
construct input showed a clear reduction in binding (to around 50%) by the N37AD
mutation and a further loss (to around 20%) by deletion of the N376-N384 sequence
(Fig. 4.5). These data imply that both the NPxxY motif and residues around or
before K385 play an important role in the interaction between ARF1-HA and the 5-
HT2Act.
To further investigate the binding of ARF1-HA to the 5-HT2ACt, GST-fusion protein
constructs of the tail were made that had truncations from the carboxyl terminal end
of the tail. GST constructs were made that contained the NPxxY motif and
subsequent residues but terminated at L406 and Q396 (Fig. 4.6a). These truncated
constructs were expressed, and exposed to ARF1-HA under the same conditions as
previously described. Densitometric ratios comparing the amount of each construct
present (as shown by Coomassie staining) to the extent of immunoreactivity to the
HA tag of the associated ARF1-HA are shown (Fig. 4.6b). There were no clear
differences in the binding of ARF1-HA to either of these two truncated constructs (5-
HT2ACtL406 and 5-HT2ACtQ396) compared to the full length 5-HT2ACt. The mean
binding levels of ARF1-HA binding were slightly lower to the shorter constructs, but
there were no statistically significant changes from the full length ct construct. In
these constructs, the NPxxY motif was preceded by the amino acids glycine (G) and
isoleucine (I). These amino acids (G and I) are not identical to the native amino
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acids, alanine (A) and valine (V), and were introduced as to produce a short link
between the GST protein and the receptor domain construct, in case the proximity of
the GST protein might restrict with the ability of the proteins of interest to access this
end of the carboxyl-terminal domain, and in particular the N/DPxxY motif. Both G
and I are neutral in charge, as are the native A and V, and no perceptible difference
was noted in the ability of the 2A ct constructs to bind to ARF1-HA or ARF6-HA in
either the presence or absence of the linker amino acids G and I.
These findings suggest that the majority of the key elements involved in 5-HT2aR:
ARF1 interaction, at least under these circumstances, may lie within the N376-N384
segment and further that the large remaining distal part of the carboxy-terminal tail,
at least beyond the region of Q396/L406, plays little role in ARF binding. Structural
modelling based on rhodopsin and secondary structure predictions (PHD predict;
http://cubic.bioc.columbia.edu/predictprotein/) suggest that the P377 residue is likely
O Q1 OQf
to form a pronounced kink in the tm7 helix and that T -K may form a flexible
hinge to an eighth helical segment that runs in the plane of the membrane until a
palmitoylation anchor at C397 (Sealfon et al., 1995; Backstrom et al., 2000; Dev et
al., 2001). In the case of rhodopsin, activation of the receptor newly exposes to the
T7R too
intracellular surface an epitope that includes residues equivalent to L -Y here
(Becamel et al., 2001), consistent with the idea that receptor activation may reveal
residues involved in ARF association. The predicted fourth intracellular loop of
<,oa 7RA
rhodopsin, in particular residues equivalent to N -Q here, is involved in
interaction with the a and y subunits of transducin (Ernst et al., 2000; Marin et al.,
2000). Interactions between amino acids in the NPxxY motif and the subsequent
seven residues are thought to influence heterotrimeric G protein activation by both
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rhodopsin and the 5-HT2cR (Thomas et al., 1995; Hunyady et al., 1995). Elements
of this surface might also contribute to ARF docking. The interaction of 5-HT2aR
with Gocq/i i however, is also thought to involve the carboxyl portion of the i3 loop
(Roth et al., 1998).
Additional functional roles have been proposed for the N/DPxxY motif. The most
consistent evidence is for a role linking the tm2 and tm7 helices (Bohm et al., 1997).
The NPxxY motif and the Y residue in particular, have also been proposed to
constitute an internalisation motif in some but by no means all GPCRs (Laporte et
al., 1996; Konvicka et al., 1998; Wilbanks et al., 2001; Barak et al., 2003). Mutation
of the N or D residue to A generally causes massive disruption of signalling
pathways and of internalisation, whereas reciprocal mutation of N or D appears to
have relatively minor effects on heterotrimeric G protein signalling (Sealfon et al.,
1995; LeGouill et al., 1997; Bohm et al., 1997; Mitchell et al., 1998). In the case of
the 5-HT2A receptor, we confirmed that the NPxxY, rather than the DPxxY mutant
motif, was necessary for functional BFA-sensitive and T31N-ARFl-HA-sensitive
PLD responses from the receptor, for 5-HT-induced co-immunoprecipitation of the
receptor with ARF 1-HA (Robertson et al., 2003), and for the major part of in vitro
binding of ARF 1-HA to the ct domain of the receptor (Figs. 4.5; 4.6; 4.7).
There is increasing evidence that particular GPCRs can interact with diverse
scaffolding and signalling proteins other than their conventional partners, the
heterotrimeric G-proteins (Zhou et al., 1994; Premont and Hall, 2002). Receptor ct
segments may dock adapter proteins containing PDZ or other domains, signalling
proteins and modulators of signalling functions (Bansal and Gierasch, 1991; Zhou et
al., 1994; Oakley et al., 2001). In the 5-HT2 receptor family, the distal ct residues
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are targeted by the PDZ-domain proteins, PSD-95 and MUPP-1 (Laporte et al., 1996;
Kitano et al., 2002; Brady and Limbird, 2002); interactions that may modify the
signalling function and localisation of the receptors. A novel PDZ domain protein,
tamalin, has been shown to bind to both mGluRl/5 receptors and the ARF-GEF,
ARNO (Slice et al., 1994). It is conceivable that a similar arrangement might occur
in the case of the 5-HT2A receptor; locating an ARF-GEF in the proximity of ARF.
ARF may not be the only small G protein that can interact with GPCRs. It has been
shown that Rho A can be co-immunoprecipitated in a complex with NPxxY GPCRs
(Mitchell et al., 1998), and there is evidence that both Gan and Gaq may interact
with Rho-GEFs to facilitate Rho function (Sagi et al., 2001). Rho has also been
shown to be required for 5-HT2C recetor-mediated activation of PLD (McGrew et al.,
2002), and the link to this pathway has been shown to have been lost in a naturally
occurring RNA edited isoform of the 5-HT2C receptor, which is deficient in 5 amino
acids of the 2nd intracellular loop (McGrew et al., 2004). The small GTP-binding
protein Rab5 has been observed to bind directly to the ATia receptor, via the last 10
amino acids of the carboxyl-terminal tail, and has been implicated in the ability of
the receptor to control targeting between intracellular compartments by directly
regulating components of the intracellular trafficking machinery (Seachrist et al.,
2002).
In experiments investigating possible links between ARF and the p2 adrenergic
receptor, ARF6 was not shown to directly bind to the P2 adrenergic receptor, but one
of the GTP-exchange factors (GEFs) for ARF6, ARNO (ADP ribosylation factor
nucleotide-binding site opener), was. Activation of the P2-adrenergic receptor
promotes the formation of a complex between GDP-ARF6, ARNO and arrestin 2. It
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is proposed that arrestin 2 functions as a scaffold to promote ARNO-dependent
ARF6 activation and thereby facilitate P2-adrenergic receptor endocytosis (Claing et
al., 2001). Other small G proteins of unknown identity have also been found to
associate with the fMLP receptor (Sagi et al., 2001).
Comparison of binding ofARFI and ARF6 to 5-HT2A and 5-HT2C
receptors
GST constructs of the equivalent ct and i3 domains of the 5-HT2C receptor were used
to compare the ability of the 5-HT2C and 5-HT2A receptor domains to bind ARF1-HA
and ARF6-HA. For similar inputs, the level of ARF1 binding to the 5-HT2cCt was
almost twice that for 5-HT2ACt (taken to be 1). In these experiments, the binding of
ARF1-HA to the N/D mutant and the K385 deletion construct of the 5-HT2ACt was
progressively reduced (Fig. 4.7) as shown previously (Robertson et al., 2003). The
difference in the binding of ARF1 to the 2Cct cannot be due to any difference in the
N376-N384 region, as both receptors have identical sequence to this point. However
there are sequence differences in the rest of the carboxy-terminal tail that may
account for the different binding capabilities, however further mutational studies
would be required to elucidate the residues or motifs responsible for this difference.
Figure 4.8 shows the binding ratio of ARF6-HA to the ct and i3 constructs of the 2A
and 2C receptors. As can be seen here, none of the constructs, with the exception of
the DPxxY-2Act, show any marked ability to bind to either the 2A or the 2C
constructs when compared to the binding of ARF6-HA to GST alone. It appears that
ARF6-HA binds better to the DPxxY form of the 5-HT2ACt, with binding of ARF6-
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HA to the NPxxY form of the ct being low, and not significantly greater than the
ARF6-HA binding to the GST alone, while the removal of the whole N/DPxxY motif
reduces the binding of ARF6-HA back to the levels of the wild type (NPxxY)
construct. The binding of ARF6-HA to the DPxxY form of the ct domain was
significantly increased over the basal binding of ARF6-HA to GST alone.
Binding of PLD1 and PLD2 to the ct and i3 domains of the 5-HT2A and 5-
HT2C receptors
The potential for PLD to interact directly with members of the family R GPCRs was
first suggested when the amino terminal domain of PLD2 was found to interact with
the carboxy-terminal tail of the p-opioid receptor by yeast two-hybrid screening, and
indeed the p-opioid receptor was also seen to constitutively interact with PLD2, but
not PLD1, in co-immunoprecipitation experiments (Koch et al., 2003). In support of
this principle, physical association of both PLDl and PLD2 with the muscarinic M3
receptor has been shown by co-immunoprecipitation assays in other work in this
laboratory. In addition the PLD isoforms have been shown to bind to the third
intracellular loop and the carboxy-terminal tail of the M3 receptor by means of GST
pulldown assays. Upon stimulation, there was a significant but transient decrease in
the association of PLDl but not PLD2 with the M3 receptor, as shown by co-
immunoprecipitation (Collins, D. and Johnson, M.S. unpublished).
To investigate whether PLD bound to the 5-HT2A receptor domains in vitro, binding
of PLD to GST-fusion protein constructs of the 5-HT2A receptor ct and i3 domains
were compared to binding of PLD to the N376D mutant 2Act; the K385 deletion
142
mutant 2Act; and the 5-HT2cCt domain. PLD1-HA and PLD2-HA were over-
expressed in COS7 cells, and cellular extracts were made under the same conditions
as described previously for the ARF-HA constructs, with the addition of the
detergents CHAPS (1% (w/v)) and deoxycholate (1% (w/v)), to solubilise the
otherwise membrane-associated PLD-HA, and the addition of 20% (v/v) glycerol to
stabilise the PLD in the soluble form. These solubilised PLD-containing extracts
were allowed to associate with the GST constructs of the i3 and ct domains of the 2A
and 2C receptors, which had been immobilised by binding to glutathione beads.
Captured proteins were then solubilised in Laemmli buffer and separated by SDS-
PAGE.
Figure 4.9 shows a Western blot, immunoblotted for HA to detect the tagged PLD1
and PLD2. The upper half of figure 4.9 shows the binding of PLD 1-HA to the
receptor domain GST-constructs, as well as to the GST alone control. PLD1-HA
bound to all constructs, although the binding to GST alone was much less. The
binding of PLD 1-HA to the GST-5-HT2ad376ct was much increased compared to that
of the GST-5-HT2an376ct, whereas the deletion of the region encompassing the
N/DPxxY motif in the GST-5-HT2AKj85ct construct returned the level of binding of
PLD 1-HA to that of the binding to the GST-5-HT2ACt wild type. PLD2-HA bound to
the GST-5-HT2ACt, and to the n376d mutant of the tail, but not to the K385 shortened
tail construct, or to the 5-HT2Ai3 domain (Fig. 4.9 lower panel). The binding of
PLD2-HA to the GST-5-HT2cct was greatly increased compared to that of the PLD2-
HA to the GST-5-HT2Act construct. PLD2-HA binding appeared similar to both the
GST-5-HT2AN376ct and the GST-5-HT2aN376D constructs, but was less to the GST-5-
HT2AK385 truncated construct. This suggests that the 376-385 sequence may play a
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role in the binding of PLD2 but not PLD1 to the 5-HT2ACt domain, but that PLD2
binding is not enhanced by the presence of a D residue at position 376.
The blots shown in figure 4.9 are representative of the results gained from the series
of experiments into the binding of PLD isoforms to the GST-5-HT receptor domains.
However with the number of constructs examined it is impossible to have the
construct inputs 100% balanced in every experiment. To allow for the quantification
of the binding patterns of PLD1 and PLD2 to the 5-HT2A and related domains,
densitometric ratios of construct present to the immunoreactivity of the HA tag on
the bound PLD1 and PLD2 were calculated (as described previously for the ARF
isoforms) and these ratios were normalised to that for binding to the GST-5-HT2ACt
construct.
Figure 4.10 shows the binding of PLD 1-HA to the 5-HT receptor constructs from
several experiments (n = 4-5), after correction for construct levels. The binding of
PLD1-HA to the 5-HT2AN376Dct and to the 5-HT2cct constructs was significantly
greater than that of PLD 1 to the 5-HT2ACt and GST over this range of experiments
(the total construct input for GST-5-HT2cct in the experiment shown in Fig 4.9 was
low). Removal of the whole NPxxY motif in the form of the K385 deletion mutant
reduced the binding of PLD 1-HA to the tail below that of the DPxxY form of the tail,
but binding of PLD 1-HA to the K385 construct was not reduced below that of the 5-
HT2Act domain, suggesting that the N376-K385 segment is not in itself crucial for
binding of PLD 1 to the receptor, and that the main binding site for PLD1 seems to be
385due to residues distal to K . However, the binding of PLD 1 to the 2Act is increased
in the presence of D376, suggesting that the proximal part of the 2Act may still have a
role to play in the binding of PLD 1. This is backed up by the difference in binding
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of PLD1 to the 2Act and the 2Cct. The differences in the 2Act and the 2Cct do not
lie in the proximal part of the domain, but further downstream, and the two carboxy-
'inf.
terminal domains are identical from N -K . The fact that PLD1 binds to a much
greater extent to the 5-HT2cct again suggests the contribution of a binding site further
down the tail.
In the case of PLD2 (Fig. 4.11) the binding to the 5-HT2A receptor domain constructs
generally showed less of an increment above GST alone controls than did PLD1.
The mean level of binding to the 2AN376ct, 2AD376ct and the 2Ai3 was greater than
that to GST alone, but with the n values that could be obtained in the present study,
these differences did not reach statistical significance. However, PLD2 showed clear
and statistically significant binding to the 5-HT2cct domain. As both the 5-HT2ACt
and the 5-HT2cCt are identical in primary structure up till amino acid TJ,S6, the key
residues dictating the increased binding of PLD2 to the 5-HT2C receptor ct must be
located further downstream to allow for such differences to be detected under these
conditions. Although basic secondary structural predictions can be made (PHD
predict; http://cubic.bioc.columbia.edu/predictprotein/), the majority of the constructs
are not predicted as helical, or any other formal structure, so the domains being
investigated are highly flexible and any 3D structure under the experimental
conditions used is completely unknown.
PLD2 and not PLDlb has previously been shown to bind to the p-opioid receptor in
HEK293 cells (Koch et al., 2003). These cells also showed BFA-sensitive activation
of PLD2, and indeed ARF-immunoreactivity was co-immunoprecipitated with the p-
opioid receptor and PLD2. It has been suggested that ARF binds to the p-opioid
receptor through PLD2, or at least that PLD2 binding to the receptor causes a
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conformational change that allows ARF to then bind. It was interesting to note that
upon agonist stimulation, the amount of PLD2 that co-immunoprecipitated with the
receptor decreases (as was seen with PLD1 with the M3 muscarinic receptor,
unpublished results Collins, D., Johnson M.S.), and yet the amount of ARF pulled
down increased, suggesting that the link between ARF and PLD2 binding may not be
as straightforward as the proposed mechanism of ARF simply binding through PLD2
(Koch et al., 2003). In the case of the 5-HT2A receptor, ARF 1-HA (but not ARF6-
HA) was seen to bind to the carboxy-terminal domain. The ARF1 was presented to
the GST construct of the domain in the form of cytosolic extract, not purified ARF.
However there is unlikely to be any significant content of PLD in the extracts as PLD
is a membrane-associated protein, and to extract PLD-HA to introduce it to the GST
constructs, an extra stage of membrane solubilisation was required. This is backed
up by the fact that purified ARF1-V5-His6 also binds to the 5-HT2A receptor domains
(Robertson et al., 2003). The profile of PLD1 binding to the 5-HT2A receptor with
higher apparent affinity than PLD2, does not follow the same pattern of binding as
that of ARF1, in that both the D3762Act and Kj8:,2Act constructs bind PLD1 better
than the N3762Act, and ARF1 to a lesser extent than the N3762Act. Furthermore
PLD2 binding is not reduced in the D376N2Act which shows significantly less ARF1
binding than the N3762Act construct. These facts together suggest that there may be
no direct link between ARF1 and PLD binding to the 5-HT2A receptor.
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Investigation of a potential role of G/3y in modulating PLD signalling by
the 5-HT2a receptor
Since we demonstrated previously that the ability of the M3 muscarinic receptor to
activate PLD via ARF1 is facilitated in the presence of GPy subunits, the potential
role of GPy on ARF1 -dependent PLD activation by the 5-HT2A receptor was
investigated. The effects of GPy upon activation of both the PLD and PLC signalling
pathways activated by the M3 muscarinic receptor and the 5-FIT2A receptor were
investigated by co-transfection of the GPy-sequestering agent GRK2ct (GRK2495-689)
with the receptors in COS7 cells. Co-transfection of the empty plasmid pcDNA3
was used as a control. As shown in figure 4.12, the PLD response to agonist
stimulation of the M3 receptor was decreased to about 50% in the presence of the
GRK2495-689 construct, whereas this had no effect upon the PLC response, as detailed
in Chapter 3. However, when cells containing the sPrC-5-HT2A receptor were
stimulated with agonist, the presence of the GPy sequestering agent had no
discernable effect on the ability of the 5-HT2A receptor to activate either PLC or
PLD. This suggests that the molecular mechanism of ARF-dependent PLD
activation differs in the case of the 5-HT2A receptor from that of the muscarinic M3
receptor. This positive effect of GPy on the M3 receptor PLD activation response
does not seem to be mirrored with the 5-HT2A receptor. So not only do the two
receptors differ in their ability to activate different isoforms of ARF, but also in the
ways in which they apparently link to ARF1.
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Arrestin binding to 5-HT2a receptor domains, and the effect of arrestin
on ARF binding
It has previously been shown that members of the arrestin family can bind to various
intracellular domains of the Type I family of GPCRs. High affinity binding of
arrestins to GPCRs generally requires both receptor activation and phosphorylation
by GRKs or other kinases (Gurevich et al., 1995). However arrestins can also bind
to non-phosphorylated sites upon receptor activation (Wu et al., 1997; DeGraff et al.,
2002; Mukherjee et al., 2002). There is a lack of evidence for agonist induced
phosphorylation accompanying the desensitisation of some GPCRs, such as the
Luteinising hormone (LH/HCG) receptor, and the 5-HT2A receptor (Lamm and
Hunzicker-Dunn, 1994; Youret-Craviari et al., 1995; Gray and Roth, 2001), and
indeed the i3 domain of the 5-HT2a receptor has been previously shown to
effectively bind arrestins under non-phosphorylated conditions (Gelber et al., 1999;
Johnson et al., 2003).
The binding of arrestin 2 and arrestin 3 to both the 5-HT2Ai3 and ct was investigated.
Figure 4.13 shows the binding of both arrestin 2 and arrestin 3 was markedly greater
than that to GST alone for both the 5-HT2a13 and 5-HT2ACt domain constructs.
The potential ability of arrestin to modulate the binding of ARF1 to the i3 and ct
domains of the 5-HT2a receptor was investigated using the GST-fusion protein
constructs of the receptor domains. Firstly, the effects of arrestin 2 on the binding of
ARF1 to the GST-5-HT2aB and ct domains was examined. The low level of binding
of ARF 1-HA to the 5-HT2Ai3 domain was unaffected by the presence of arrestin 2
(Fig 4.14a, right hand panel). However, the ability of ARF1-HA to bind to the 5-
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HT2ACt domain was markedly increased by the presence of arrestin 2 under these
conditions (Fig 4.14a left hand panel). The converse question was also investigated,
i.e. whether binding of arrestin 2 to the 5-HT2ACt domain was altered in the presence
of ARF1-HA. The binding of arrestin 2 showed no change in the presence of ARF1-
HA under the conditions tested (Fig. 4.14b).
There have been studies into the functional interactions between arrestin 2 and ARF6
in the regulation of endocytosis of the p2-adrenergic receptor. Arrestin 2 has been
found in complex with ARNO, a GEF for ARF6. Upon agonist stimulation of the p2-
adrenergic receptor, arrestin 2 also interacts with the GDP-bound form of ARF6,
becoming an interface for the GTP activation of ARF6 by ARNO, therefore agonist
stimulation of the p2-adrenergic receptor drives the formation of a complex including
arrestin 2, ARNO and ARF6, leading to the activation of ARF6, and allowing for the
endocytotic process (Claing et al., 2001). It is possible that a similar relationship
between arrestin, ARF and an ARF-GEF may be occurring in the case of the 5-HT2a
receptor, involving here ARF1 and arrestin 2, and allowing for the association of
GDP- ARF1 and ARF-GEF upon agonist activation of the receptor. However, there
is no evidence that the activation of ARF1 by the 5-HT2A receptor has a role in the
endocytosis or desensitisation of the 5-HT2a receptor, as is seen in the case of the p2-
adrenergic receptor with ARF6. The possible inclusion of any ARF-GEFs for ARF1,
e.g. BIG1, in the interaction complex was not investigated in this study.
In conclusion, these experiments provide intracellular signalling and in vitro domain
interaction evidence for ARF association with the 5-HT2a receptor, corresponding to
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its functional activation of PLD. Furthermore, ARF1 rather than ARF6 appears to
participate in this mechanism, through a GTP-dependent interaction with
predominantly the ct domain of the receptor. The ARF-dependent PLD activation
by the 5-HT2A receptor is not diminished by sequestration of free G(3y subunits, as is
the case in the M3 receptor. However modulation of ARF1 binding to the 5-HT2ACt
can be seen in the presence of arrestin 2. There is evidence for a direct interaction of
PLD1 and PLD2 with the carboxy-terminal domain of the 5-HT2a and 5-HT2C
receptors, but binding of PLD seems to be through a mechanism that is distinct from
that for ARF. The binding of ARF to the 5-HT2A receptor does not seem to require
the presence of PLD, however further work is required to examine any potential




Effects of mutant ARF1-HA and ARF6-HA constructs on signalling responses
of the sPrC-5-HT2A receptor.
COS7 cells were co-transfected with the sPrC-5-HT2AR together with either empty
vector (•), T31N-ARF1-HA (■) or T27N-ARF6-HA (□). Values are means ±
SEM, n = 6-8. a) Shows the concentration-dependence of 5-HT-induced PLC
activation; there was no discernable effect of the negative mutant ARFs on this
response, b) Shows the concentration-dependence of 5-HT-induced PLD activation.
The addition of T27N-ARF6-HA had no significant effect on the ability of the 5-
HT2AR to activate PLD, whereas the presence of T31N-ARF1-HA significantly
attenuated the PLD response to 5-HT concentrations of 10 nM and above (*p<0.05
by Wilcoxon test), c) Shows the brefeldin A (BFA)-sensitivity of the 5-HT (1 pM)-
induced 5-HT2AR PLD response; a concentration-dependent inhibition that was
statistically significant (*p< 0.05, Wilcoxon test) for BFA concentrations of 50 pM
and above in empty vector and T27N-ARF6-HA samples. Co-transfection of T27N-
ARF6-HA had no discernable effect on BFA sensitivity compared to empty vector,
whereas the remaining PLD response in the presence of T31N-ARF1-HA was no
longer significantly inhibited by BFA.
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Figure 4.1
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Figure 4.2
Amino acid sequence of the 5-HT2a receptor carboxy-terminal tail and third
intracellular loop.
GST-fusion protein constructs were made of the 5-HT2a N376-V471 carboxy-terminal
tail (ct); the N376D mutant version of the ct domain; the truncated (K385-V471; N376-
q396; |^376_j^406-j versjons 0f taj|. as wejj as tjje j258_q326 ^jj.^ intracellular loop




Interactions of ARF isoforms with GST fusion proteins of domains from the 5-
HT2A receptor.
GST-5-HT2Ai3, GST-5-HT2Act and (control) GST-BK channel (STREX exon)
constructs were incubated with cellular extracts enriched in particular HA-tagged
ARF isoforms. a) Input levels of fusion protein constructs and ARF isoforms were
balanced in terms of GST immunoreactivity and HA-immunoreactivity respectively.
The fusion protein-construct input levels are shown for GST-5-HT2Ai3 (GST-2Ai3),
GST-5-HT2Act (GST-2Act) and GST-BK running at apparent molecular masses of
approximately 36, 40 and 34 kDa respectively. Unconjugated GST ran at
approximately 29 kDa (not shown). The ARF input levels are shown for ARF 1-HA,
ARF6-HA, T31N-ARF1-HA and T27N-ARF6-HA. b) and c) show association of
the indicated ARF form with GST-5-HT2Ai3, GST-5-HT2Act and GST-BKstrex
constructs respectively. ARF 1-HA bound selectively to the GST-5-HT2Act construct,
with little binding to the GST-5-HT2Ai3, or GST-BK constructs. ARF6-HA showed
a similar profile but bound to a much lesser extent than ARF 1-HA. The T31N
mutation in ARF 1-HA severely reduced the ability of the protein to bind to the GST-
5-HT2Act construct, but the equivalent mutation in ARF6-HA had no discernable
effect. In d) GST-5-HT2Ai3 and GST-5-HT2Act constructs were incubated with
cellular extracts enriched in the indicated HA-tagged ARF isoforms in the presence
or absence of GTPyS (100 pM). GTPyS increased the binding of wild type ARF1-
HA to both GST-5-HT2Ai3 and GST-5-HT2Act constructs, but did not alter the lack of
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Figure 4.4
Concentration-dependence of ARF1-HA and ARF6-HA binding to the GST
fusion proteins of domains from the 5-HT2A receptor.
GST-5-HT2Ai3 and GST-5-HT2ACt constructs were exposed to increasing amounts of
cellular extracts containing ARF1-HA and ARF6-HA. The content of HA-
immunoreactive ARF per jul of the ARF1-HA and ARF6-HA extracts was balanced
to contain equivalent amounts of the ARF isoforms. Appropriate volume
compensation was made with extract from non-transfected COS7 cells, a) Shows the
binding of ARF 1-HA and ARF6-HA to the GST-5-HT2Ai3 construct. ARF 1-HA
bound to the construct in a concentration-dependent manner, as did ARF6 but to a
much lesser extent, b) Shows the binding of ARF1-HA and ARF6-HA to the GST-5-
HT2Act construct. ARF 1-HA bound in a concentration-dependent manner, whereas
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Figure 4.5
Effects of changes in the proximal part of the 5-HT2A receptor ct domain on
ARF1-HA binding.
Matched levels of GST-fusion proteins incorporating the (N376-V471) wild type 5-
HT2a receptor ct domain, the corresponding N376D mutant or a truncated K385-V471
sequence, as well as GST alone were attached to glutathione-Sepharose beads and
incubated with equivalent levels of ARF1-HA. Immunoreactivity for bound ARF1-
HA was quantified by densitometry and the ratio to the level of input for each GST-
fusion protein construct was calculated. These ratios were then normalised to that
found for the wild type ct construct. Values are means ± SEM, n=3 (for 2Act 385-
471) -5 (for all other constructs). A typical example of ECL film images for EIA-
immunoreactivity bound to these constructs, and GST-immunoreactivity is shown
below. The mutation of the N376-D at the membrane end of the 5-HT2ACt construct
leads to a 50% reduction in the constructs ability to bind ARF1-HA in vitro. The
removal of the 8 amino acids at this end of the 5-HT2ACt construct further reduces the
constructs ability significantly to bind ARF1-HA, compared to the 5-HT2ACt376-471
construct (*p< 0.01, Wilcoxon test).
159
Figure 4.5


























































Effects of changes in the distal part of the 5-HT2a receptor ct domain on ARF1-
HA binding.
a) Shows a map of the GST constructs that were made of the 5-HT2A carboxy-
terminal tail to investigate deletions of various parts of the tail: GIN376PLVY- V471
(Full length tail), GIN376PLVY- L406 and GIN376PLVY- Q396 (i4 loop).
b) Shows matched levels of GST constructs of the 5-HT2ACt domain (GIN376PLVY-
V471; GIN376PLVY- L406; GIN376PLVY- Q396) and GST alone when attached to
glutathione-Sepharose beads, and incubated with ARF1-HA-enriched COS7 cell
cytosolic extract. Immunoreactivity for bound ARF 1-HA was quantified by
densitometry and the ratio to the level of input for each GST-fusion protein construct
was calculated. These ratios were normalised to that found for the 5-HT2ACt
construct. Values are means + SEM, n=4-6.
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Figure 4.6
Effects of changes in the distal part of the 5-HT2A receptor ct domain on ARF1-HA binding









































Comparison of ARF1-HA binding to various GST fusion protein constructs of
5-HT2A and 5-HT2C receptor domains.
Matched levels of the constructs: GST-5-HT2ACt376-47i (N3762Act); GST-5-
HT2ActN376D376-47i (D3762Act); GST-5-HT2Act385-47i (K3852Act); GST-5-HT2Ai3258-326
(2ai3); GST-5-HT2cct364-458 (2Cct); and GST alone were attached to glutathione-
Sepharose beads and incubated with equivalent levels of ARF1-HA.
Immunoreactivity for bound ARF1-HA was quantified by densitometry and the ratio
to the level of input for each GST-fusion protein construct was calculated. These
ratios were then normalised to that found for the wild type 5-HT2A ct construct.
Values are means ± SEM, n=3-8. The 5-HT2cct construct seemed to display a
greater degree of binding to ARF1-HA in vitro than the 5-HT2Act construct, however
it cannot be said to be significant, due to a low n number. The binding of ARF1-HA
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Comparison of ARF6-HA binding to various GST fusion protein constructs of
5-HT2A and 5-HT2C receptor domains.
Matched levels of the constructs: GST-5-HT2Act376-47i (N3762Act); GST-5-
HT2ActN376D376-47i (D3762Act); GST-5-HT2Act385-47i (K3852Act); GST-5-HT2Ai3258-326
(2ai3); GST-5-HT2cct364_458 (2Cct); and GST alone were attached to glutathione-
Sepharose beads and incubated with equivalent levels of ARE6-HA.
Immunoreactivity for bound ARF6-HA was quantified by densitometry and the ratio
to the level of input for each GST-fusion protein construct was calculated. These
ratios were then normalised to that found for the wild type 5-HT2Act construct.
Values are means ± SEM, n=4-5. ARF6-HA showed no significant increase in
binding to the 5-HT2Ai3258-326 or 5-HT2cct376-47i constructs, compared to the 5-HT2Act
construct, and this itself was not discernibly different from the binding of ARF6-HA
to GST alone. The deletion of the first 9 amino acids (N376-N384) from the 5-HT2Act
construct had no apparent effect on the ability of the ARF6-HA to bind the construct
which was minimal anyway. However, the mutation of N376-D had the effect of
increasing the ability of ARF6-HA to bind to the construct to over twice the binding
of ARF6-HA to the N376 construct (2.343 ± 0.82 fold), and this level of binding was
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Binding of PLD1-HA and PLD2-HA to GST fusion protein constructs of 5-
HT2a and 5-HT2C receptor domains.
Matched levels of the constructs: GST-5-HT2Act376-47i (N3762Act); GST-5-
HT2ActN376D376-47i (D3762Act); GST-5-HT2Act385-47i (K3852Act); GST-5-HT2Ai3258-326
(2ai3); GST-5-HT2cCt364-458 (2Cct); and GST alone, were attached to glutathione
Sepharose beads, and exposed to equal amounts of PLDl-HA-containing COS7 cell
extract as previously described. As seen in the upper panel, PLD1-HA bound to all
constructs, to a greater extent than to GST alone, however the binding of the PLD1 -
HA to the N376D mutant version of the 5-HT2Act construct was greater than that of
the other constructs (Fig. 4.9 upper panel). The binding of PLD2-HA to the same
constructs is also shown (Fig 4.9 lower panel). As can be seen here, the binding to
the 5-HT2Ai3 construct was no greater than that to the GST alone, however, PLD2-
HA showed detectable binding to both N376 and D376 forms of the 5-HT2Act, as well
as to the 5-HT2cct. GST construct input levels were balanced as much as possible,
although small fluctuations in construct levels account for the differences between
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Figure 4.10
Quantification of PLD1-HA binding to GST fusion protein constructs of
constructs 5-HT2A and 5-HT2C receptor domain.
Matched levels of the constructs: GST-5-HT2Act376-47i (N3762Act); GST-5-
HT2ActN376D376-47i (D3762Act); GST-5-HT2Act385-47i (K3852Act); GST-5-HT2Ai3258-326
(2ai3); GST-5-HT2cct364-458 (2Cct); and GST alone were attached to glutathione-
Sepharose beads and incubated with equivalent levels of PLD1-HA.
Immunoreactivity for bound PLD1-HA was quantified by densitometry and the ratio
to the level of input for each GST-fusion protein construct was calculated. These
ratios were then normalised to that found for the wild type 5-HT2A receptor ct
construct. Values are means ± SEM, n=4-5. A modest but significantly greater level
of PLD1-HA binding to the 5-HT2AN376ct construct was observed compared to GST
alone (*p<0.05 Wilcoxon test), however mutation of the N376-D, and the deletion of
the 9 amino acids N376-N384 allowed for a significant increase in the binding of
PLD1-HA to the 5-HT2AD376ct constructs compared to the binding of PLD1-HA to
the N3762Act alone (+p<0.05 Wilcoxon test). PLD1-HA bound significantly better to
the 5-HT2cct when compared to the binding of PLD1-HA to GST alone, or to the 5-
HT2AN376ct (* or + respectively p<0.05 Wilcoxon test).
169
Figure 4.10
Quantification of PLD1-HA binding to GST fusion protein
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Quantification of PLD2-HA binding to GST fusion protein constructs of
constructs 5-HT2A and 5-HT2C receptor domain.
Matched levels of the constructs: GST-5-HT2Act376-47i (N3762Act); GST-5-
HT2ActN376D376-47i (D3762Act); GST-5-HT2Act385-47i (K3852Act); GST-5-HT2Ai3258-326
(2ai3); GST-5-HT2cct364_458 (2Cct); and GST alone were attached to glutathione-
Sepharose beads and incubated with equivalent levels of PLD2-HA.
Immunoreactivity for bound PLD1-HA was quantified by densitometry and the ratio
to the level of input for each GST-fusion protein construct was calculated. These
ratios were then normalised to that found for the wild type 5-HT2A receptor ct
construct. Values are means ± SEM, n=3-4. There was binding of PLD2-HA to the
5-HT2AN376ct construct, which seemed greater than that to GST alone, however, the
overall level of binding of PLD2-HA to the constructs seemed to be less than that of
PLD1-HA and the apparent binding of PLD2-HA to the 5-HT2AN376ct construct was
not statistically significant compared to GST alone. Binding of PLD2-HA to the 5-
HT2Act was not discernibly affected by either mutation of N376-D, or by deletion of
amino acids N376-N384. PLD2-HA bound to a significantly greater extent to the 5-
HT2cct construct than to either GST alone or the 5-HT2AN376 receptor constructs (*





























Effects of co-transfection of the Gpy sequestering agent GRKct (GRK249s_659) on
PLD and PLC signalling by the muscarinic M3 and 5-HT2A receptors.
The Gpy subunit-sequestering agent GRK2ct, or control vector pcDNA3 were co-
transfected into COS7 cells with either the sPrC-5-HT2A receptor or the SFM3
receptor. The signalling via PLC and PLD of both receptors was then measured after
stimulation by the appropriate agonist (lpM 5-HT, or 200 p.M CCh). Responses in
the presence of the GRK2ct construct were compared with control responses. Values
are means ± SEM (n=6). Co-transfection of the GRKct construct significantly
reduced the PLD response of the M3 receptor to 200pM carbachol, but not that of the
5-HT2A receptor to lpM 5-HT (p<0.05, Wilcoxon test). PLC responses of the
receptor were unaffected by GRK2ct.
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Effects of co-transfection of of the GPy-sequestering agent GRKct
































Quantification of arrestin 2 and arrestin 3 binding to GST fusion protein
constructs of 5-HT2A and 5-HT2C receptor domains.
Matched levels of the constructs: GST-5-HT2ACt376-47i (2act); GST-5- HT2Ai3258-326;
(2Ai3); and GST alone were attached to glutathione-Sepharose beads and incubated
with equivalent levels of arrestins. Immunoreactivity for bound arrestin was
quantified by densitometry and the ratio to the level of input for each GST-fusion
protein construct was calculated. These ratios were then normalised to that found for
the 5-HT2Act construct. Arrestin 2 bound strongly to both the 5-HT2Act and the 5-
HT2Ai3 constructs but not to GST alone as shown in figure 4.13a. Values are means
± SEM for n=2 experiments. Arrestin 3 binding displayed a very similar pattern,
with strong binding to both the 5-HT2Act and the 5-HT2Ai3 constructs as can be seen
in figure 4.13b. Values are means, showing individual data for n=2 experiments.
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Quantification of arrestin 2 binding to GST fusion protein













































Quantification of arrestin 3 binding to GST fusion protein





























































Investigation of interactions between ARF1-HA and arrestin 2 in association
with the 5-HT2A receptor domain GST-fusion proteins.
a) The constructs GST-5-HT2ACt376-47i (2Act) and GST-5-HT2Ai3258-326 (2Ai3) were
incubated with ARF1-HA in cytosolic extracts and additionally further extracts,
which were enriched with arrestin 2, or non-enriched cytosolic extract. The addition
of the arrestin 2 increased the ability of ARF1-HA to bind to the 5-HT2ACt construct,
but had no effect on the binding of ARF1-HA to the 5-HT2Ai3 construct, b) The
construct GST-5-HT2ACt376-47i (2Act) was attached to glutathione-Sepharose beads
and incubated with arrestin 2-containing cytosolic extract. Additional samples of
extract containing ARF1-HA (or control) were added to samples. Binding of the
arrestin2 to the construct was not detectably affected by the addition of ARF1-HA.
The blots show results from a typical experiment repeated several times.
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Figure 4.14
Investigation of interactions between ARF1-HA and arrestin 2 in association with
the 5-HT2A receptor domain GST-fusion proteins
a























Various GPCRs have been shown to have a considerable number of binding partners,
(not just the heterotrimeric G-proteins) and the bulk of GPCR interacting proteins
(GIPs), of which more than 40 have been found to date, often interact with the
carboxyl-terminal domain of the GPCRs (Bockaert et al., 2003). The exact areas or
motifs on the carboxyl-terminal domain to which the GIPs bind are known to vary
considerably. A minority of GPCR C-termini have a consensus PDZ target motif.
The last 3 or 4 amino acids at the carboxyl end of the tail constitute the minimal
sequence required to PDZ domain proteins to associate, with the 3-4 amino acids
upstream of this determining the exact nature of the proteins interacting (Sheng and
Sala, 2001). Binding partners to the carboxyl terminal tail of the 5-HT2 receptors
have been recently investigated. The multi-PDZ domain protein MUPP1 was shown
to bind to the 5-HT2A, 5-HT2B and 5-HT2C receptors and, in the case of the 5-HT2C
receptor, this has been proved to be via the PDZ target motif at the extreme carboxyl
terminus of the receptor (Becamel et al., 2001). Both the 5-HT2A and 5-HT2B
receptors share this PDZ target domain. The homologous, but not identical, PDZ
target domain of the 5-HT2C receptor has also been shown to bind to PSD-95
(Becamel et al., 2002; Becamel et al., 2004) (we have independently confirmed the
interaction of PSD-95 with the 5-HT2A receptor, unpublished findings).
The N/DPxxY motif at the proximal end of the carboxy-terminal tail of many family
R GPCRs may allow for selection of ARF1/6 dependent signalling pathways,
(although not necessarily through direct binding of ARF to these residues). The
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adjacent region of the tail upstream of a paimitoylated cysteine membrane anchor
(which has been described as a putative fourth intracellular loop) is thought to
contribute additionally to ARF docking (Robertson et al., 2003). Alpha-helical
structures within the fourth intracellular loop of some GPCRs have also been shown
to bind to various other partners including periplakin and actin binding proteins
(Feng et al., 2003), and the binding site for JAK2 to the AT] receptor has also been
shown to be a YIPP motif in a putative eighth helical domain (amino acids 319-322)
within the receptor carboxyl terminal tail (although the AT) receptor does not contain
the consensus Palmitoylation site that would constrain this region into a fourth
intracellular loop) (Ali et al., 1997).
JAK2 has also been shown to associate with the 5-HT2A receptor, via co-
immunoprecipitation with the receptor and also associates with its downstream target
STAT3 (Signal Transducers and Activators of Transcription). The exact region of
JAK2 binding within the 5-HT2A receptor is unknown, (with no obvious YIPP-like
motif being present) although the carboxyl tail is a good candidate (GuilletDeniau et
al., 1997).
Furthermore, through proteomic analysis, a range of proteins have been found to
bind to the 5-HT2c receptor carboxy-terminal tail, through a variety of motifs. These
include Veli-3, Dlgh3 (MPP3), calmodulin, and dynamin I (Becamel et al., 2002). A
ternary complex that involves Veli-3, CASK and Mintl that has been found to bind
to the 5-F1T2C receptor, however the 5-HT2A receptor does not associate with a
similar complex (Becamel et al., 2004), so some marked differences in
protein:protein interactions exist, even between these two highly related receptors.
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The technique of Matrix Assisted Laser Desorption/ Ionisation Time of Flight Mass
Spectrometry (MALD1-TOF MS) is now a frequently used approach for the
identification of candidate protein:protein interactions. Any captured proteins are
digested with specific proteases, to produce accurate peptide molecular weight
'fingerprints' of proteins. These can then be screened against a database of analogous
peptides from known proteins to gain a variety of end results, such as detecting
mutations and polymorphisms, characterising post-translational modifications, or (as
in this case) the identification of unknown proteins (Pappin et al., 1993).
It was decided use this approach to search for novel protein binding partners for both
the third intracellular loop and the carboxy-terminal tail of the 5-FFT2A receptor, since
these domains are implicated in the signalling and cellular deployment of the
receptor.
Results
Identification of a novel binding partner for the 5-HT2a receptor carboxy
terminal tail: SIOOB.
GST-fusion proteins of the 5-HT2A receptor i3 and ct domains and GST alone were
incubated with rat brain soluble extract. Captured proteins were separated by SDS-
PAGE and bands of interest (Fig 5.1) were excised for analysis by MALDI-TOF MS,
Of the protein bands tested (since they were apparent in the SDS-PAGE lanes from
the 5-HT2A receptor constructs, but not GST alone), bands number 2, 3, 4 and 6 had
high probability matches for GST, suggesting that they are in fact breakdown
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products of the GST constructs (Table 5.1). Band number 1 was identified with high
probability as an E. coli protein, Elongation factor Tu (EF-Tu) (Table 5.1). It is
likely that this is a contaminant from the original expression of the GST-5-HT2A
receptor domains in the E. coli strain BL-21. Band 5 emerged from the database
search as the most promising result. The highest match, with 5 out of 45 peptides
matched, coverage of 40% and a MOWSE score of 7.986e+04, was a protein named
S100B (table 5.1). The database search engine matched the protein as the human
version of S100B. As the original cytosol was from rat brain, a search was done on
the homology of human and rat S100B. The amino acid composition of both
proteins is shown below, with the human version of the protein as the top line, and
the rat S100B sequence below:
0 10 20 30 40 50
SELEKAMVAL IDVFHQYSGR EGDKHKLKKS ELKELINNEL SHFLEEIKEQ
SELEKAMVAL IDVFHQYSGR EGDKHKLKKS ELKELINNEL SHFLEEIKEQ
60 70 80 90
EVVDKVMETL DNDGDGECDF QEFMAFVAMV TTACHEFFEH E
EVVDKVMETL DEDGDGECDF QEFMAFVSMV TTACHEFFEH E
As can be seen, there is a difference of only 1 amino acid between the two species at
position 62, which would not be likely have any significant difference on their match
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results and indicate that the G1P identified was indeed rat S100B (sequences from
Swissprot Protein database http://us.expasy.org/sprot/)
An antibody to S100B was used to confirm if this was indeed the unknown protein
isolated as band 5. Figure 5.3 indicates that not only was the unknown partner
correctly identified as S100B, but that it also binds specifically to the GST- 5-HT2ACt
construct, and not to either the GST 5-HT2Ai3 or to GST alone.
SWOB binds to the carboxyl-terminal tail of the 5-HT2A receptor in a
calcium dependent manner.
The SI 00 group of proteins are members of the SlOO/calmodulin/troponin C super
family of EF-hand calcium-binding proteins. There are 2 main subgroups of SI 00
proteins: SI00A, S100B (Donato, 1991; Donato, 1999), which can form homo- and
heterodimers. S100B is found predominantly in the central nervous system. The
SI00 proteins contain two EF-hand calcium binding sites. S100B has been shown to
bind to several different proteins, including p53 (Baudier et al., 1992; Rustandi et al.,
1998) and glial fibrillary acidic protein (GFAP) (Bianchi et al., 1994) in a calcium-
dependent manner. To determine the effect of calcium on the binding of S100B to
the 5-HT2ACt, S100B binding was examined under control conditions, in the presence
of ImM Ca2+, or with the calcium-chelating agent BAPTA, at a concentration of
2mM. It was observed that both S100B at 12kDa and a 24kDa immunoreactive
species (quite possibly a dimeric form(s) of S100B) bound under basal conditions to
the GST-5-HT2ACt, but not the GST-5-HT2Ai3 construct. The addition of BAPTA to
9+ •
chelate any Ca present in the brain extract markedly decreased the ability of the
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S100B to bind to the GST-5-HT2ACt, whereas the addition of ImM Ca2+ increased
the ability of both the S100B monomer and (putative) dimer to bind to the GST-5-
HT2Act construct. In the presence of additional calcium, a small amount of binding
of SI 00B was observed to the GST-5-HT2Ai3, but to a much lesser degree than to the
GST-5-HT2ACt. No additional magnesium was present in these experiments, and the
level of magnesium present in the experiments was unknown.
Discussion
The SI 00 proteins, of which up to 19 variants have been described, belong to the
superfamily of S100/calmodulin/troponin C calcium-binding proteins. A highly
conserved group of calcium binding proteins, ranging in size form 10-12 kDa, the
SI 00 family of proteins are differentially expressed in a large number of cell types.
The family is organised into 2 main groups: S100A, of which there are 14 isoforms
(S100A1-13, plus S100A8-like); S100B which consists of S100B alone; and another
4 proteins that do not fit into either of the previous sub groups (SI OOP, Profilaggrin,
Trychohyalin and Repetin which are larger proteins that exhibit an SI 00 motif along
their primary sequence) (Donato, 1999; Donato, 2003). The most common member
of this family is S100B, which was first described as a major constituent of glia
(Moore, 1965), but is now known to be more widely expressed in a range of tissues
(Donato, 1991). SI00 is present in the nervous system where it is substantially found
as homodimers of the S100A or S100B isoforms and also as S100A/S100B
heterodimers. S100A12, SI00B2 homodimers and S100A1 /S100B dimers are
especially common (Donato, 1999). The B isoform is most represented in the brain
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(-85% of the total S100)(Donato, 1986), where it is found intracellularly in the
cytoplasm of glial cells. Isoforms of the S100A group are present in the nervous
system as about 5% of the total SI 00 pool (Isobe et al., 1984), and they are also
present in muscle and kidney. SI00 is also found extracellularly and although the
mechanism of and reasons for its export from the cell are uncertain, a role in
neurotrophic and mitogenic activity has been suggested (see Fano et al., 1995 for a
review). There is also a direct correlation between the extracellular levels of SI 00
and damage to the brain tissues, as documented in the cases of Alzheimer's disease
(AD) (Peskind et al., 2001), dementia caused by Down's syndrome (DS) (Mrak et
al., 1997), progressive neurodegeneration in AIDS (Soderlund et al., 2004), autopsy-
diagnosed Creutzfeld-Jacob disease (CJD)(Nooijen et al., 1997), and schizophrenia
(Lara et al., 2001). For this reason, S100B is used as a sensitive marker of brain
damage.
The intracellular location of SI 00 proteins is mostly the cytoplasm, where these
proteins are thought to have many different roles, which are likely to be calcium-
dependent manner. S100B for example has been shown to bind to a range of targets,
including: p53, where it protects p53 from thermal denaturation and degradation;
fructose-1-6-bisphosphate aldolase and phosphoglucomutase where S100B been
suggested to have a role in the regulation of energy metabolism; membrane-bound
guanylate cyclase, where S100B may have a function in cell cycle regulation;
microtubules, where S100B may inhibit assembly via sequestration of tubulin and
stimulation of Ca2+ sensitivity of performed microtubules. S100B has also been
shown to bind to a large number of intracellular targets, where no clear function has
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yet been suggested, these include Annexin II, GAP-43 (neuromodulin) and
neurogranin (see Donato, 2003 for a review).
Dimerisation seems to be important for the biological activities of the SI 00 proteins.
The SI 00 monomers dimerise by means of the monomers interacting in an
antiparallel fashion. Upon Ca2+ binding, a hinge region on each monomer swings
out, forming a cleft, which is though to be important in the binding of SI 00 to target
molecules. (Donato, 1999; McClintock et al., 2002; Donato, 2003). By this
mechanism, the SI00 dimer functionally crosslinks two homologous or heterologous
target proteins (Donato, 2003)
There is no previous evidence to suggest that SI 00 can bind to any of the GPCRs,
although a small amount of SI 00 (5-7% of the total amount) has been shown to be
membrane associated (Rusca and Calissano, 1970). It has been shown that S100AB
can activate the membrane associated adenylate cyclase (AC) of cerebral cortex
membranes, in the presence of GTP. What is more intriguing is the fact that the
effect of SI 00 on AC was not detectable in the presence of an antibody to the
pertussis toxin sensitive G-protein Gj (Fulle et al., 1992), suggesting a possible role
of S100 in the activation of AC by Gj or at least modulation of this process.
Another calcium- binding protein calmodulin (CaM), which belongs to the same
superfamily of calcium binding proteins as SI 00 has recently been shown to co-
immunoprecipitate with the 5-HT2A receptor in an agonist-dependent manner.
Furthermore, the binding sites for calmodulin were shown to be on the second
intracellular loop (i2) and the carboxy-terminal tail domains. The interaction is
• 989 9Q9
thought to involve putative CaM binding sites at amino acid positions L and F
on the ct domain, which overlaps with a putative PKC substrate site that is readily
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phosphorlylated by PKC in vitro. Since the PKC-mediated phosphorylation and
CaM binding on the ct were mutually exclusive, it has been suggested that CaM
binding to the 5-HT2ACt has a role in regulation of 5-HT2A receptor phosphorylation
and desensitisation (Turner and Raymond, 2005).
Recent work suggests another possibly relevant role of SI 00 in that S100A10
(formerly known as pi 1 or calpactin I light chain) has been shown to participate in
the trafficking of the membrane ion channel Na(V)l .8 and acid-sensing ion channels
(ASICs ) to the plasma membrane (Okuse et al., 2002; Donier et al., 2005).
In conclusion, through the means of protein capture by binding to GST constructs of
5-HT2A receptor domains, and identification via Matrix Assisted Laser Desorption/
Ionisation Time of Flight Mass Spectrometry (MALDI-TOF MS), the novel binding
partner, S100B was found to bind to the 5-HT2ACt, but not the 5-FlT2Ai3. This
binding to the carboxy-terminal tail domain was found to be increased in the
presence or Ca2+ and decreased to an undetectable level in the absence of Ca2+. The
possible functional significance of this interaction is not yet clear and sufficient time
was not available within the project to investigate the question further. Nevertheless,
potential roles in 5-HT2A receptor trafficking, interactions with other proteins and





Proteins captured from rat brain cytosol by GST-fusion proteins of 5-HT2A
receptor domains.
GST constructs of the 5-HT2A receptor 3rd intracellular loop (i3) and carboxyl tail (ct)
and GST alone were exposed to cytosolic extract of homogenised rat brain which had
been pre-incubated with GST to pre-clear non-specific binding. Proteins that bound
to the domain constructs were eluted from the constructs first by high salt solution
(1M NaCl), and then by x2 Laemmli buffer. Eluates were then run on a 12.5% SDS-
PAGE gel and transferred to PVDF membranes. Figure 5.1 shows the resulting
membranes after staining with colloidal Coomassie stain. Lane 1-3 show the
proteins removed from the glutathione beads by x2 Laemmli buffer, lanes 4-6 show
the proteins eluted by high salt. Proteins eluted from the GST alone are shown in
lanes 1 and 4. Lanes 2 and 5 show the proteins removed from the GST-5-HT2Ai3




Proteins captured from rat brain cytosol by GST-fusion proteins




GST i3 ct GST i3 ct
Figure 5.2
MALDI-TOF MS of tryptic digest of protein band 5 resolved on SDS-PAGE gel.
The data here were collected in positive ion and reflector mode. Experimentally
determined mass/charge are labelled on the peptides. Band 5 from Fig 5.1 was
matched as S100B, with 40% peptide coverage, and 5/45 peptide masses matched.
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S100B binds specifically to the GST-5-HT2ACt construct.
GST constructs of the 5-HT2ai3 and 5-HT2ACt domains as well as a GST alone
control were exposed to rat brain cytosol, which had been pre-absorbed for any
interactions to GST alone. Protein bound to the construct was solubilised by
incubation in x2 Laemmli buffer, and run on a 12.5% gel, transferred to PVDF
membrane, and immunoblotted with HRP-linked S100B antibody. S100B bound
strongly to the 5-HT2ACt construct, but not to either the GST-5-HT2Ai3 construct or
GST alone. Figure is representative of 3 separate experiments. The lower panle




S100B binds specifically to the GST-5-HT2Act construct
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S100B binding to the 5-HT2ACt construct is calcium-dependent.
The binding of S100B to the GST constructs of the 5-HT2A i3 and ct domains was
carried out as previously (Fig 5.3), and in the presence of ImM Ca2+, and 2mM
BAPTA, a calcium chelating agent. The 3 right hand lanes of Figure 5.4 show the
ability of S100B to bind to the GST-5-HT2ACt construct under the various conditions,
and the left hand lanes show the binding of S100B to the GST-5-HT2Ai3 construct.
Equivalent levels of each construct were present in all lanes.
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Figure 5.4
S100B binding to the GST-5-HT2Act is calcium-dependent
GST-5-HT2Act GST-5-HT2Ai3 kDa
1: +lmM Ca2+
2: No added Ca2+
3: +2mM BAPTA
Table 5.1
Potential identities of protein bands bound to GST constructs of 5-HT2A
domains, as indicated by Protein Prospector software surveying the NCBI and
Swissprot databases.
Results from MALDI-Time of flight (TOF) mass spectroscopy (MS) analysis are
shown. The criteria used to identify a good match include the extent of sequence
coverage, the number of peptides matched, the probability (MOWSE) score and the
molecular mass of the protein identified. This table shows the top search results
using Protein Prospector software, in the NCBI or Swissprot databases, for the
protein bands extracted from the gel shown previously (Fig 5.1). Band No
corresponds with the band numbers shown in Fig 5.1. From this table it can be seen
that bands 2, 3, 4 and 6 are most likely fragments of the GST protein. Band number
1 seems to be the E.coli protein Elongation factor Tu (EF-Tu). Band number 5
seems to have the strongest correlation of all, with 5/45 peptide masses matched,
40% coverage, and a high MOWSE score of 7.986e+04 and was identified as S100B.
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Table 5.1
Potential identities of protein bands bound to GST constructs of 5-
HT2A domains, as indicated by Protein Prospector software












1 1.37e+10 14/24 42 43313.8 Elongation factor Tu (EF-Tu)
E.coli
1 8.37e+17 27/35 66 43182.6 Elongation Factor Tu (EF-Tu-
A) E.coli
2 6.33e+9 17/43 56 25498.8 Glutathione S-Transferase









Heamoglobin beta chain (Rat)
Heamoglobin alpha chain
(Rat)
3 1.31e+5 10/43 39 25498.8 Glutathione S-Transferase
3 1.85e+3 4/83 86645.5 Serine/Threonine protein
phosphatase with EF-hands-2
4 1.30e+6 8/27 51 15980 Haemoglobin beta chain (Rat)
4 3.2e+5 7/25 51 15979.5 Haemoglobin beta chain (Rat)
4 1.99e+4 7/37 13 89122.9 Homoserine Dehydrogenase
(E.coli)
4 3.02e+7 11/52 40 25498.8 Glutathione S-Transferase
5 7.986e+04 5/45 40 10744 S-100 protein, beta chain
(human)
5 1.28e+5 5/45 35 10430 3 OS ribosomal protein S19
(E.coli)
5 5.72e+3 6/61 13 65464.0 T-box transcription factor
(mouse)





















The recognition and characterisation of the various intracellular signalling pathways
activated by the family R GPCRs is very important when attempting to understand
the physiological mechanisms of intercellular and intracellular communication. The
family R GPCRs represent the largest family of GPCRs, which is in turn the largest
super-family of cell surface receptors in nature, containing receptors for a wide range
of ligands. The variation available at the receptor level is further amplified by the
fact that these cell surface receptors can each activate multiple intracellular
pathways. Most GPCRs signal through heterotrimeric G-proteins, to activate the
specific intracellular signalling pathway evoked by that G-protein (Figure 6.1 a), but
there is growing evidence that GPCRs can activate multiple intracellular pathways,
and are not linked to a single intracellular pathway as was once thought (Figure 6.1b
shows the complex interaction of signalling proteins elucidated by this study). The
new challenge is to decode how the receptors are selecting to activate the pathways
they have available to them.
One method the receptors may use to gain selective access to signalling pathways is
selection at the level of the ligand. There is evidence that some receptors can
activate different pathways within the cell when activated by different agonists
(Offermann etal., 1994; Robb etal., 1994; Kenakin, 1997; Berg et al., 1998;
Pommier et al., 1999). This suggests that the receptor can exist in different active
conformations, and these conformations can interact with and selectively activate
different signalling pathways. One example of this is the 5-HT2A receptor can select
for either PLA2 or PLC pathways in NIH3T3 cells upon activation by structurally
distinct ligands (Kurrasch-Orbaugh et al., 2003b).
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There is also evidence that there may be some means of selecting between pathways
by masking the ability of the receptor to couple to one or another pathway, for
example, in the 5-HT2A receptor, calmodulin has been shown to bind to the second
intracellular loop, thereby dampening the ability of the receptor to bind to and
activate the trimeric G-proteins (Turner and Raymond, 2005). The same sites bound
by calmodulin on the 5-HT2a receptor are also sites of PKC-phosphorylation, and by
binding to the receptor at these sites in an agonist-dependent manner calmodulin
could partially protect the receptor from PKC-mediated internalisation and
desensitisation, perhaps allowing the receptor to continue signalling via an
alternative second messenger system than that induced by the trimeric G-proteins
(Turner and Raymond, 2005). This consensus sequence for calmodulin binding
which may attenuate both trimeric G-protein association and PKC-phosphorylation
has also been seen in the most of the 5-HT receptors, M1.5 muscarinic receptors, and
the ot2A-D and Pi-3-adrenergic receptors (Turner and Raymond, 2005). Whether this
attenuation of trimeric G-protein interaction still allows for interaction of other
signalling partners, for example the small G-proteins like ARF and RhoA, has still to
be elucidated.
Another factor to be taken into account is the presence of various signalling partners
within cell types. For a receptor to be able to activate any of the pathways mentioned
previously, the components of that pathway have to be present in the cell studied,
and they also have to be available for the receptor to associate with, either expressed
in the cell type, or indeed within the same cellular compartment as the receptor.
A current field of enquiry in the study of GPCRs that is of considerable interest, is
the discovery that GPCRs seem to need to be in the form of either homodimers, or
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heterodimers to function properly (see Milligan et al., 2003; Milligan, 2004 for a
review). Furthermore whether this interaction is as a homodimer or a heterodimer
seems to affect the signalling abilities of the receptors involved. The role of receptor
dimerisation and selection of signalling pathways is an area of much present and
future research. It is known that dimers appear to activate a single heterotrimeric G-
protein (Fotiadis et al., 2003; Liang et al., 2003; Fotiadis et al., 2004), and indeed
this is also true for the activation of the ERK pathway by the M3 receptor (Novi et
al., 2004). However, what of the other signalling pathways, for example PLA2 and
PLD, do they also become activated by dimers in the same manner, i.e. one GPCR
dimer pair activates a single pathway-activating protein (PLD, PLC or PLA2, in this
case the triggering of PLD signalling)? Furthermore, can pathways activated by the
small G proteins also be activated by the same GPCR dimer that is also linked to one
heterotrimeric G-protein in either a concurrent or sequential manner? Thus there
remain many unknowns in the field of selectivity and stoichiometry of transduction
by GPCRs.
For many years the activation of PLD by GPCRs was seen as downstream of the
activation of PLC, via PKC activation, however, in recent years many studies have
shown that indeed PLD can be activated by a more direct route, namely via the small
G-proteins ARF and RhoA. It has been shown in chapter 3 of this study, by the use
of dominant negative ARF mutants, that both ARF1 and ARF6 are major
contributors to the activation of PLD by the M3 receptor in 132 IN 1 cells, and in
transfected COS7 cells, whilst the PLC response of the M3 receptor remained
unaffected. Similar observationshave been made for the angiotensin II and ET-1
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receptors in A10 cells (Shome et al., 2000). It has further been shown in that there is
a direct interaction between ARF1 or ARF6 and the M3 muscarinic receptor, as both
ARF1 and ARF6 can be co-immunoprecipitated with the receptor under basal
conditions, with the amount of ARF1 associated with the receptor increasing after
carbachol stimulation (Mitchell et al., 2003). The site of this interaction was
narrowed down in chapter 3 to the i3 and ct domains of the M3 receptor, where both
isoforms of ARF were seen to bind to both the M3B and the M3Ct GST-fusion protein
constructs, with ARF1 binding to the M3Ct domain (which contains the NPxxY
motif) to a greater extent than ARF6. The NPxxY motif was shown to have a great
influence on the binding of ARF1 and ARF6 to the carboxy-terminal tail domain of
the 5-HT2A receptor, which, unlike the M3 receptor, seems to stimulate PLD
activation via ARF1 alone and not ARF6. One interesting point is that the N376 to D
mutant form of the 5-HT2A receptor, as well as the P2U purinergic receptor (the native
sequence of which contains a DPxxY motif) do not activate PLD via ARF1, but
instead appear to activate PLD via ARF6 and PKC (Mitchell et al., 2003). This
backs up the results shown in chapter 4, where ARF1 binding to the 5-HT2ACt
domain is decreased in the presence of the N376D mutation, whereas the binding of
ARF6 is increased over that of ARF1.
It seems that the NPxxY motif is not the whole story though, since although the M3
and 5-HT2A receptors both contain the NPxxY motif, they seem to bind the ARF
isoforms via different mechanisms, with the M3 utilising both the i3 and ct domains,
whereas the 5-HT2a receptor seems to prefer the ct domain alone, with any
contribution by the 2Ai3 being much less than that of the M3B. The M3 muscarinic
receptor is also able to utilise ARF6 to activate PLD upon agonist stimulation, which
204
seems to be through the M3B domain. The differences between these two receptors
are not limited to their ability to activate PLD via ARF6. ARF-dependent PLD
activation by the M3 muscarinic receptor is not only sensitive to co-transfection of
dominant negative ARF1 and ARF6 constructs, and the ARF-GEF inhibitor brefeldin
A (BFA), but also to co-transfection with the G(3y-sequestering agent GRK2495.689.
This peptide seems to block the activation of PLD via ARF1 in the case of the M3
receptor, but not in the case of the 5-HT2A receptor, suggesting that the means of
activation of the ARF isoforms by these two receptors differ not only in the isoforms
of ARF which they can activate, but also seemingly in the means of activation. The
M3 receptor seems to utilise GPy in its activation of ARF in some way that the 5-
HT2A receptor does not. The difference may be in the binding site for ARF in the
receptors. The M3 muscarinic receptor has an unusually long i3 domain (R253-Q491)
at 239 amino acids in length, and this is utilised in the binding of both ARF1 and
ARF6 to the receptor. The i3 domain of the 5-HT2A receptor is not as large (I258-
Gj26) at a third of the size (68 amino acids), and so it might be predicted that there is
at least the potential for a number of additional interaction sites in the M3B Some of
these have already been characterised (Tobin et al., 1997; Wu et al., 1998; Wu et al.,
2000), but the exact nature of the interaction between G(3y, ARF and the M3B
remains unknown.
In the case of the 5-HT2A receptor, the interaction between ARF1 and the carboxy-
terminal tail of the receptor seems to be highly influenced by the N/DPxxY domain,
and not by the presence of GPy. However, the presence of arrestin 2 binding to the ct
domain increases the ability of ARF1 to interact with the ct, leading to further
differentiation between the mechanism of action of the M3 and 5-HT2A receptor in
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ARF-dependent activation of PLD. The interaction of arrestin 2 with ARF6 upon
activation of the P2-adrenergic receptor is well documented, whereby recruitment and
activation of ARF6, which is involved in the endocytosis of the receptor, is attained
(Claing et al., 2001). However it is unsure if the interaction of ARF1, arrestin 2 and
the 5-HT2A receptor delivers the same effect as that in the case of ARF6 and the P2-
adrenergic receptor. To further investigate this interaction requires assays of the
signalling events upon 5-HT2a receptor stimulation in the presence of arrestins. The
use of dominant negative and positive mutants of arrestin need some caution in
interpretation, as arrestins have varied roles within the cell, so ensuring selective
blockade of arrestin function in this context alone could prove to be difficult. What
is known, is that arrestin's usual role in a cell is to desensitise receptors by binding to
phosphorylated sites on intracellular receptor domains (usually the i3 and ct
domains) and leading to uncoupling of the heterotrimeric G-protein signalling and
endocytosis of the receptor. In the example of binding to the 5-HT2A receptor
domain GST-fusion proteins in vitro, no phosphorylation of the receptor domains
was in place and yet the arrestins still bound. Although the affinity of this interaction
was not directly investigated and it may be lower than that to phosphorylated target
sites, it seems possible that this binding may play a significant role in vivo.
This mechanism for ARF interaction with the 5-HT2A receptor is again at odds with
that of the M3 receptor. Arrestin interactions with the M3 muscarinic receptor are
thought to lead to the desensitisation of the receptor (reviewed in Hosey et al., 1995),
whereas there is no direct evidence of this being the case for the 5-HT2A receptor and
indeed desensitisation of the 5-HT2A receptor may well be via an arrestin-
independent route (Gray et al., 2001).
206
The role of the association of PLD with the 5-HT2 family of GPCRs requires further
investigation. It seems the ARF and PLD are binding to different motifs within the
carboxy-terminal domain of the 5-HT2 receptors, so they may interact independently
with the receptor, although indirect interactions might modify each other's abilities
to bind to this domain. Furthermore, it is impossible to tell from these experiments
whether PLD and ARF binding occur concurrently in the cell, and whether or not this
interaction is dependent upon activation of the receptor. So more experiments for
example investigation of the components of the ARF/PLD: receptor complex and
their dynamics could be studied by co-immunoprecipitation. It may be that both the
ARF and PLD are part of the same larger complex that interacts with the 5-HT
receptor, and that they interact with each other, with either the receptor itself, or
some other protein (possibly arrestin) acting as a scaffold for this interaction.
Further experimentation into the ability of receptors to signal through the various
pathways available, and how the pathway selection is determined, for example the
role of GPCR homo- and heterodimers formation, and the role this plays in the
signalling of the receptors, be an obvious next step in the progression of these
findings, as is looking at these binding pattern in situ, by use of confocal techniques
to discover when and where these proteins interact in vivo.
Chapter 5 discusses the ability of S100B monomers and dimers to bind to the 5-HT2A
receptor carboxy-terminal tail domain, although under physiological conditions, may
well be that the S100B binds as a dimer. This interaction is Ca2+ dependent, but
further work is required to discover if these proteins indeed interact under
physiological conditions, and if any role of this possible interaction can be discerned.
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A more exact definition of the binding motif for S100B may lead to a firmer
understanding of the physiological importance of this coupling. This function may
be similar to that of calmodulin in modulation of 5-HT2A receptor signalling, or it
may be in the role of a scaffolding protein, linking the 5-HT2A receptor with other
protein partners, or even other receptors. Any role of S100B in signalling of the 5-
HT2A receptor could be easily be clarified by use of mutant forms of the S100B in the
same signalling assays used in this study. Roles in scaffolding, and/or discovery of
the role of S100B in vivo could be discovered through confocal experimentation, to
see if these proteins are found to co-localise within cells.
The number of signalling pathways available to the superfamily of GPCRs increase
the complexity and diversity available to what is already a complex and diverse
system. Beyond the genomically defined diversity of GPCR function, splice
variations and the context-specific selection of particular signalling pathways further
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G protein-coupled receptors can potentially activate
phospholipase D (PLD) by a number of routes. We show
here that the native M3 muscarinic receptor in 1321N1
cells and an epitope-tagged M3 receptor expressed in
COS7 cells substantially utilize an ADP-ribosylation fac¬
tor (ARF)-dependent route of PLD activation. This path¬
way is activated at the plasma membrane but appears to
be largely independent of Gq/11, phospholipase C, Ca2+,
protein kinase C, tyrosine kinases, and phosphatidyl
inositol 3-kinase. We report instead that it involves
physical association of ARF with the M3 receptor as
demonstrated by co-immunoprecipitation and by in
vitro interaction with a glutathione S-transferase fusion
protein of the receptor's third intracellular loop do¬
main. Experiments with mutant constructs of ARF1/6
and PLD1/2 indicate that the M3 receptor displays a
major ARFl-dependent route of PLD1 activation with
an additional ARF6-dependent pathway to PLD1 or
PLD2. Examples of other G protein-coupled receptors
assessed in comparison display alternative pathways of
protein kinase C- or ARF6-dependent activation of
PLD2.
Many G protein-coupled receptors (GPCRs)1 can activate
phospholipase D (PLD), which catalyzes the hydrolysis of phos¬
phatidylcholine to phosphatidic acid and choline. Both phos-
phatidates and diacylglycerols (formed by phosphatidate hy¬
drolysis) may act as intracellular messengers. PLD has been
implicated as a key regulator of vesicular trafficking, cytoskel-
etal organization, exocytosis, endocytosis, and further signal¬
ing pathways (1-4). Activation of PLD can be brought about by
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1 The abbreviations used are: GPCR, G protein-coupled receptor; TP,
thromboxane A2; i3, third intracellular loop; tm7, transmembrane do¬
main 7; FLAG, DYKDDDD epitope tag; HA, hemagglutinin; GST, glu¬
tathione S-transferase; sFM;1, signal sequence-FLAG-tagged M:) recep¬
tor; PLC, phospholipase C; PLD, phospholipase D; PKC, protein kinase
C; PI 3-kinase, phosphatidylinositol 3-kinase; ARF, ADP-ribosylation
factor; [3H]NMe-QNB, 13HIA'-methylquinuclidinyl benzilate; i3H]InsP,
[3H]inositol phosphate; PHJPtdBut, PHlphosphatidylbutanol; PMTx,
P. multocida toxin; AEBSF, [4-(2-aminoethyl)-benzenelsulfonyl fluoride;
BFA, brefeldin A; GEF, GTP exchange factor; PDBu, phorbol 12,13-
dibutyrate; CHAPS, 3-l(3-cholamidopropyl)dimethylammonio]-l-pro-
panesulfonic acid; Bis-Tris, 2-[bis(2-hydroxyethyl)aminol2-(hydroxy-
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a variety of signaling events (5-8), many of which could poten¬
tially contribute to the stimulation of PLD activity by GPCRs.
These include the activation ofprotein kinase C (PKC), protein-
tyrosine kinases, phosphatidylinositol 3-kinase (PI 3-kinase),
small G proteins of the ARF and Rho families, and possibly the
elevation of intracellular Ca2+ levels.
This study addresses the mechanism of PLD activation by
the M3 muscarinic receptor expressed endogenously in 1321N1
human astrocytoma cells and heterologously in COS7 cells. The
M3 receptor is a member of the Group I, rhodopsin-related
GPCR family that is expressed in the nervous system and
peripheral tissues. The best established signaling pathway
from the M3 receptor is the pertussis toxin-insensitive activa¬
tion of phospholipase C (PLC) via the heterotrimeric G protein
Gq/U, although PLD is also strongly activated. In various cell
types, PKC, protein-tyrosine kinases, ARF, and Rho have each
been specifically implicated in M3 receptor-mediated PLD ac¬
tivation (6, 9-12). The data here emphasize the importance of
a pathway to PLD that involves direct association between
ARF and the M3 receptor (12).
ARF1 and ARF6 are representative of the main classes of
cellular ARFs (Classes I and III) and have distinct subcellular
distributions in many cell types. In resting cells, ARF1 is
largely cytosolic or Golgi-associated, whereas ARF6 is often
localized to the plasma membrane (13-17). Nevertheless ARFs
can translocate to Golgi membranes upon GTP loading (13, 18)
and to unspecified membranes following formyl-Met-Leu-Phe
or M.j receptor activation (10, 19, 20), so their precise intracel¬
lular location following stimulation is not clear.
The isoform of PLD that mediates ARF-dependent responses
was thought for several years to be PLD1 because of its acti¬
vation in vitro by ARF (and Rho and PKC) (5, 21). Neverthe¬
less, recent evidence suggests that PLD2, and especially an
amino-terminally truncated form of PLD2 can also be activated
by ARF (22, 23). Both PLD1 and the truncated form of PLD2
are activated in vitro by ARF1 more effectively than by ARF6
(23). In contrast, PLD2 heterologously expressed in cells can be
activated to a similar extent by constitutively active ARF1 and
ARF6 (7). ARF-dependent PLD activity and GPCR-mediated
PLD responses have been described in the plasma membrane
compartment (24-26), although the identity of the isoform
responsible was not clear. PLD1 is largely associated with
Golgi and other intracellular membranes (27-29), but some is
also associated with the plasma membrane (30-32), and the
enzyme can be recruited to the plasma membrane during exo¬
cytosis (26, 33). In contrast, PLD2 is more generally associated
with the plasma membrane (27, 34), although it too can be
associated with Golgi structures (35).
33818 This paper is available on line at http://www.jbc.org
Ms Receptor-ARF Interactions 33819
The present experiments investigate the mechanisms of M3
receptor-mediated PLD activation in 132 IN 1 and COS7 cells in
comparison to those utilized by other GPCRs in the same
conditions. We address specifically the roles played by ARF1/6
and PLD 1/2 as well as the subcellular location of the relevant
components and the site at which the PLD activation response
occurs. In addition, we provide explicit evidence for agonist-
regulated physical association of ARFs with the M3 receptor
and show that this may involve binding to its third intracellu¬
lar loop (i3) domain.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media were obtained from Invitrogen. Lab¬
oratory chemicals were obtained from Merck and were of Analar stand¬
ard. Pharmacological agents were obtained from Sigma unless other¬
wise indicated. U73122 and 4-(2-aminoethyl)-benzenesulfonyl fluoride
(AEBSF) were from Alexis Biochemicals Ltd. (Nottingham, UK).
U46619, Pasteurella multocida toxin (PMTx), chelerythrine chloride,
myr-PKCa19_27, bisindolylmaleimide I, PP1, genistein, and AG 213
were from CN-Biosciences (UK) Ltd. (Nottingham, UK). Ilimaquinone
was from Biomol, Affiniti (Exeter, UK). Aceclidine was from Tocris
(Bristol, UK). [3HINMe-quinuclindinyl benzilate ([3H]NMe-QNB; 84 Ci/
mmol), [3H]oxotremorine-M (69 Ci/mmol), [3H]myo-inositol (20 Ci/
mmol), and [3H]palmitate (40 Ci/mmol) were from PerkinElmer Life
Sciences. CGP 41251 (36) was kindly provided by Ciba-Geigy.
Molecular Reagents—In order to prepare the SPFLAGhM3R.pcDNA3
construct, the human M3 receptor was PCR-amplified from first strand
cDNA made from RNA extracted from the human neuroblastoma SH-SY5Y
cell line using the Stratagene reverse transcriptase-PCR kit. In the first
round, a 1.9-kb fragment encoding the FLAG epitope (DYKDDDDA) at the
5'-end was amplified using primer pair FLAGhM3R.fp [5'-GACTACAAA-
GACGATGACGACGCCATGACCTTGCACAATAAC] and hM3R.rp [5'-AT-
CATCACCAGAAGTCACCCC], utilizing the Expand High Fidelity PCR
System (Roche Applied Science) according to the manufacturer's instruc¬
tions. In the second round, 0.5 p.1 of the first round PCR was amplified with
the primer 5'-CAGGCATGAAGACGATCATCGCCCTGAGCTACATCTTC-
TGCCTGGTATTCGCCGACTACAAAGACGATGACG-3', encoding a modi¬
fied influenza hemagglutinin signal sequence, and the hM3R.rp. The 1.9-kb
fragment was purified by agarose gel electrophoresis and Qiaex II (Qiagen
Ltd., Crawley, UK) and then subcloned into the pGEMTEasy cloning vector
(Promega Biosciences Inc., Southampton, UK). The reading frame and PCR
integrity of the cloned construct were verified by nucleotide sequence anal¬
ysis. For expression studies, the 1.9-kb insert was released from the
pGEMTEasy vector by restriction digestion with EcoRI and SpeI and sub-
cloned into the EcoRUXbal sites ofpcDNA3 (Invitrogen). GST fusion protein
constructs ofArg^-GLn490 from the M3 receptor third intracellular domain,
M;}i3 (in pGEX-4T-l) (37), and the 58-amino acid STREX exon of the BK
channel (in pGEX-5X-l) were kindly provided by Steve Lanier and Mike
Shipston, respectively. The expression construct for the N376D mutant
5-HT2A receptor (12), kindly provided by Stuart Sealfon, was subcloned into
pcDNA3, incorporating a signal sequence and epitope tag.
Wild type and dominant negative ARF constructs with a C terminus
HA epitope tag were kindly provided by Julie Donaldson. The mutant
constructs, T31N-ARF1 and T27N-ARF6, are defective in the exchange
of GTP for GDP and act as functional dominant negative forms (14).
Wild type constructs of PLD lb and PLD2 as well as corresponding
catalytically inactive mutants (K898R-PLD1 and K758R-PLD2) and the
PIM87 mutant PLD1 (which is selectively defective in activation by
PKC) (6, 7) were kindly provided by Mike Frohman.
Cell Culture and Transfection—1321N1 human astrocytoma cells
were maintained in Dulbecco's minimal essential medium containing
100 /xg/ml penicillin and streptomycin and supplemented with 10%
fetal calf serum. COS7 cells were grown in Dulbecco's minimal essential
medium containing 10% normal calf serum and 100 /xg/ml of penicillin
and streptomycin. Prior to transfection, COS7 cells were grown to
- 70% confluence and were then transfected using FuGENE-6 (Roche
Applied Science) according to the manufacturer's guidelines. Trans¬
fected cells were used in experiments 72 h after transfection. In a small
number of experiments, HEK 293 cells were similarly transfected. In all
experiments involving transfection, equivalent amounts of empty vec¬
tor were substituted in control samples to compensate for any omitted
plasmid.
Ligand Binding Assays—Specific binding of [3HlNMe-QNB was
measured in membrane fractions of 1321N1 and sFM3 receptor-trans-
fected COS7 cells. Cells were washed in Hanks' balanced salt solution
and then homogenized in ice-cold 50 mM sodium phosphate buffer, pH
7.4 with 2 mM MgCl2, 2 /xg/ml aprotinin, and aliquots were taken for
protein assay (Coomassie binding method; Pierce). Homogenates were
centrifuged at 12,000 x g for 30 min at 4 °C, and the pellet was washed
twice more. For the binding assay, 1% bovine serum albumin was
added. Ligand concentrations were varied from 20 pM to 2 nM, and
nonspecific binding was defined by 1 /xM NMe-atropine. After 4 h at
25 °C, an excess of ice-cold buffer was added, tubes were centrifuged,
and the supernatant was aspirated from the pellet. Data were curve-
fitted by nonlinear regression (Fig P, Elsevier-Biosoft, Cambridge, UK).
Cell surface specific binding of [3H]oxotremorine-M was measured to
1321N1 and sFM3 receptor-transfected COS7 cells in 12-well plates at
4 °C. Culture medium was replaced with phosphate-buffered saline
containing 2 mM MgCl2 and 1% bovine serum albumin and then plates
were chilled on ice. Ligand (5 nM), with or without 3 /xM NMe-atropine
to determine nonspecific binding, was added, and samples were incu¬
bated for 16 h at 4 °C to minimize internalization. Incubations were
then quenched with excess ice-cold buffer and washed once. Ice-cold
"acid strip" solution (0.2 M acetic acid, 0.5 M NaCl) was added for 5 min
to release surface-bound ligand. The internalization of specific [3H]ox-
otremorine-M binding sites into COS7 cells was measured at 37 °C over
a time course of 0-50 min following the addition of ligand. Both ligand
and NMe-atropine concentrations were as in the experiments carried
out at 4 °C. Total and nonspecific binding levels were assessed at each
time point. Following 5 min with cold acid strip solution to remove
surface-bound ligand, cells were solubilized in 1% SDS, 1 m NaOH and
then neutralized, to determine [3H] ligand in both cell surface and
internalized compartments.
Signal Transduction Assays—Cellular [3H] inositol phosphate
([3H]InsP) production (PLC activity) was measured in 12-well plates
following labeling with 1 /xCi/ml [3H]inositol for 18 h in serum-free
medium. Agonist responses were measured usually over 30 min in the
presence of 10 mM LiCl before cells were lysed in ice-cold 10 mM formic
acid, and [3H]inositol phosphates were separated by ion exchange (38).
Inhibitory agents and the LiCl were added 30 min and 15 min prior to
agonist, respectively. [3H]Phosphatidylbutanol ([3H]PtdBut) production
(PLD activity) was measured in 12-well plates following labeling with
1.5 /xCiAvell [3H]palmitate for 18 h in serum-free medium. It has been
shown that the presence of serum causes elevated basal activity of PLD
(21). Agonist responses were measured usually over 30 min in the
presence of 30 mM butan-l-ol. Assays were terminated, phospholipids
were extracted into chloroform/methanol, and l3H]PtdBut was sepa¬
rated by thin layer chromatography (39). Inhibitory agents and the
butan-l-ol were added 30 min prior to and immediately before agonist,
respectively. In experiments with PMTx (40), agonist incubations were
carried out over a total period of 4 h, with replacement of medium
containing fresh PMTx and LiCl or butan-l-ol at 2 h. All data from
signal transduction and ligand binding experiments are expressed as
means ± S.E. from between 4 and 10 separate determinations.
Immunoprecipitation of sFM3 Receptor—In order to immunoprecipi-
tate the sFM3 receptor with any associated proteins, plasmids encoding
the sFM;} receptor and either ARF1-HA or ARF6-HA were transiently
transfected into COS7 cells. 72 h later, the cells were serum-deprived
for 4 h. Cells were then exposed to carbachol (20 /xm) or no drug for 15
min and washed once in Hanks' balanced salt solution before being
solubilized in immunoprecipitation buffer (phosphate-buffered saline,
pH 7.5, 1% CHAPS, 0.75% sodium deoxycholate, 2 /xg/ml aprotinin, 4
/xg/ml leupeptin, 1 mM AEBSF, 2 /xg/ml pepstatin, 1 mM sodium or-
thovanadate, 1 mM sodium fluoride, 5 mM sodium molybdate, and 50
/xg/ml soybean trypsin inhibitor (2 ml/175-cm2 flask for 1 h on ice).
Carbachol was readded where appropriate. Extracts were centrifuged
at 12,000 x g for 15 min at 4 °C to remove particulate material and
precleared with Protein G-Sepharose 4B fast flow (Sigma) (20 /xl of 1:1
suspension/ml for 45 min at 4 °C). After centrifugation, the supernatant
was removed to tubes containing either mouse monoclonal FLAG anti¬
body (clone M2, 10 /xg/ml; Sigma) or nonimmune mouse IgG (10 /xg/ml;
Sigma) with 40 /xl/ml Protein G-Sepharose suspension, before rolling at
4 °C overnight. Beads were collected by centrifugation and washed
twice in immunoprecipitation buffer before 40 /xl of 2x Laemmli buffer
(2% SDS, 5% mercaptoethanol, 20 mM Tris, pH 7.4) was added per ml of
original supernatant. SDS-PAGE and electroblotting onto "Immo-
bilon-P" polyvinylidene difluoride membranes (Millipore Ltd., Watford,
UK) were carried out using a Phastsystem apparatus (Amersham Bio¬
sciences). Western blots were carried out on the samples and original
supernatants to detect immunoprecipitated proteins and monitor input
levels. The primary antibodies were rabbit polyclonal raised to the third
intracellular loop of the M3 receptor (41) (gift from Andrew Tobin) and
rabbit polyclonal against the HA epitope tag (Santa Cruz Biotechnol¬
ogy, Autogen Bioclear Ltd., Calne, UK), followed by preabsorbed sec-
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ondary antibodies conjugated to horseradish peroxidase (Chemicon
International Ltd., Harrow, UK). Bands were visualized by ECL
(Amersham Biosciences) and then measured by quantitative
densitometry.
In further experiments, an alternative procedure was used in which
the sFM;} receptor associated with ARF1-HA or ARF6-HA immunopre-
cipitates was measured by specific [3H]NMe-QNB binding. Cells treated
with or without carbachol were solubilized in immunoprecipitation
buffer with 10% glycerol, and precleared supernatants were immuno-
precipitated with 2 /Ag/ml 12CA5 mouse monoclonal HA antibody (or
nonimmune mouse IgG) for 90 min followed by Protein G-Sepharose for
40 min. This more rapid procedure was designed to minimize the
possibility of any nonspecific interactions of the solubilized proteins.
Immunoprecipitates were washed in immunoprecipitation buffer with
10% glycerol and then resuspended into [3H]NMe-QNB binding buffer
(above) with 10% glycerol and 0.3 mg/ml sonicated phosphatidyl choline
prior to ligand binding, as above.
Cell Surface Biotinylation—In some experiments, cell surface pro¬
teins were biotinylated using a membrane-impermeant reagent (bio-
tinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt)
(Sigma); 1 mM for 2 h at 4 °C). The reaction was quenched with 75 mM
glycine (10 min at 4 °C), and cells were washed in phosphate-buffered
saline before returning to minimal essential medium and warming to
37 °C. Cells were then stimulated with 20 /am carbachol (10 min) or
control before solubilization. Extracts were incubated with monomeric
avidin-agarose (1 h at 4 °C) and washed in solubilization buffer before
biotinylated proteins were eluted by incubation in 2 mm biotin for 30
min at 4 °C. These supernatants were then subjected to immunopre¬
cipitation with 12CA5 HA antibody (or nonimmune IgG control) and
subsequently used in specific [3H]NMe-QNB binding assays, as above.
GST Fusion Protein Interaction Assays—The GST-M3i3 (Arg252-
Gln490) construct in pGEX-4T-l and the control GST-BKgTREX construct
in pGEX-5X-l were expressed in BL21-RIL bacterial cells, which were
then grown up in standard 2x YT (yeast extract, tryptone, NaCl)
medium with 2% glucose added. When the cells had reached an A600 of
0.6-0.8 units/ml, expression of the fusion proteins was induced by the
addition of 0.1 mM isopropyl-/3-D-thiogalactoside for 3 h at 37 °C. Cells
were harvested by centrifugation and then lysed with BugBuster rea¬
gent (Novagen, CN-Biosciences) for 10 min and again centrifuged. The
supernatant, containing the GST fusion proteins, was added to gluta-
thione-Sepharose beads (Amersham Biosciences). The beads were incu¬
bated with the bacterial supernatant for 20 min at room temperature to
allow binding of the GST fusion proteins to the beads. The matrix
formed was then washed extensively with phosphate-buffered saline
and used immediately.
In order to provide cytosolic extracts enriched with various ARF
constructs, transfected COS7 cells were homogenized in ice-cold extrac¬
tion buffer (2 ml/175-cm2 flask, 2 /Ag/ml aprotinin, 1 mM AEBSF, 1 mM
dithiothreitol, 2 /xg/ml pepstatin, 1 mM sodium orthovanadate, 1 mM
sodium fluoride, 50 /xg/ml soybean trypsin inhibitor in phosphate-buff¬
ered saline). The cells were then homogenized (Ystral homogenizer;
setting 3, 15 s) before being centrifuged (12,000 x g for 20 min at 4 °C).
The supernatant was aliquoted and stored at —40 °C. ARF-HA-en-
riched extracts were incubated with the GST fusion protein affinity
matrix in 250 /xl of Buffer A (20 mM Tris-HCl, pH 7.5, 0.6 mM EDTA, 1
mM dithiothreitol, 70 mM NaCl, 0.05% Tween 80) for 90 min at 4 °C with
rolling. The beads were washed four times in Buffer A, and then the
retained proteins were removed from the beads with 2x Laemmli buffer
and applied to 20% homogenous Phastgels (Amersham Biosciences) for
SDS-PAGE and subsequent Western blotting. Membranes were probed
for HA immunoreactivity to monitor captured ARFs and for GST im-
munoreactivity to assess levels of fusion protein input (GST alone --29
kDa, GST-M3i3 —49 kDa, and GST-BKstkex —35 kDa). Antibodies were
rabbit polyclonal anti-HA and polyclonal anti-GST (Santa Cruz Bio¬
technology). Horseradish peroxidase-conjugated secondary antibodies
and ECL were as used in the immunoprecipitation studies. Input levels
ofARF-HA immunoreactivity in extracts were also monitored, and both
fusion protein and ARF inputs were carefully balanced to ensure com¬
parability between samples.
Subcellular Fractionation—Homogenates of sFM;J receptor-trans-
fected COS7 cells (in 175-cm2 flasks), either control or treated with 200
//.M carbachol for 10 min, were prepared and initially centrifuged at
1000 x g for 8 min to remove nuclei and unbroken cells. The remaining
membranes were fractionated through gradients of Percoll (Amersham
Biosciences) under alkaline conditions designed to optimally separate
endoplasmic reticulum, Golgi, and plasma membrane fractions (24).
Fractions (0.5 ml) were downloaded from the bottom of the gradient by
peristaltic pump (1 ml/min), and adjacent fractions were combined into
Laemmli buffer for SDS-PAGE on Nu-PAGE 4-12% gradient Bis-Tris
gels (Invitrogen) before immunoblotting for organelle marker proteins
as well as for PLD1 and ARF1. The antibodies used were goat polyclonal
anti-EEAl (endoplasmic reticulum marker; Santa Cruz Biotechnology),
mouse monoclonal anti-GM130 (Golgi marker; Transduction Laborato¬
ries, BD Biosciences, Cowley, UK), mouse monoclonal anti-Na+/K+
ATPase oq subunit (plasma membrane marker; Upstate Biotech Ltd.,
Milton Keynes, UK), rabbit polyclonal anti-PLDl (N-terminal region)
(BIOSOURCE International Inc., Nivelles, Belgium), and sheep poly¬
clonal anti-ARFl/3 (Upstate Biotech). For [3H]PtdBut production ex¬
periments, each 175-cm2 flask of cells was labeled with 150 /xCi of
[3H]palmitate in serum-free medium for 16 h prior to the experiment.
Subcellular fractions were extracted with chloroform/methanol accord¬
ing to the standard PLD assay procedure, and [3H]PtdBut was similarly
separated by thin layer chromatography.
RESULTS
PLD Activation by Native Ms Receptors in 132IN1 Cells—
Ligand binding studies with [3H]NMe-QNB demonstrated spe¬
cific muscarinic binding sites in 1321N1 cells and sFM3 recep-
tor-transfected COS7 cells but not in mock-transfected COS7
cells. In 1321N1 cells, the KD and Bmax of specific [3H]NMe-
QNB binding were 0.26 ± 0.03 nM and 193 ± 27 fmol/mg
protein, similar to previous work (42), which showed that the
muscarinic receptors present were almost entirely of the M3
subtype. In sFM3 receptor-transfected COS7 cells, the KD and
Bmax of specific [3H]NMe-QNB binding were 0.58 ± 0.04 nM
and 2.64 ± 0.47 pmol/mg protein. In pilot experiments with
wild-type M3 receptor cDNA (lacking the signal sequence and
FLAG tag), binding showed similar affinity but lower Bmax,
values.
In 1321N1 cells, the M3 agonist carbachol caused concentra¬
tion-dependent increases in both [3H]PtdBut and [3H]InsP pro¬
duction (Fig. la). The EC50 values for these PLD and PLC
responses were similar, being 10.2 ± 2.0 and 8.1 ± 1.7 /am,
respectively. The nicotinic cholinergic agonist 1,1-dimethyl-4-
phenyl-piperazinium iodide caused no discernible increase in
[3H]PtdBut production through the range 3-100 /am (1.20 ±
0.17-fold of basal control at 100 /am l,l-dimethyl-4-phenyl-
piperazinium iodide, n = 4), indicating that nicotinic receptors
made no significant contribution. The muscarinic partial ago¬
nist, aceclidine, activated PLD with a lower maximum re¬
sponse, in the order of 30% of that for carbachol (in line with its
reported efficacy in PLC activation). 1321N1 cells also express
the thromboxane A2 (TP) receptor, which like the M3 receptor
is coupled to PLC activation via Gq/11 but contains an alterna¬
tive motif in transmembrane domain 7 (tm7) that is believed to
disrupt ARF-dependent coupling to PLD activation (12). The
selective TP receptor agonist U46619 caused concentration-de¬
pendent activation of PLD (Fig. la) but with properties distinct
from the M3 receptor response.
The PLD response to 200 /am carbachol was inhibited in a
concentration-dependent manner by brefeldin A (BFA; a selec¬
tive inhibitor of a subfamily of ARF GTP exchange factors
(ARF-GEFs), known as BIG1/2) (43). The corresponding PLC
response was unaffected (Fig. lb). PLD responses to a low
concentration of carbachol (10 /am) or to aceclidine (500 /am)
showed similar BFA sensitivity to that with 200 /am carbachol,
having IC50 values of 61.4 ± 9.5, 56.8 ± 11.1, and 55.5 ± 13.5
/am, respectively. In contrast, PLD activation by the TP receptor
agonist U46619 was unaffected by BFA. The time course of
PLD and PLC activation by carbachol in 1321N1 cells is shown
in Fig. lc. There was rapid desensitization of the PLD, but not
the PLC response, over the times examined. BFA had no effect
on the time course of PLC activation but diminished the initial
rate and maximal extent of PLD activity, although the profile
of desensitization was unaltered. Since PLD responses can
occur downstream of PLC activation, we examined effects of
the selective PLC inhibitor U73122. Fig. Id shows that U73122
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Fig. 1. Differential involvement of
ARF and PLC in the PLD responses
of M3 and TP receptors in 1321N1
cells. The [3H]PtdBut (PLD) and
[3H]InsP (PLC) responses elicited by the
M3 receptor agonist carbachol and the
partial agonist aceclidine as well as the
TP receptor agonist U46619 were charac¬
terized, together with the effects of the
PLC inhibitor, U73122, and the ARF-
GEF inhibitor, BFA, on these responses.
Values are means ± S.E., n = 4-12. a,
concentration dependence of PLD re¬
sponses to carbachol (•), aceclidine (▼),
and U46619 (A) as well as the PLC re¬
sponse to carbachol (■). b, concentration
dependence of BFA effects on PLD re¬
sponses to 200 pM carbachol (•), 10 pM
carbachol (A), 500 pM aceclidine (▼), and
30 pM U46619 (■) as well as PLC re¬
sponses to 200 pM carbachol (O). BFA
caused statistically significant inhibition
of the PLD responses to carbachol and
aceclidine at concentrations of 50-200 pM
BFA (p < 0.05, Wilcoxon test), c, time
course of PLD and PLC responses to 200
pM carbachol in the presence/absence of
100 pM BFA. •, control PLD response to
carbachol; ■, in the presence of BFA. O,
control PLC response to carbachol; ▼, in
the presence of BFA. d, concentration de¬
pendence of U73122 effects on PLD re¬
sponses to 200 pM carbachol (#) and 30
pM U46619 (■) as well as on PLC re¬
sponses to 200 pM carbachol (O). PLD re¬
sponses to U46619 and PLC responses to
carbachol showed statistically significant
inhibition by U73122 at concentrations of
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had no effect on PLD responses of the M3 receptor despite
inhibiting PLC responses with an IC50 value of 3.6 ± 1.9 pM. In
contrast, PLD activation by the TP receptor agonist U46619
was readily inhibited by U73122 (ICn0 value of 3.4 ± 1.4 pM). In
case Gq/n might play a role that was independent of PLC, we
used the selective direct activator of Gq/11, PMTx, which was
found to cause concentration-dependent activation of [3H]InsP
production (Fig. 2a). PMTx also caused [3H]PtdBut production,
and the response to a nearly maximally effective concentration
(0.7 nM; 2.84 ± 0.36-fold of basal) was found to be inhibited
readily by U73122 (IC50 value of 3.1 ± 0.6 pM) but not by BFA
(Fig. 26). Pertussis toxin (100 ng/ml; 16 h) had no effect on
carbachol-induced [3H]PtdBut production (data not shown), in¬
dicating that Gjy0 do not play a role here.
Since PKC and ARF can act synergistically to activate PLD
(5), we further investigated a potential role for PKC in M3
receptor responses. The selective PKC inhibitors CGP 41251,
NPC-15437, chelerythrine chloride, and myristoyl-PKCa19_27
all had little or no effect on carbachol-induced PLD activation
in 1321N1 cells (only chelerythrine chloride at the highest
concentration tested, 30 pM, caused a statistically significant
inhibition) (Fig. 2c). In contrast, CGP 41251 clearly inhibited
the PLD response to phorbol 12,13-dibutyrate (PDBu) at the
same concentrations. Any involvement of Ca2+ elevation in M3
receptor PLD responses was investigated using the cell-perme¬
able Ca2+ chelator l,2-bis(2-aminophenoxy)ethane-A(rA^V'//'-
tetraacetic acid acetoxymethyl ester (1-10 pM). This caused
only very minor inhibition of carbachol-induced PLD activation
(data not shown).
PLD activation by the M3 receptor may involve protein-
tyrosine kinases in HEK 293 cells (9) but not 1321N1 cells (44),
so we investigated the effects of the selective inhibitor of Src
family tyrosine kinases, PP1 and the broad-spectrum tyrosine
kinase inhibitors genistein and AG 213. None of these had any
significant effect on carbachol-induced PLD activation in
1321N1 cells (Fig. 2d). However, in HEK 293 cells transiently
transfected with the sFM3 receptor construct, we found that
carbachol-induced [3H|PtdBut production was inhibited signif¬
icantly by genistein and AG 213 with IC5() values of 6.3 ± 1.3
and 15.8 ± 4.2 pM, respectively (n = 6).
Receptor-mediated PLD activation in some cells is sensitive
to PI 3-kinase inhibitors (45), but we found no effect of wort-
mannin (1 pM) or LY 294002 (50 pM) on the concentration
dependence, time course, or BFA sensitivity of carbachol-in¬
duced PLD activation in 1321N1 cells (data not shown).
The Role ofARF1 and ARF6 in PLD Activation by the sFM:i
Receptor Expressed in COS7 Cells—In order to elucidate which
ARF isoforms were mediating the M3 receptor response, we
carried out complementary experiments in COS7 cells trans¬
fected with the sFM3 receptor. Carbachol caused concentration-
dependent activation of PLD and PLC with ECS0 values of
9.4 ± 2.2 and 1.2 ± 0.1 pM, respectively (Fig. 3, a and 6). As in
1321N1 cells, the PLD response was inhibited by BFA, with an
IC50 value of 64.1 ± 16.3 pM, but was resistant to the PKC
inhibitor CGP 41251 (86.4 ± 12.2% of control at 10 pM, n = 4).
Co-transfection of negative mutant ARF1 or ARF6 constructs
caused inhibition of carbachol-induced activation of PLD, but
not PLC. In cells with the sFM3 receptor alone, 200 pM carba-
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Fig. 2. Evidence for the lack of ma¬
jor involvement of Gq/11, PKC, or ty¬
rosine kinases in M3 receptor PLD
responses in 1321N1 cells. The l3H]Pt-
dBut (PLD) and [3H]InsP (PLC) re¬
sponses elicited by the Gq/11 activator
PMTx, carbachol, and PDBu were charac¬
terized, and their sensitivity to inhibitors
of PLC, ARF-GEFs, PKC, and tyrosine
kinases was assessed. Values are the
means ± S.E., n = 5-10. a, concentration
dependence of PLC activation in response
to PMTx (O). b, concentration dependence
of the effects of U73122 (•) and BFA (□)
on PLD responses to 0.7 nM PMTx. Effects
of U73122 were statistically significant at
concentrations of 2-20 /am U73122 (p <
0.05, Wilcoxon test), c, concentration de¬
pendence of the effects of PKC inhibitors
on the PLD responses to 200 /am carbachol
(•, CGP 41251; ■, NPC-15437; A, chel-
erythrine chloride; ▼, myristoyl-PKCa1S)_
27) and to 300 nM PDBu (O, CGP 41251).
The only statistically significant effect on
PLD responses to carbachol was that of 30
/am chelerythrine chloride, whereas re¬
sponses to PDBu were inhibited by 0.3-10
/am CGP 41251 (p < 0.05, Wilcoxon test).
Bisindolylmaleimide I and calphostin C
were not used because of known effects on
the M.j receptor and PLD, respectively, d,
concentration dependence of the effects of
tyrosine kinase inhibitors on the PLD re¬
sponses to 200 pM carbachol (•, PP1; ■,
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chol caused 5.18 ± 0.50-fold basal [3H]PtdBut production,
whereas co-transfection with T31N-ARF1 gave a 2.80 ± 0.21-
fold response, co-transfection with T27N-ARF6 gave a 3.26 ±
0.48-fold response, and co-transfection with a combination of
the ARF1/6 mutant constructs resulted in a 1.68 ± 0.28-fold
response (re = 8). Omissions of constructs were fully substi¬
tuted by empty vector. The negative mutant ARF values were
significantly less than carbachol alone, and the combination
showed a further significant reduction. A small residual com¬
ponent of sFM:i receptor-mediated [3H]PtdBut production re¬
mained in the presence of both T31N-ARF1 and T27N-ARF6.
The co-transfection of wild type ARF1 or ARF6 had no sig¬
nificant effect on the activation of PLD by carbachol (Fig. 3a).
None of the ARF constructs significantly modified basal PLD
activity (Fig. 3, a, c, and d; data not shown) or reduced the
expression of sFM3 receptors at the plasma membrane, as
assessed by the specific acid-displaceable binding of [3H]ox-
otremorine-M. For example, specific binding of [3Hloxotremo-
rine-M removed by acid strip represented 372 ± 31 dpm/well
for sFM3 receptor alone, with corresponding values of 348 ± 40
for sFM:i receptor plus T31N-ARF1 and 328 ± 46 for sFM3
receptor plus T27N-ARF6 (re = 6). Similarly, 45-min preincu¬
bation of 1321N1 cells with 150 /am BFA had no discernible
effect on cell surface-specific binding of [3H]oxotremorine-M
(data not shown). Fig. 3c illustrates the BFA sensitivity of
carbachol-induced [3HlPtdBut production with or without the
negative mutant ARF1/6 constructs. Controls showed inhibi¬
tion of responses by BFA with an IC50 of 64.1 ± 16.3 /am. The
attenuated PLD activation in the presence of T27N-ARF6 re¬
mained sensitive to BFA with an IC50 of 29.8 ± 17.1 /am. In
contrast, the residual responses in the presence of T31N-ARF1
or both T31N-ARF1 and T27N-ARF6 were no longer reduced by
BFA. This suggests that the sFM3 receptor can utilize both
ARF1 and ARF6 for activation of PLD, but the BFA sensitivity
of the response reflects predominantly ARF1.
In comparison, we examined the PLD response to ATP (act¬
ing at native P2U receptors). This was unaffected by BFA but
was clearly reduced by the PKC inhibitor CGP 41251 and by
transfection of T27N-ARF6 but not T31N-ARF1 (Fig. 3d). In
contrast to the sFM3 receptor, the native P2u receptor thus
appears to utilize PKC- and ARF6-dependent (but ARFl-inde-
pendent) pathways for PLD activation. It seems unlikely that
the difference between sFM3 and P2U receptors is due to het¬
erologous expression because the findings with the sFM3 re¬
ceptor here mirror those obtained with the native M3 receptor
in 1321N1 cells (Figs, lb and 2c) (12). To corroborate this, we
transfected COS7 cells with the N376D mutant 5-HT2A recep¬
tor, which displays BFA-insensitive responses (in contrast to
the wild type 5-HT2A receptor, where BFA is effective) (12).
PLD responses of the N376D mutant 5-HT2A receptor were also
significantly inhibited by the PKC inhibitors, CGP 41251 and
bisindolylmaleimide I, but not by BFA, T31N-ARF1, genistein,
or AG 213. Although T27N-ARF6 reduced responses by 20-
25%, this did not reach statistical significance (Fig. 3d and data
not shown).
Physical Association of ARFHARF6 with the sFM:t Recep¬
tor—The question of whether ARF1 or ARF6 could participate
in some form of direct complex with the receptor was investi¬
gated first by co-immunoprecipitation and second by in vitro
interaction with a GST fusion protein of the M3 receptor i3
domain. Fig. 4 shows co-immunoprecipitation data from COS7
cells co-transfected with sFM:i receptor and wild type ARF1-HA
or ARF6-HA. Input levels ofARF-HA and the efficiency of sFM3
receptor pull-down were monitored to ensure balance between
samples. In Fig. 4a, low levels of ARF1-HA and ARF6-HA
immunoreactivity were associated with the sFM3 receptor in
basal conditions, apparently in excess of nonimmune IgG con¬
trols. Preincubation of cells with carbachol caused increased
association of ARF1-HA but not ARF6-HA with the sFM3 re¬
ceptor, as monitored by densitometry of the immunoblots
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Fig. 3. Effects of co-transfection with wild type or negative mutant ARF constructs on the PLD and PLC responses of the sFM3
receptor in COS7 cells. The PH]PtdBut (PLD) and [3H]InsP (PLC) responses evoked by carbachol were measured in C0S7 cells transfected with
the sFM3 receptor and wild type or dominant negative constructs of either ARF1 or ARF6. Values are means ± S.E., n = 6-10. a, concentration
dependence of PLD activation evoked by carbachol acting at the sFM3 receptor in the presence of control vector (•), wild type ARF1 (■). wild type
ARF6 (a), T31N-ARF1 (□), and T27N-ARF6 (A). The negative mutant forms of both ARF1 and ARF6 significantly reduced PLD responses to
carbachol at concentrations of 2-200 p.m (p < 0.05, Wilcoxon test), b, shows the concentration dependence of PLC activation evoked by carbachol
acting at the sFM3 receptor in the presence of control vector (•), T31N-ARF1 (□), and T27N-ARF6 (A), c, concentration dependence of BFA effects
on PLD responses to 200 p.m carbachol in the presence of control vector (•), T31N-ARF1 (■), T27N-ARF6 (a), and T31N-ARF1 plus T27N-ARF6
(▼). O, effects of BFA on PLD responses of cells transfected with sFM3 receptor, but no ARF constructs, in the absence of carbachol stimulation.
All controls for transfections contained equivalent levels of empty vector. The carbachol-evoked PLC responses of sFMa receptor-transfected cells
were unaffected by BFA (data not shown). BFA (50-200 /j.m) caused significant inhibition of the PLD responses to carbachol only in the presence
of control vector or of the negative mutant form of ARF6 (p < 0.05, Wilcoxon test), d, shows the effects of the ARF-GEF inhibitor, BFA (150 p.m;
light gray columns) the PKC inhibitor, CGP 41251 (10 pM; medium gray columns), and transfected T31N-ARF1 (dark gray columns) or T27N-ARF6
(black columns) on basal PHJPtdBut production or that in the presence of ATP (10 pM), acting at the native P2U receptor or 5-HT (10 pM) acting
at the co-transfected N376D mutant 5-HT2A receptor. *, statistically significant differences from corresponding control responses (white columns)
(p < 0.05, Wilcoxon test).
(3.50 ± 1.15- and 1.35 ± 0.40-fold control respectively;
means ± S.E., n = 6). Fig. 4b shows an alternative, more rapid
and quantifiable procedure in which sFM3 receptor association
with ARF1-HA/ARF6-HA immunoprecipitates was measured
as specific (3H)NMe-QNB binding. This showed low basal levels
of co-immunoprecipitated binding sites but increased associa¬
tion with the receptor for ARF1-HA and (to a lesser extent)
ARF6-HA following carbachol stimulation. Fig. 4c character¬
izes the time course of sFM3 receptor-ARFl-HA association
following the addition of carbachol, showing a peak around 5
min and then gradual return to basal levels by 25 min.
The subcellular location of the sFM3 receptor-ARFl-HA as¬
sociation was investigated by cell surface biotinylation experi¬
ments. COS7 cells co-transfected with sFM3 receptor plus
ARF1-HA (or sFM3 receptor alone) were stimulated with car¬
bachol (or control), surface-biotinylated, and then solubilized.
Biotinylated proteins were captured on monomelic avidin
beads and eluted before HA immunoprecipitation. In both ba¬
sal and carbachol-stimulated conditions, 75-90% of the specific
[JH|NMe-QNB binding found in direct HA immunoprecipitates
was recovered in the biotinylation/avidin recovery procedure.
Values for direct HA immunoprecipitates were 202 ±31 and
384 ± 55 dpm/assay for basal and carbachol-stimulated respec¬
tively, whereas corresponding values from biotin/avidin cap¬
ture were 157 ± 20 and 312 ± 32 dpm/assay (n = 5). All
equivalent values for cells transfected with sFM3 receptor
alone did not exceed 55 dpm/assay and were similar.
Fig. 5 shows in vitro association of ARF1-HA or ARF6-HA
with a GST fusion protein construct of the M:Ji3 domain, a
control construct, or GST alone. The levels of each GST con¬
struct were shown to be similar by Coomassie Blue staining
and by GST immunoreactivity. ARFs were supplied as enriched
extracts from transfected COS7 cells, and binding was moni¬
tored by HA immunoblot. The data (which are representative of
at least three separate experiments) demonstrate specific in
vitro interaction of both ARF1-HA and ARF6-HA with the
GST-M3i3 but not control constructs.
The Role ofPLD1 and PLD2 in [3H]PtdBu.t Production by the
sFM:) Receptor in COS7 Cells—Since both PLD1 and PLD2 can
potentially be activated by ARFs, we investigated which PLD
isoform was responsible for the ARF-mediated response of the
receptor. Immunoblots for PLD isoforms in membranes of
1321N1, COS7, and HEK293 cells showed that both PLD1 and
PLD2 were present in each case (as in most cell types) (46) with
a mean ratio of PLD1/PLD2 levels decreasing in the order
COS7 > 1321N1 > I-IEK 293 (data not shown). Catalytically
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Fig. 4. Co-immunoprecipitation of the sFM3 receptor and either ARF1-HA or ARF6-HA from COS7 cells, a, COS7 cells co-transfected
with sFM3 receptor plus ARF1-HA or ARF6-HA were stimulated with carbachol (20 jum, 15 min) or control prior to solubilization. Extracts were
immunoprecipitated with FLAG antibody (or nonimmune IgG control) before SDS-PAGE and Western blotting. The left panel is from colls
co-transfected with sFM.( receptor and ARF1-HA; the right panel is from cells with sFMs receptor and ARF6-HA. In the top sections, the
immunoprecipitate was probed with an antibody against the M3 receptor i3 sequence. The middle sections show the input levels of immunoreactive
ARF-HA in original extracts. The bottom sections show HA immunoreactivity associated with the immunoprecipitated receptor and indicate a
carbachol-induced increase in the association of ARF1-HA but not ARF6-HA. The receptor runs as a broad band centered at about 90 kDa, diffuse
because of glycosylation. ARFl-HA and ARF6-HA run at —20 kDa. A nonspecific band was seen at —30 kDa in all samples, which is likely to reflect
nonspecific cross-reaction with immunoglobulins. These observations were typical of six separate experiments, b, results from an alternative
procedure in which ARF-HA immunoprecipitates were probed for the presence of sFM3 receptor by the measurement of specific [3H]NMe-QNB
binding. Extracts from control mock immunoprecipitation with nonimmune IgG are shown for unstimulated cells (white columns) or following 20
pM carbachol for 5 min [dark gray columns). Corresponding anti-HA immunoprecipitates are shown from cells that were unstimulated {light gray
columns) or carbachol-stimulated (black columns). Both ARF1-HA and ARF6-HA showed significantly increased association with specific
PHlNMe-QNB binding sites following carbachol compared with unstimulated or nonimmune IgG controls. Values are means ± S.E., n 6. *, p <
0.05, Mann-Whitney U test. Input levels of both sFM3 receptor and ARF1-HA/ARF6-HA in original cell extracts were shown to be matched between
samples (data not shown), c, time course of association between ARF1-HA and the sFM3 receptor as reflected by specific [3H]NMe-QNB binding.
The ARF1-HA immunoprecipitates, but not nonimmune IgG controls (• and □, respectively), showed a rapid time course of carbachol-induced
increases in interaction (peaking at around 5 min and declining again to basal levels within 30 min).
inactive mutants of PLD1 (K898R-PLD1) and PLD2 (K758R-
PLD2) were co-transfeeted with the sFM3 receptor to assess
any disruption of carbachol-induced [3H]PtdBut and [3H]InsP
responses (Fig. 6, a and b). K898R-PLD1 but not K758R-PLD2
significantly reduced carbachol-induced ['1H]PtdBut responses
(Fig. 6a), although both constructs were adequately expressed
(data not shown). In contrast, transfection of a PLD1 mutant
with selectively reduced responsiveness to activation by PKC
but not ARF/Rho (PIM87-PLD1 (6, 7), caused a significant
increase in sFM3 receptor responses, which remained sensitive
to BFA with an IC50 of 65.4 ± 13.1 p.m (n = 4). Neither
K898R-PLD1 nor PIM87-PLD1 affected basal [3HlPtdBut re¬
sponses, whereas K758R-PLD2 caused a small, but consistent
reduction (in the order of 20-30%) (Fig. 6, a and e). The cata-
lytically inactive PLD mutants had no discernible effect on PLC
responses of the receptor (Fig. 66).
We then asked whether the K898R-PLDl-sensitive or -re¬
sistant components of the sFM3 receptor [3H]PtdBut response
corresponded to the sensitivity to BFA, T31N-ARF1, or T27N-
ARF6 (Fig. 6, c and d). Whereas control responses were inhib¬
ited by BFA with an IC50 of 47.4 ± 6.3 pM, and those in the
presence of K758R-PLD2 were still clearly inhibited (IC50 of
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Fig. 5. In vitro association of ARF1-HA or ARF6-HA with GST
fusion protein of the M3 receptor third intracellular loop. GST
fusion proteins were captured on glutathione-Sepharose to form affinity
matrices, which were incubated with cytosolic extracts from COS7 cells
transfected with ARF1-HA or ARF6-HA. Attached proteins were sepa¬
rated by SDS-PAGE and immunoblotted. Control GST constructs (GST-
BK, a segment of the BK potassium channel (—35 kDa), and GST alone
(—29 kDa)) were compared with the M3i3 construct (—49 kDa)). a, input
of constructs, immunoblotted for GST. b, HA immunoblots to detect
bound ARF1-HA or ARF6-HA, demonstrating specific binding ofeach to
the M:,i3 construct. The positive control lanes reflect the level of ARF
input (with a 12.5-fold dilution factor).
33.1 ± 8.9 p.m, n = 10), the residual response in the presence of
K898R-PLD1 was unaffected by BFA (Fig. 6c). We further
examined the effects of T31N-ARF1 and T27N-ARF6 on re¬
sponses in the presence of K898R-PLD1 or K758R-PLD2 ex¬
pression. Fig. 6d shows that negative mutant ARF1 and ARF6
constructs significantly inhibited both control responses and
those in the presence of K758R-PLD2. The residual [3H]PtdBut
response in the presence of K898R-PLD1 was no longer sensi¬
tive to further inhibition by the negative mutant ARF1 con¬
struct but retained a small yet significant inhibitory effect of
T27N-ARF6. These data suggest that the receptor uses an
ARFl-mediated (BFA-sensitive) pathway to PLD1 and an
ARF6-mediated (BFA-insensitive) pathway that can lead to
either PLD1 or P.LD2.
Fig. 6e demonstrates, in contrast, that K758R-PLD2 (but not
K898R-PLD1) inhibits [jH]PtdBut responses of the P2u recep¬
tor. Matching observations were made with the (similarly BFA-
insensitive) N376D mutant 5-HT2A receptor. The responses to
5-HT (10 pM) were 2.67 ± 0.36-, 2.89 ± 0.46-, and 1.28 ±
0.15-fold basal for the N376D-5-HT2A receptor alone and that
in the presence of K898R-PLD1 or K758R-PLD2, respectively.
The inhibition due to K758R-PLD2 was statistically significant
(p < 0.05, Mann-Whitney U test, n = 6). Fig. 6e also shows that
PDBu-induced [3H]PtdBut production was attenuated by both
K898R-PLD1 and K758R-PLD2, consistent with evidence that
not only PLD1 (5-7) but also PLD2 (47-49) can be targeted by
PKC. In addition, effects of wild type PLD1, wild type PLD2,
and PIM87-PLD1 expression were compared on basal, PDBu-
evoked, sFM3 receptor, and P2U receptor-mediated responses.
Wild type PLD2, but not the other constructs, caused a marked
increase in basal [3H]PtdBut levels, matching reports of its
constitutive activity (27). Responses to PDBu, carbachol, and
ATP were all nonselectively increased. In contrast, wild-type
PLD.1 increased PDBu-evoked and sFM;J receptor-mediated,
but not P2U receptor-mediated responses. PIM87-PLD1 caused
a significant increase in sFM3 receptor-mediated responses
only, consistent with the idea that the role of PLD1 in sFM3
receptor responses is independent of PKC.
Subcellular Trafficking of Components in M:i Receptor PLD
Activation—Since BFA disrupts the structural integrity of the
Golgi apparatus at concentrations less than or equal to those
used here (50), we asked whether altered trafficking ofproteins
needed for the signaling pathway, such as PLD itself, might
contribute to the inhibitory effect of BFA. First, it is clear that
a number of other GPCRs have PLD responses that are unaf¬
fected by BFA (Fig. 16) (12). Second, when we compared the
effects of BFA (Fig. 16) with those of two further Golgi-disrupt-
ing agents, ilimaquinone and nocodazole (31, 35, 51), on PLD
responses mediated by M3 and TP receptors in 1321N1 cells,
neither mimicked the effect of BFA receptor; nor did they affect
responses to U46619 (30 /xm) or PDBu (300 n.\i) (Fig. 16; data
not shown). ["'HJPtdBut responses to 200 /xm carbachol were
6.62 ± 0.46- and 5.72 ± 0.64-fold basal with ilimaquinone (25
/xm for 30 min) and nocodazole (10 /xm for 4 h), respectively,
compared with values of 6.67 ± 0.34 and 3.31 ± 0.52 for
carbachol alone and carbachol plus 100 /xm BFA (n = 6). In the
presence of ilimaquinone, the IC50 for BFA was 72.1 ± 14.1 /xm,
similar to that in control conditions (Fig. 16) and further sug¬
gesting that the effect of BFA on M3 receptor PLD responses
was distinct from any effects on Golgi structure.
To investigate whether endocytosis of the sFM3 receptor
might be necessary for its PLD responses, we utilized a domi¬
nant negative construct of dynamin 1, which reduces the inter¬
nalization of agonist-occupied M3 receptors (52, 53). Whereas
transfection of K44A-dynamin 1 clearly reduced internaliza¬
tion of specific [''H]oxotremorine-M binding to the sFM3 recep¬
tor in COS7 cells, carbachol-induced [3H|PtdBut production
was unaltered, suggesting that endocytosis is not important for
receptor PLD response (Fig. 7a). The internalization of specific
[*'H]oxotremorine-M binding was unaffected by BFA (150 /xm
for 30 min) or by transfection of either T31N-ARF1 or T27N-
ARF6 (data not shown). To address more directly the possibil¬
ity that sFM3 receptor-mediated PLD activation might occur in
endocytosing vesicles, we carried out subcellular fractionation
of COS7 cell membranes after carbachol stimulation and ana¬
lyzed the location of the ["'HJPtdBut production. Alkaline Per-
coll gradients (24) were used to separate plasma membrane,
Golgi, and endoplasmic reticulum fractions, characterized by
immunoreactivity for Na+/K+ ATPase, GM130, and EEA1, re¬
spectively (Fig. 76). Carbachol induced a large increase in
[3HJPtdBut production in plasma membrane fractions, with a
much smaller response being detected in Golgi and endoplas¬
mic reticulum fractions.
The question of whether ARF and PLD proteins undergo
translocation to the plasma membrane following stimulation
with carbachol was addressed by immunoblots on the Percoll
gradient fractions. Under basal conditions, ARF1 was distributed
through plasma membrane and Golgi fractions, whereas PLD1
was detectable only in non-plasma membrane fractions (Fig. 76).
After carbachol stimulation, ARF1 and PLD1 became concen¬
trated or newly detectable, respectively, in plasma membrane
fractions, and this translocation was not prevented by the pres¬
ence of BFA (Fig. 76). ARF6 and PLD2 were detectable in plasma
membrane fractions with or without carbachol (data not shown).
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Fig. 6. Effects of co-transfection
with mutant or wild type PLD con¬
structs on the PLD and PLC re¬
sponses of the sFM3 receptor in COS7
cells. The [3H]PtdBut (PLD) and
[3H]InsP (PLC) responses evoked by car-
bachol (and other stimuli) were measured
in C0S7 cells transfected with the sFM3
receptor and PLD 1/2 constructs. Values
are means ± S.E., n = 6-10. a, concen¬
tration dependence of PLD responses to
carbachol in the presence of control vector
(•), K898R-PLD1 (catalytically inactive;
□), K758R-PLD2 (catalytically inactive;
A), and PIM87-PLD1 (PKC activation-de¬
ficient; O). Responses to 10-200 fXM. car¬
bachol were significantly reduced in the
presence of K898R-PLD1, and responses
to 50-200 /xM carbachol were significantly
increased in the presence of PIM87-PLD1
(p < 0.05, Wilcoxon test), b, concentration
dependence of PLC activation by carba¬
chol in the presence of control vector (•),
K898R-PLD1 (□), and K758R-PLD2 (A),
c, concentration dependence of BFA ef¬
fects on PLD responses to 200 /xM carba¬
chol in the presence of control vector (•),
K898R-PLD1 (■), and K758R-PLD2 (▲)
as well as on basal levels of [3H]PtdBut
accumulation (O). BFA (50-200 /xm)
caused significant inhibition of the PLD
responses to carbachol in the presence of
control vector or negative mutant PLD2
(p < 0.05, Wilcoxon test), d, effects of co-
transfection with negative mutant ARFs
on sFM3 receptor-mediated PLD re¬
sponses, either control (empty vector) or
the residual responses in the presence of
K898R-PLD1 or K758R-PLD2. Cells were
additionally transfected with vector
(white columns), T31N-ARF1 (light gray
columns), or T27N-ARF6 (medium gray
columns), and the (3H]PtdBut production
induced by 200 /xM carbachol was meas¬
ured. Values are means ± S.E., n = 6.
Statistically significant differences from
control carbachol-induced responses are
indicated with asterisks (p < 0.05, Wilc¬
oxon test), e, comparison of the effects of
various PLD1/2 constructs on [3H]PtdBut
production mediated by the sFM3 recep¬
tor and the native P2U receptor in COS7
cells as well as basal activity and that
induced by PDBu. Basal, PDBu (300 nm)-,
carbachol (CCh\ 200 /xm)-, and ATP (10
pM)-evoked responses were assessed in
the presence of control empty vector
(white columns), K898R-PLD1 (light gray
columns), K758R-PLD2 (medium gray
columns), wild type PLD1 (dark gray col¬
umns), wild type PLD2 (charcoal gray col¬
umns), and PIM87-PLD1 (black columns).
Values are means ± S.E., n — 6-8. Sta¬
tistical significance of differences from
empty vector controls is indicated by as¬
terisks (p < 0.05, Wilcoxon test).
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DISCUSSION
A BFA-sensitive Route ofPLD Activation for the M.} Receptor
hut Not Other GPCRs—The M3 muscarinic receptor shows
BFA-sensitive activation of PLD when expressed as a native
receptor in 1321N1 cells or heterologously in COS7 cells. Time
course experiments showed rapid desensitization of M3 recep¬
tor PLD responses in 1321N1 cells as reported previously (44)
and revealed that this was unaltered by BFA. BFA sensitivity
of PLD responses was seen at low as well as high agonist
concentrations and for a partial agonist, indicating that cou¬
pling to this pathway was not restricted to a particular level of
agonist occupancy. PLC responses of the Ma receptor in both
cell types were unaffected by BFA as were the PLD responses
of control GPCRs, the TP receptor in 132 IN 1 cells and the P2U
receptor and N376D mutant 5-HT2A receptor in COS7 cells. In
contrast to the M3 receptor, which contains an NPXXY motif in
tm7, each of these contains the alternative DPXXY sequence,
which is believed to prevent receptor coupling to BFA-sensitive
PLD activation (12). PLD responses elicited by PMTx or
U46619, but not by carbachol, were inhibited by the PLC in¬
hibitor U73122, suggesting an indirect PLC-dependent route of
PLD activation for the TP receptor but not the Ma receptor.
We considered further whether Ca2+ elevation or PKC activ¬
ity might still play a role in Ma receptor PLD responses. Ca2+












































Fig. 7. Evidence that sFM;} receptor-mediated [3H]PtdBut production occurs at the plasma membrane of COS7 cells and involves
agonist-induced translocation of mediator proteins to that compartment, a, the left panel shows the inhibitory effect of transfection with
the K44A-dynamin 1 (dominant negative mutant) on internalization of [3H]oxotremorine-M (a hydrophilic agonist ligand) into an acid strip-
resistant compartment. #, cells with sFM3 receptor alone; ■, cells with sFM3 receptor and K44A-dynamin 1. The cell surface-specific binding of
[3Hjoxotremorine-M was unaffected (data not shown). The right panel shows [3H]PtdBut production in control cells in basal (white column) or
carbachol (200 /xm)-stimulated conditions {mediumgray column) as well as in cells co-transfected with K44A-dynamin 1 in basal {light gray column)
or carbachol-stimulated conditions {black column). sFM3 receptor-mediated PLD activation was unaltered by K44A-dynamin 1. b, subcellular
distribution of membrane-associated basal (O) or carbachol (200 /xm)-stimulated (•) [3H]PtdBut production in sFM;, receptor-transfected COS7
cells. Membranes were separated on Percoll gradients into fractions, which were characterized by immunoblot for the endoplasmic reticulum,
Golgi, and plasma membrane markers (EEA1, GM130, and Na+/K+-ATPase, respectively). The response to carbachol was associated predomi¬
nantly with plasma membrane fractions, c, the subcellular distribution of immunoreactivity for native PLD1 and ARF1/3 in membranes of cells
under basal conditions or stimulated with carbachol (200 /am) or carbachol plus 150 /am BFA. Although the ARF antibody used cross-reacts with
ARF3 as well as ARF1, the latter form is greatly predominant in cells. Under basal conditions, PLD1 was widely distributed, except in plasma
membrane fractions, and ARF1/3 was present mainly in Golgi and plasma membrane fractions. Following carbachol stimulation, PLD1 immu¬
noreactivity extended through to the plasma membrane, and ARF1/3 immunoreactivity became concentrated in plasma membrane fractions. BFA
treatment did not disrupt carbachol-induced translocation of either PLD1 or ARF1/3.
mobilization does not appear to be an important mediator in
1321N1 (54) or HEK 293 cells (9) but the evidence for a role of
PKC in M3 receptor PLD responses is equivocal. In 1321N1, but
not HEK 293 cells, PKC down-regulation is reported to inhibit
the M3 response (9, 55). However, the profound PKC activation
involved in the procedure makes interpretation difficult. In
apparent contrast, in M3 receptor-transfected HEK293 cells,
co-transfection of the PKC activation-deficient mutant, PIM87-
PLD1, yielded smaller PLD responses to carbachol than did
excess wild type PLD1 (6), but it was not clear how this com-
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pared with responses with native PLD alone. However, in
experiments with the related M, receptor, PIM87-PLD1 facil¬
itated the response to carbachol, compared with untransfected
cells (7), suggesting that PKC-independent pathways to PLD
were being utilized, as we found here with the M3 receptor. Our
observations with various PKC inhibitors, designed to block
both catalytic and regulatory domains, provide no evidence to
suggest a major contribution of PKC to the M3 receptor PLD
response in 1321N1 cells.
BFA inhibited M3 receptor PLD responses here in 1321N1
and COS7 cells with IC50 values of about 50 /xm. BFA sensitiv¬
ity of M3 receptor PLD responses in HEK 293 cells has been
reported previously but with some 2-3-fold lower potency (10),
as we confirmed in transiently transfected HEK 293 cells (IC50
of 157 ± 23 p.m, n = 4). The lower potency in HEK 293 cells may
reflect greater involvement of an alternative tyrosine kinase-
dependent pathway. In A10 smooth muscle cells, PLD re¬
sponses of angiotensin II and ET-1 receptors were strongly
inhibited by BFA (56), whereas formyl-Met-Leu-Phe and ATP
receptor responses in differentiated HL60 cells and bradykinin
and sphingosine 1-phosphate receptor responses in A549 ade¬
nocarcinoma cells were not (57, 58). The extent to which a
GPCR demonstrates BFA-sensitive PLD responses in different
cell types may well be influenced by the cellular content of
mediators for particular pathways. The concentrations of BFA
that selectively inhibit M3 receptor PLD responses here exceed
those needed to disrupt the integrity of Golgi membranes (50,
57, 58), but are similar to those that inhibit the ARF-GEFs,
BIG1/2 (43). Considering whether disruption of Golgi traffic
might play a role here, we confirmed that the cell surface
expression of M3 receptors and their PLC activation were un¬
affected by BFA (although these measures may not be very
sensitive to acute disruption of trafficking). It is possible that
PLD responses, but not other responses of GPCRs, may have a
selective requirement for protein trafficking and thus may be
selectively sensitive to Golgi disruption by BFA. Other GPCRs
have clearly BFA-insensitive PLD responses, although theoret¬
ically they might generate their PLD responses by different
mediators that are unaffected by disruption of the Golgi. How¬
ever, the selective effect of BFA on M3 receptor PLD responses
was not mimicked by ilimaquinone and nocodazole, which also
profoundly disrupt Golgi structure and function. Furthermore,
we established that the subcellular location of carbachol-in-
duced (3H]PtdBut production in sFM3 receptor-containing
COS7 cells was predominantly in the plasma membrane frac¬
tion and showed directly that whereas the response involved a
movement of both PLD1 and ARF1 to this site, the transloca¬
tion was not prevented by BFA. Similar observations were
found using confocal microscopy (data not shown). Therefore,
the effects of BFA on PLD responses of particular receptors
appear to reflect a specific intervention in signal transduction
rather than a general disruption of protein trafficking.
ARF1 and ARF6 Involvement in PLD Activation by the sFM3
Receptor but Not Other GPCRs—We addressed the role of dif¬
ferent subtypes of ARF in sFM3 receptor PLD activation by
transfection of either wild type ARFI or ARF6 or their domi¬
nant negative constructs, T31N-ARF1 and T27N-ARF6 (14).
Neither wild type ARF construct significantly affected PLD
activation by carbachol, suggesting that the cellular content of
endogenous ARFs is probably not a limiting factor. However,
dominant-negative ARFI and ARF6 constructs each inhibited
PLD responses without modifying PLC responses. Effects of
negative mutant ARFI and ARF6 in combination were signif¬
icantly greater than either alone, suggesting that the two ARF
isoforms might each play a distinct role. Although negative or
positive mutants of ARFs can disrupt Golgi and other vesicular
trafficking (14, 59-62), we found that neither the levels of
specific cell surface [3H]oxotremorine-M binding sites nor sFM:J
receptor PLC responses were affected by the ARF constructs
here. In parallel with our observations, PLD responses of the
angiotensin II and ET-1 receptors in A10 cells were inhibited
by both T31N-ARF1 and T27N-ARF6 constructs (56). In con¬
trast, we showed that the responses of two DRXXY-contaming
receptors, the P2U receptor and the N376D mutant 5-HT2A
receptor, were unaffected by T31N-ARF1 but were clearly in¬
hibited by T27N-ARF6 and PKC inhibitors (P2U receptor) or by
PKC inhibitors alone (N376D mutant 5-HT2A receptor). This
suggests that ARF6 and PKC may be important in alternative
pathways that underlie the BFA-insensitive [3H]PtdBut pro¬
duction seen with some GPCRs. The BFA sensitivity of M3
receptor PLD responses was clearly preempted in the presence
of dominant negative ARFI but not ARF6, indicating that an
ARFl-dependent pathway from the receptor, probably involv¬
ing BIG1/2, is responsible for the sensitivity to BFA. Corre¬
spondingly, it has been shown that BIG1/2 can act as effective,
BFA-sensitive ARF-GEFs for ARFI but not ARF6 (43) and that
in vivo functional effects of ARF6 are often BFA-insensitive
(63, 64). The sFM3 receptor PLD response in COS7 cells there¬
fore appears to comprise at least two components: an ARFl-de¬
pendent BFA-sensitive pathway and an ARF6-dependent,
BFA-insensitive pathway.
Physical Association of Both ARFI and ARF6 with the M3
Receptor through Its i3 Domain—Low levels of ARF1-HA and
ARF6-HA were associated with sFM3 receptor immunoprecipi-
tates under basal conditions, whereas the amount of associated
ARF1-HA but not ARF6-HA was clearly increased when cells
were incubated with carbachol. In an alternative, rapid proce¬
dure where reduced nonspecific interactions were expected, we
found that a small, carbachol-induced increase in ARF6-HA
interaction with the receptor could be shown as well as that for
ARF1-HA. The time course of carbachol-induced association of
ARF1-HA with the receptor was similar to that for the increase
in [3H]PtdBut production.
Using GST fusion proteins, we further investigated the in¬
teraction of ARFI and ARF6 with the M3 i3 domain, which is
known to contain sites for interaction with heterotrimeric G
proteins, arrestins, G/3y, and the kinases GRK2 and CKl-a (37,
65-67). We showed previously that i3 domain splice variants of
the PACj receptor show marked differences in their BFA-sen¬
sitive activation of PLD but not other signaling responses (39),
suggesting that M3 i3 might be a good candidate site for ARF
docking here. Specific binding of each ARF was demonstrated
to the M3i3 GST fusion protein but not control constructs.
PLD1 Involvement in PLD Activation by the M:j Receptor but
Not Other GPCRs—A catalytically inactive mutant of PLD1,
but not PLD2, specifically attenuated carbachol-induced PLD
responses in sFM3 receptor-transfected COS7 cells. A compo¬
nent of the response remained unaffected by either negative
mutant PLD1 or PLD2, perhaps due to limited ability of the
constructs to access the necessary sites and compete effectively
with endogenous PLD. Other studies on the PLD isozyme me¬
diating GPCR responses have given varying results that may
partly depend on cell type. In HEK 293 cells, M3 receptor PLD
responses were large in the presence of additional wild type
PLD1, but not K898R-PLD1 (6, 7), although it was not clear
whether K898R-PLD1 could reduce responses mediated by en¬
dogenous PLD. In our experiments, [3H]PtdBut responses of
the sFM3 receptor but not other GPCRs were selectively in¬
creased by both wild type PLD1 and PIM87-PLD1 and inhib¬
ited by K898R-PLD1, implicating PLD1 as the key effector. Our
evidence that PKC inhibitors are ineffective on M3 receptor
PLD responses in 1321N1 or COS7 cells further supports the
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agonist
Fig. 8. Schematic diagram of major routes of ARF-dependent
PLD activation used by the M., receptor. Additional routes of PLD
activation by the M3 receptor have been documented and the extent to
which each is used is likely to depend on cell type and circumstances.
An ARF-independent component may also contribute to the overall PLD
response of the M:! receptor here. Examples of other GPCRs compared
under the same conditions appear to use differing pathways of PLD
activation.
idea that this connection between the receptor and PLD1 is
independent of PKC. In contrast, ['HJPtdBut responses of the
P2U receptor and the N376D mutant 5-HT2A receptor were
inhibited by K758R-PLD2 but not K898R-PLD1. The addition
of wild type PLD2, but not wild type PLD1, facilitated these
responses, but effects were nonselective in that basal, M3 re¬
ceptor, and PDBu-induced responses were all increased. Other
reports also indicate a role of PLD2 in the responses of some
GPCRs; in A10 cells, PLD responses to angiotensin II were
inhibited by K758R-PLD2 but not K898R-PLD1 constructs
(56), and in PC12 cells overexpressing PLD2, bradykinin re¬
ceptors activate PLD2 through a PKC-dependent mechanism
(47). Furthermore, the ^.-opioid receptor can elicit a BFA-sen-
sitive PLD response in HEK 293 cells overexpressing PLD2,
but not PLD1, that has been proposed to involve PLD2 associ¬
ation with the carboxyl-terminal tail domain of the receptor
(68).
Relationship between M3 Receptor Interaction with a BFA-
sensitive, ARF1-dependent Pathway and Its Activation of
PLD1—When sFM3 receptor responses are partially reduced in
the presence of K898R-PLD1 (but not K758R-PLD2), any fur¬
ther sensitivity to BFA or T31N-ARF1 is removed. This sug¬
gests that the inhibitory effect of BFA seen under normal
conditions reflects primarily a pathway involving ARF1 and
PLD1. T27N-ARF6 still caused some inhibition of responses in
the presence ofeither K898R-PLD1 or K758R-PLD2, consistent
with the idea that the ARF6-mediated component from the
receptor may lead to either PLD1 or PLD2. However, we cannot
definitively assign a PLD isoform to the ARF6-mediated com¬
ponent, because we are not sure that blockade by negative
mutant PLD1 is complete and also negative mutant PLD2 did
not significantly reduce control sFM3 responses.
The Subcellular Localization of sFM3 Receptor-mediated,
ARF1-dependent Activation of PLD1—Since ARF1 (13-18, 69)
and PLD1 (27-31) are not normally localized to a large extent
at the plasma membrane, either the receptor or these media¬
tors may need to undergo translocation to enable sFM3 recep¬
tor-induced [3H]PtdBut production. One possibility might be
that the receptor causes PLD activation in endocytosing vesi¬
cles following agonist stimulation. For some GPCRs, such a
mechanism involving endocytosis of GPCR and/or transacti-
vated growth factor receptors, is important in their activation
of extracellular signal-regulated kinase mitogen-activated pro¬
tein kinase (70). PLD may be integral to these processes, since
it participates in insulin-induced extracellular signal-regulated
kinase mitogen-activated protein kinase activation by generat¬
ing phosphatidic acid in endocytosing vesicles and thereby
recruiting the mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase kinase, Raf-1 (71, 72). However,
our findings seem inconsistent with such a mechanism here.
Dominant negative mutant dynamin 1 inhibited endocytosis of
agonist-occupied sFM3 receptors but had no effect on PLD
activation, whereas cell surface biotinylation indicated that the
great majority of sFMa receptors associated with ARF1-HA
immunoprecipitates had been present on the cell surface. Fur¬
thermore, sFM3 receptor-mediated [3H]PtdBut production was
associated with subcellular fractions containing plasma mem¬
brane rather than Golgi or endoplasmic reticulum. In addition,
the content of native ARF1 and PLD1 in plasma membrane
was clearly and selectively increased following carbachol stim¬
ulation. Corresponding results were found in confocal micros¬
copy experiments (data not shown). These observations suggest
that agonist-induced translocation of ARF1 and PLD1 to the
plasma membrane, into the vicinity of sFM3 receptors, is im¬
portant in enabling the receptor to signal via PLD.
In conclusion, the present experiments describe an ARF-de-
pendent activation of PLD by the Ms muscarinic receptor that
appears to be essentially independent of conventional routes of
GPCR signaling. Instead, both ARF1 and ARF6 can associate
physically with the receptor, as shown by co-immunoprecipita-
tion and GST fusion protein experiments. Dominant negative
constructs of ARF1/6 and PLD 1/2 showed that the character¬
istic BFA-sensitive PLD activation shown by the M3 receptor
appears to involve ARFl-mediated activation of PLD 1 (Fig. 8).
We demonstrated that agonist induces the translocation of
ARF1 and PLD1 into the vicinity of the M3 receptor at the
plasma membrane, where the response takes place. An addi¬
tional ARF6-mediated component may involve PLD1 or PLD2,
whereas other factors such as Rho family small G proteins
could potentially also be involved. In contrast, examples of
DRXXY-containing GPCRs, which lack BFA-sensitive PLD re¬
sponses, utilize PKC (and also in some cases ARF6) to bring
about activation of PLD2. The range of GPCR motifs and cel¬
lular factors that determine receptor selectivity for these dif¬
ferent pathways of PLD activation remains to be determined.
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ABSTRACT
The 5-hydroxytryptamine 2A receptor (5-HT2AR) is a member of
the class I family of rhodopsin-related G protein-coupled re¬
ceptors. The receptor is known to activate phospholipase C via
the heterotrimeric G proteins Gq/1,, but we showed previously
that it can also signal through the phospholipase D (PLD) path¬
way in an ADP-ribosylation factor (ARF)-dependent manner
that seems to be independent of Gq/11 (Mitchell et al., 1998).
Both coimmunoprecipitation experiments and the effects of
negative mutant ARF constructs on 5-HT2AR-induced PLD ac¬
tivation here suggested that ARF1 may play a greater role than
ARF6 in the function of this receptor. Furthermore, we demon¬
strated using glutathione S-transferase (GST)-fusion proteins of
receptor domains that ARF1 and ARF6 bind to the third intra¬
cellular loop (i3) and the carboxy terminal tail (ct) of the
5-HT2AR. The association of ARF1 with the ct domain of the
receptor was stronger than its interaction with 13, or the inter¬
actions of ARF6 with either construct. Experiments using ARF
mutants that are deficient in GTP loading, and the in vitro
addition of GTP-yS suggested that GTP loading enhances ARF1
binding to the receptor. The N376PxxY motif in the transmem¬
brane 7 domain of the receptor (rather than a N376DPxxY
mutant form) was shown to be essential for ARF-dependent
PLD signaling and ARF1 coimmunoprecipitation. In GST-fusion
proteins of the 5-HT2AR ct domain, mutation of Asn376 to Asp
also markedly reduced ARF1-HA binding, although additional
motifs in the Asn376-Asn384 sequence and to a lesser extent
elsewhere, seem also to contribute to the interaction.
The 5-hydroxytryptamine (5-HT) receptor superfamily rep¬
resents a diverse group of receptors encompassing 14 differ¬
ent subtypes. All but one of them (5-HT3) signal through
G-protein-linked pathways. The different families of G pro¬
tein-coupled receptors (GPCRs) for 5-HT transduce their sig¬
nals via different heterotrimeric G proteins, with 5-HT-l (and
5-HT5) linking to G^0 effectors, 5-HT2 signaling through Gq/11
to generate inositol trisphosphate and increase intracellular
Ca2+ levels, and 5-HT4, 5-HT6, and 5-HT7 all signaling
through Gs to increase production of cyclic AMP (Raymond et
al., 2001). The 5-HT2AR is of particular interest because it
This work was supported by grants from the Medical Research Council
(to R.M.) and the Wellcome Trust (to E.M.L.).
has been implicated in a variety of major psychiatric disor¬
ders and in hallucinogenic drug action.
GPCR interactions with heterotrimeric G proteins often
(but not exclusively) seem to involve the third intracellular
loop (i3) (Wess et al., 1997). The i3 domains ofvarious GPCRs
have been shown to provide docking sites for heterotrimeric
G protein j3y subunits (Wu et al., 1998) as well as arrestins
(Wu et al., 1997; Gelber et al., 1999), GPCR-kinases (Wu et
al., 1998), and indeed ARFs (McCulloch et al., 2001; Ronald-
son et al., 2002). In a number of GPCRs, other intracellular
loops and ct domains have also been implicated in interac¬
tions with heterotrimeric G proteins and arrestins (Wu et al.,
1997; Oakley et al., 2001). In the 5-HT2AR, the i3 domain has
been shown to be important for coupling to Gq/11 and the
carboxyl terminal segment of the i3 loop in particular may
ABBREVIATIONS: 5-HT, 5-hydroxytryptamine, serotonin; 5-HT2AR, 5-hydroxytryptamine 2A receptor; GPCR, G protein-coupled receptor; PLD,
phospholipase D; ARF, ADP-ribosylation factor; i3, third intracellular loop domain; ct, carboxy-terminal tail domain; tm7, 7th transmembrane
domain; sPrC, protein C epitope tag with signal sequence; HA, hemagglutinin epitope tag; BFA, brefeldin A; GST, glutathione S-transferase; Nl
IgG, nonimmune mouse IgG; PLC, phospholipase C; PCR, polymerase chain reaction; PrC, Protein C; bp, base pair(s); DMEM, Dulbecco's
modified Eagle's medium; USG, Ultroser G; AEBSF, 4-(2-aminoethyl)-benzenesulfonylfluoride; PAGE, polyacrylamide gel electrophoresis; GTPyS,
guanosine 5'-0-(3-thio)triphosphate; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate; SBTI, soybean trypsin inhibitor; ECL,
enhanced chemiluminescence; MEM, minimum essential medium; PEG, polyethylene glycol; GEF, GTP-exchange factor; BK, large-conductance
potassium channel; PDZ, postsynaptic density 95/disc-large/ZO-1.
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play a key role in the interaction (Roth et al., 1998). Arrestin
isoforms bind to the i3 loop of the 5-HT2AR as they do to i3
domains of the M2 and M3 muscarinic receptors, but show
broader specificity in that both nonvisual and visual ar-
restins are bound (Wu et al., 1997; Gelber et al., 1999).
In addition to Gq/11-mediated phospholipase C (PLC) acti¬
vation, the 5-HT2AR can activate several other signaling
pathways that may involve alternative direct coupling to the
receptor. These include activation of phospholipase A2 [which
may be mediated by a coupling mechanism other than Gq/11
(Berg et al., 1998)], activation of tyrosine phosphorylation
[correlating with evidence for association of the tyrosine ki¬
nase Jak2 with the ct domain (Guillet-Deniau et al., 1997)]
and ARF-dependent activation of phospholipase D (PLD)
(Mitchell et al., 1998).
A specific conserved motif, NPxxY, which is found at the
junction of the tm7 and ct domains in a number of rhodopsin
family GPCRs, has been implicated as a determinant ofARF-
receptor interactions and ARF-mediated signaling, because
native receptors with an alternative DPxxY motif, or Asn-to-
Asp mutant receptors, show selective defects in this pathway
(Mitchell et al., 1998, 2003). However, it has not been clear
whether this motif might be accessible as a direct docking
site or it instead regulates access to a distinct site.
The two main classes of cellular ARFs are exemplified by
ARF1 and ARF6, which are thought to have characteristi¬
cally distinct subcellular distributions. In many cells, ARF1
is cytosolic or associated with Golgi membranes, whereas
ARF6 may be substantially associated with plasma mem¬
brane and play a role in regulating endocytosis (D'Souza-
Schorey et al., 1995; Peters et al., 1995; Cavenagh et al.,
1996). Nevertheless, GTP loading and GPCR activation can
cause translocation of ARFs to Golgi and other membranes,
and we have shown marked translocation of ARF1 to the
plasma membrane after activation of the M:i muscarinic re¬
ceptor (Mitchell et al., 2003) and the 5-HT2AR (M. Johnson
and R. Mitchell, unpublished observations). Thus both ARF1
and ARF6 are potentially available for interaction with
plasma membrane GPCRs after agonist stimulation.
In this study, we have addressed the role of ARF1 and
ARF6 in 5-HT2AR-mediated PLD signaling, demonstrated
coimmunoprecipitation of ARF1 (and to a lesser extent
ARF6) with the receptor, and gone on to characterize the
docking of ARFs to GST fusion proteins of receptor i3 and ct
domains.
Materials and Methods
Preparation of sPrC-Tagged 5-HT2A Receptor and sPrC-
Tagged N376D-5-HT2A Mutant Receptor Constructs. The wild-
type human 5-HT2AR cDNA (SCS93) and N376D-5-HT2AR mutant
cDNA (SCS103), cloned into pcDNAl-amp (Invitrogen, Paisley, UK),
were kindly provided by Stuart Sealfon (Mount Sinai School of Med¬
icine, New York, NY). To create an amino terminal epitope-tagged
receptor, SCS93 was PCR-amplified with the synthetic oligonucleo¬
tide primers [5'-GAAGATCAGGTAGATCCACGGTTAATC-
GATGGTAAGGCCATGGATATTCTTTGTGAAG-3' ] encoding the
12-amino acid Protein C tag (PrC) epitope (EDQVDPRLIDGK) and
the reverse primer named 5HT2A.rp, [5'-GAATTCTCACACA-
CAGCTCACCTTTTCATT-3'] using "the Herculase-enhanced DNA
polymerase (Stratagene Europe, Amsterdam, NL). The resulting
PCR product was checked by agarose gel electrophoresis and ex¬
tracted with Wizard PCR clean-up resin (Promega, Southampton,
UK) before amplifying with the primer [5'-GCCACCATGAAGAC-
GATCATCGCCCTGAGCTACATCTTCTGC-
CTGGTATTCGC CGAAGATCAGGTAGATC CAC-3' ] encoding a
modified influenza hemagglutinin signal sequence and 5HT2A.rp.
The 1.4-kilobase fragment was purified by agarose gel electrophore¬
sis and Qiaex II (QIAGEN Ltd.,Crawley, UK), then subcloned into
TOPO TA cloning vector (Invitrogen). The sPrC-5-HT2A insert was
checked by sequencing. For expression studies, the sPrC-tagged
wild-type receptor was constructed by subcloning the 200-bp EcoRl/
Sail fragment from sPrC-5-HT2A cDNA and the 1.5-kilobase Sail/
Xbal fragment from SCS93 into the EcoRVXbal site of pcDNAS
(Invitrogen). The sPrC-tagged (N376D) mutant receptor was con¬
structed by subcloning the 450-bp EcoRI/PstI fragment from sPrC-
5-HT2A cDNA and the 1.3-kilobase PstVXbal fragment from SCS103
into the EcoRVXbal site of pcDNA3 (Invitrogen).
Construction of 5-HT2A Receptor Intracellular Loop 3 and
Carboxy Terminal Tail GST-Fusion Proteins. The human
5-HT2AR intracellular loop 3 (Ile258-Gly326) was PCR-amplified
from SCS93 with primer pair [5'-GGGTGATCAAGTCACTTCA-
GAAAGAAGCTAC-31 and [5'-CGGAATTCTAGCCCAGCACCTTG-
CATGCTTTTGCTCATTGCT-3'], and the resulting 200-bp PCR
product was purified, digested with Bcll/EcoRl, and subcloned into
the BamHI/EcoRI sites of pGEX-3X (Amersham Biosciences, Little
Chalfont, UK). The 347-bp Hincll fragment encoding the human
5-HT2AR carboxy-terminal tail and including the NPLVY motif
(Asn376-Val471) was subcloned into the modified (with Mung bean
nuclease; Stratagene, La Jolla, CA) BamYll site of pGEX-2T. The
sequences encoding the carboxy-terminal tail amino acids (Lys385-
Val471) were PCR-amplified from SCS93 using primer pair
Bh2ARCT.KTYRS [5'-CGGGATCCAAAGACCTATAGGTCAGC-
CTTTTCACG-3'] and h2ARCT.rp [5'-CAACTCAATTGTCACACA-
CAGCTCACCTTTTCATT-3'], and the mutant (N376D-Val471) car-
boxyl tail was PCR-amplified from SCS103 with primer pair
h2ARCT.DPLVY [5'-CGGGATCCAGACCCACTAGTCTACA-
CACTGTTCAA-3'] and h2ARCT.rp using Taq polymerase (Promega)
and the resulting PCR products purified by Wizard cDNA clean-up
resin (Promega), digested with BamHVMfel and subcloned into the
BamHl/EcoRl sites of pGEX-2T. The BamHl sites then were modi¬
fied with Mung bean nuclease. Cloned inserts were checked by se¬
quence analysis.
Transient Transfections of Cells. COS-7 cells were grown to
60% confluence in Dulbecco's modified Eagle's medium (DMEM;
Invitrogen) containing 10% normal calf serum and 100 units/ml
penicillin and 100 pg/ml streptomycin. Before transfection, medium
was changed for DMEM containing 2% Ultroser G (USG; Invitrogen)
instead of serum. The cells were then transfected with combinations
of the cDNAs for sPrC-5-HT2AR, ARFl-V5-HisK (Invitrogen), ARF1
and ARF6 tagged with the hemagglutinin epitope (HA) at the car-
boxyl terminal, or the dominant-negative mutants T31N-ARF1-HA
and T27N-ARF6-HA (Peters et al., 1995) (kindly provided by Julie
Donaldson, National Institutes of Health). All transfections (normal¬
ly at a ratio of 4 pg of receptor construct cDNA to 1 pg of ARF
construct cDNA per 75-cm2 flask) were carried out using FuGENE-6
reagent (Roche Diagnostics Ltd, Lewes, UK) according to the man¬
ufacturer's guidelines, and appropriate substitutions of empty vec¬
tors were made in control samples. Transfected cells were used 72 h
after transfection.
Preparation of ARF-Enriched Extracts. COS-7 cells trans¬
fected with various ARF-HA constructs were washed with 10 ml of
Earle's balanced salt solution (Invitrogen) before being scraped into
ice-cold extraction buffer [2 ml/175-cm2 flask, 2 pg/ml aprotinin, 1
mM 4-(2-aminoethyl)-benzenesulfonylfluoride (AEBSF) (Alexis Bio-
chemicals, San Diego, CA), 1 mM dithiothreitol, 1 mM pepstatin, 1
mM sodium orthovanadate, 1 mM NaF, 50 pg/ml soybean trypsin
inhibitor (SBTI) in PBS). All chemicals were from Sigma Chemical
Co. (Poole, Dorset, UK) unless otherwise indicated. The cells were
then homogenized [Ystral homogenizer (Scientific Industries Intl.
UK Ltd, Loughborough, UK) setting 3, 15 s] before being centrifuged
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at 12,000g for 20 min at 4°C. The supernatant was aliquoted and
stored at -40°C.
Purification of ARF1-V5-His6 on Cobalt Affinity Resin.
COS-7 cells were transfected with an expression plasmid encoding
ARF1-V5-His6, and enriched cytosol was isolated as described above.
The cytosolic extracts over-expressing the ARF1-V5-His6 were then
incubated with 'Talon' cobalt affinity resin (BD Biosciences Clontech,
Palo Alto, CA) that had been pre-equilibrated with wash buffer (10
mM sodium phosphate, 60 mM NaCl, pH 7.0), for 1 h at 4°C. The
resin was washed thoroughly with extraction/wash buffer (addition¬
ally containing 5 mM imidazole) before being eluted using elution
buffer (additionally containing 300 mM imidazole) according to the
manufacturer's instructions. The purified ARF1-V5-His6 was then
concentrated using Centriplus centrifugal filters (YM-3; Millipore,
Bedford, MA) according to the manufacturer's instructions. The
amount of protein present was verified by colorimetric measurement
using Coomassie protein reagent (Perbio Science UK Ltd., Tatten-
hall, Cheshire, UK). The percentage purity of the harvested protein
purity was then assessed by staining with high sensitivity Colloidal
Coomassie (Simply Blue Safe stain; Invitrogen) on an SDS-PAGE
gel, identifying the correct band by Western blotting using mouse
monoclonal V5-tag antibody (Invitrogen). Standard curves were pro¬
duced from the purified ARF1-V5-His6 (linear range from 0.4-7.2 ng
ARF1-V5-Hiss per well). These were coprocessed with experimental
samples of cytosolic inputs and of proteins associating with the
receptor in either coimmunoprecipitation or GST-fusion protein ex¬
periments, enabling us to assess the amounts of ARFl-VS-Hisg
present.
Expression of GST Proteins. GST-5-HT2Ai3 and GST-5-HT2Act
constructs, in the pGEX-3X and pGEX-2T vectors, as well as a
control GST fusion protein of the STREX insert of the large conduc¬
tance Ca21 - and voltage-activated K+ (BK) channel, in the pGEX-5 X
1 vector (kindly supplied by Mike Shipston, University of Edinburgh)
were expressed in BL21-RIL bacterial cells, grown in standard 2X
yeast extract/tryptone/NaCl medium with 2% glucose. When the
cells had reached an A600 of 0.6 to 0.8 units/ml, expression of the
fusion proteins was induced by the addition of 0.1 mM isopropyl-fl-
D-thiogalactoside for 3 h at 37°C. Cells were harvested by centrifu-
gation then lysed with BugBuster reagent (Merck Biosciences,
Beeston, Nottingham, UK) for 10 min and again centrifuged. The
supernatant, containing the GST fusion proteins, was added to glu-
tathione-Sepharose beads (Amersham Biosciences). The beads were
incubated with the bacterial supernatant for 20 min at room tem¬
perature to allow binding of the GST fusion proteins to the beads.
The matrix formed was then washed extensively with PBS and used
immediately.
In Vitro Protein Interaction Assays. Cellular extracts en¬
riched in the various HA-tagged ARF constructs were incubated with
GST fusion proteins bound to glutathione-Sepharose beads (Amer¬
sham Biosciences) in 250 p.1 of buffer A (20 mM Tris-HCl, pH 7.5, 0.6
mM EDTA, 1 mM dithiothreitol, 70 mM NaCl, and 0.05% Tween 80)
for 90 min at 4°C, with rolling. In some experiments, GTPyS (100
p,M) was added to the incubations. The beads were washed four
times in buffer A and then the retained proteins were removed from
the beads with 2x Laemmli buffer (2% SDS, 5% mercaptoethanol, 20
mM Tris-HCl, pH 7.4) before SDS-PAGE and immunoblotting (see
below). Input levels of fusion proteins (monitored by GST immuno-
reactivity) were carefully balanced to ensure comparability between
samples. Protein interaction assays using ARF1-V5-Hisfi were car¬
ried out in an identical manner, except that increased amounts of
bacterial cytosol containing GST construct was added to the gluta¬
thione-Sepharose beads (~2X).
Coimmunoprecipitation of sPrC-5-HT2A Receptor and
ARF1/6-HA. Transfected COS-7 cells were incubated in medium
alone (no serum or USG) for 4 h before being exposed to 5-HT (10
nM-10 /aM) and/or brefeldin A (BFA, 100 pM). Cells were washed
once in Hank's balanced salt solution (HBSS; Invitrogen) before the
addition of 1 ml/75-cm2 flask of immunoprecipitation buffer (HEPES
20 mM, pH 7.5, NaCl 150 mM, 1% CHAPS, 0.5% sodium deoxy-
cholate, 2 pg/ml aprotinin, 4 pg/ml leupeptin, 1 mM AEBSF, 2 pg/ml
pepstatin, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 5
mM sodium molybdate, and 50 pg/ml SBTI) with 5-HT if it had been
used in the initial stimulation. Extraction was carried out on ice for
40 min with occasional agitation. Solubilized cellular extracts were
centrifuged at 12,000g for 15 min at 4°C to remove particulate
material. One ml of supernatant was precleared with 20 pi of protein
G-Sepharose 4B fast flow (50% suspension in immunoprecipitation
buffer) for 45 min at 4°C. After centrifugation (to pellet the beads),
the supernatant was added to a tube containing either mouse mono¬
clonal (Ca2+-dependent) PrC-tag antibody (clone IIPC4, 4 pg/ml;
Roche) or control, nonimmune mouse IgG, 4 pg/ml; Sigma) with 40
pl/ml protein G-Sepharose suspension and 1 mM CaCl2. Samples
were incubated with rolling, at 4°C overnight. In the standard pro¬
cedure, the beads were pelleted, washed twice in immunoprecipita¬
tion buffer before 40 pi of 2 x Laemmli buffer containing 5 mM EGTA
was added per sample equivalent to 1 ml of original supernatant. In
some experiments, the receptor complex was removed from the PrC
antibody-protein G-Sepharose beads by incubation in 50 mM Tris
and 2 mM EGTA, pH 7.5, for 30 min at room temperature. The
supernatant was removed and SDS and mercaptoethanol added
equivalent to 2X Laemmli buffer.
Western Blots. Western blots were carried out on samples from
immunoprecipitation and GST fusion protein interaction assays. Ei¬
ther 20% or 12.5% precast homogeneous PhastGels (Amersham Bio¬
sciences) were used. SDS-PAGE and electroblotting onto polyvinyli-
dene difluoride membranes (Immobilon-PSG!, Millipore, Watford,
UK) were performed on a PhastSystem apparatus (Amersham Bio¬
sciences). The detection antibodies were rabbit polyclonal anti-HA
(Autogen Bioclear, Calne, Wilts, UK), goat polyclonal anti-GST (Am¬
ersham Biosciences) and mouse monoclonal anti-PrC (Roche) fol¬
lowed by preabsorbed secondary antibodies conjugated to horserad¬
ish peroxidase (Chemicon Intl. Ltd., Harrow, UK). Visualization of
antibody bands was by Luminol (New England Biolabs, Hitchin,
UK), and blots were exposed to ECL film (Amersham Biosciences).
Densitometric analysis of ECL images from Western blots was car¬
ried out using the ScanAnalysis program (Biosoft, Cambridge, UK).
Immunoprecipitation samples were also run on larger gels on the
NuPAGE SureLock mini-cell system (Invitrogen) under reducing
conditions, with 10% homogenous Bis-Tris gels and then blotted on
the same system according to the manufacturer's instructions.
PLD Assays. Transfected cells in 12-well plates were deprived of
USG by transferring to DMEM for 18 h, during which time they were
labeled with [3H]palmitate (1.5 /xCi/well; PerkinElmer Biosciences,
Hounslow, UK). After washing with minimal essential medium con¬
taining HEPES (25 mM, pH 7.5) and 0.5% fatty acid-free bovine
serum albumin, cells were preincubated for 20 min in similar me¬
dium with or without BFA, before addition of butan-l-ol (30 mM) and
various concentrations of 5-HT for a further 30 min. The vehicle for
BFA (dimethylformamide at 0.2%) was added to control wells and
has been shown previously to have no detectable effect on signaling
responses. Reactions were terminated by removal of medium and
addition of 0.5 ml ice-cold methanol to each well. Phospholipids were
extracted and [3H]phosphatidyl butanol was separated on Whatman
LK5D thin-layer chromatography plates (Whatman, Maidstone,
Kent, UK) as described previously (Mitchell et al., 2003).
PLC Assays. Transfected cells in 12-well plates were deprived of
USG by transferring to Earle's balanced salt solution containing 1.0
mM HEPES, pH 7.5, and 0.18% glucose for 18 h, during which time
they were labeled with [:iH]inositol (0.75 p,Ci/well; PerkinElmer Bio¬
sciences). The medium was changed for Earle's balanced salt solu¬
tion containing 10 mM HEPES, 0.18% glucose, and 0.2% bovine
serum albumin and washed once. Cells were preincubated for 20 min
with 10 mM LiCl (and BFA where required) before being incubated
for 30 min with various concentrations of 5-HT with or without BFA.
Reactions were terminated by the removal of medium and the addi¬
tion of 1 ml of ice-cold 10 mM formic acid (Sealfon et ah, 1995) and
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the cells were left on ice for at least an hour to ensure lysis. Inositol
phosphates l[3H]InsP) were separated by anion exchange chroma¬
tography as described previously (Mitchell et al., 2003).
[3H]Ketanserin Binding. Assessment of PrC-5-HT2A receptor
expression in the transfected COS-7 cells was by homologous dis¬
placement of [3H] ketanserin binding (specific activity, 88.0 Ci/mmol;
PerkinElmer Life Sciences). After removal of USG from the culture
medium for the last 4 h, cell membranes were prepared by harvest¬
ing the cells into ice-cold ketanserin binding buffer (50 mM Tris, 5
niM MgCl2, and 1 mM EGTA, pH 7.2) and disrupted with an Ystral
homogenizer. Membranes were washed twice in buffer, centrifuging
each time at 12,000g, 30 min, 4°C. Finally the membranes were
suspended in buffer at —200 jug/ml protein. Membranes were incu¬
bated for 60 min at 37°C with 0.8 nM [3H]ketanserin and either no
other drug, increasing concentrations of unlabeled ketanserin, or 10
p.M mianserin to determine nonspecific binding. At the end of the
assay, binding was stopped by addition of ice-cold buffer, the mem¬
branes were pelleted by centrifugation (10 min at 12,000g) and the
supernatant was aspirated. Bound radioactivity was determined by
liquid scintillation counting. The homologous displacement curves
were fitted to a Hill model using nonlinear curve fitting program,
Fig-P (Biosoft, Cambridge, UK). This allowed measurement of KD
and number of binding sites. For experiments to determine receptor
binding where cell membranes were solubilized in immunoprecipi-
tation buffer, the lysate was first treated with polyethylene glycol-
8000 (PEG; final concentration, 15%) to precipitate solubilized pro¬
teins, including PrC-5-HT2A receptor, and washed, again
precipitating with PEG before trituration of the pellet in ketanserin
binding buffer for the assay. Additionally, PEG was used to termi¬
nate the assay, and nonsolubilized membranes included in the ex¬
periments as controls were treated in the same way.
When membranes were treated with solubilization buffer, the
total amount of specific [3H]ketanserin binding that was recovered
from the supernatant plus residual membrane fractions was much
less than the input levels of binding in untreated membranes (ap¬
proximately 15%). It is not clear to what extent this was caused by
deleterious effects of detergent/PEG exposure on the ligand binding
site or by inefficient capture of solubilized receptor. However, some
loss of ligand binding capacity is likely to result during these proce¬
dures. It therefore seems likely that the amount of receptor still
detectable by ligand binding after extraction represents an underes¬
timate of the amount of receptor protein actually solubilized. Never¬
theless, some 97% of the [3H] ketanserin binding that could be recov¬
ered was found in the solubilized fraction. When this fraction was
immunoprecipitated with PrC-tag antibody, the proportion of solu¬
bilized specific binding that became associated with the protein G
beads rather than remaining in the supernatant was 70 ± 18%.
[3H]Ketanserin Binding to Coimmunoprecipitates. Cells
transfected with wild-type or N376D mutant sPrC-5-HT2A con¬
structs and wild-type ARF1-HA were transferred to USG-free
DMEM for 16 h before assay. After washing in PBS at 37°C, and
incubation with 5-HT (1 /xM, 5 min) in some cases, cells were scraped
into ice-cold buffer (PBS, 10% glycerol, 2 pg/ml aprotinin, 4 pg/ml
leupeptin, 1 mM AEBSF, 2 pg/ml pepstatin A, 50 pg/ml SBTI, 1 mM
sodium orthovanadate, and 1 mM sodium fluoride) and homogenized
using an Ystral homogenizer. Nuclei and debris were removed by
centrifugation at lOOOg for 8 min before the supernatant was cen-
trifuged (12,000g for 30 min) to obtain a membrane fragment pellet.
The pellet was washed once before trituration in the above buffer
containing V/o CHAPS and 0.75% deoxycholate and rolling for 30
min at 4°C. Samples were precleared with protein G-Sepharose and
then centrifuged (12,000g; 30 min) to obtain the solubilized extracts
used for immunoprecipitation. Samples were incubated with 2 pg/ml
mouse monoclonal anti-HA tag (clone 12CA5) or nonimmune mouse
IgG for 90 min at 4°C and then immune complexes were collected by
incubation with protein G-Sepharose for 45 min at 4°C. The pellets
from centrifugation at 12,000g for 10 min were washed once in
solubilizing buffer and then resuspended in [3H]ketanserin binding
buffer (see above) that additionally contained 10% glycerol. Ligand
binding was assayed as described above. Incubations (250 pi) were
stopped by the addition at 4°C of 100 pi of 0.05% bovine y-globulin in
PBS and 1 ml of 30% PEG in PBS. After 15 min on ice, samples were
centrifuged at 12,000g for 20 min, the supernatant was aspirated,
and the tube tips were removed for liquid scintillation counting.
Results
Figure 1 illustrates functional signaling responses of the
sPrC-5-HT2AR expressed in COS-7 cells. [3H]Ketanserin
binding experiments indicated that the sPrC-5-HT2AR was
expressed in COS-7 cell membranes at a mean level of 0.84 ±
0.04 pmol/mg of total protein, with an IC50 for homologous
displacement of 4.8 ± 0.4 nM. The receptor produced robust
PLC and PLD activation responses to 5-HT stimulation that
were similar to the untagged receptor (Sealfon et al., 1995;
Mitchell et al., 1998) but with slightly greater potency; the
EC50 values for PLC and PLD responses were 5.0 ± 2.2 and
6.8 ± 1.9 nM, respectively (Fig. 1, A and B). The EC50 value
for PLC activation by the untagged receptor in similar exper¬
iments was found to be 28 ± 2 nM (R. Mitchell and M.
Johnson, unpublished observations) and 22 ± 5 nM (Sealfon
et al., 1995). The effects of cotransfection of ARF mutants
were investigated on 5-HT-induced signaling events medi¬
ated by the sPrC-5-HT2AR expressed in COS-7 cells. PLC
activation was unaffected by cotransfection of either T31N-
ARF1-HA or T27N-ARF6-HA; mutant constructs of the ARF
isoforms that have a dysfunctional GTP binding domain (Pe¬
ters et al., 1995) (Fig. 1A). However, T31N-ARF1-HA, but not
T27N-ARF6-HA, significantly inhibited 5-HT2AR-mediated
PLD activation (Fig. IB). Figure 1C shows the inhibitory
effect of BFA [a blocker of the BIG1/2 class of ARF GTP-
exchange factor (GEF) (Morinaga et al., 1999)] on the PLD
response of the 5-HT2A receptor. When only the receptor was
expressed, BFA caused a concentration-dependent inhibition
of 5-HT-induced PLD activation, with significant inhibition
at 50 p.M and above. In cells additionally expressing T27N-
ARF6-HA, BFA was also inhibitory throughout a similar
concentration range. However, in cells expressing T31N-
ARF1-HA, the residual 5-HT-induced PLD response became
insensitive to BFA. The PLC response of the 5-HT2AR was
unaffected by BFA (data not shown).
To investigate whether a physical interaction of either
ARF1 or ARF6 with the receptor occurs upon activation, we
looked for coimmunoprecipitation of HA-tagged ARF iso¬
forms with the sPrC-5-HT2AR (Fig. 2). When nonimmune
mouse IgG (NI IgG) was substituted for the PrC-tag antibody
in the immunoprecipitation, minimal levels of either
ARF1-HA or ARF6-HA immunoreactivity could be detected
in the pulldown assays. Significant levels of ARF1-HA (and
to a much lesser extent, ARF6-HA) seemed to be specifically
associated with the PrC-tag antibody pulldown assays of the
sPrC-5-HT2AR, even under basal conditions (Fig. 2A). Den¬
sitometry analysis indicated that basal levels of ARF1-HA
coimmunoprecipitated were increased on average 3.32 ±
1.58-fold (n = 5) over nonspecific, as determined with NI
IgG. The corresponding value for ARF6-HA was lower, a
0.32 ± 0.05-fold (n = 3) increase over nonspecific. Relative
densitometry values of anti-HA tag blots for coimmuno¬
precipitated ARF1-HA as a percentage of the input of total
expressed ARF1-HA were 0.13 ± 0.03% in unstimulated
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Fig. 1. Effects of mutant ARF1 and ARF6 constructs on signaling
responses of the sPrC-5-HT2A receptor. COS-7 cells were cotransfeeted
with the sPrC-5-HT2AR together with either empty vector (•), T31N-
ARF1-HA (■), or T27N-ARF6-HA (□). Values are means ± S.E.M., n =
6-8. A, concentration-dependence of 5-HT-induced PLC activation;
there was no discernible effect of the negative mutant ARFs on this
response. B, concentration-dependence of 5-HT-induced PLD activa¬
tion. The addition of T27N-ARF6-HA had no significant effect on the
ability of the 5-HT2AR to activate PLD, whereas the presence of T31N-
ARF1-HA significantly attenuated the PLD response to 5-HT concen¬
trations of 10 nM and above (*, p < 0.05 by Wilcoxon test). C, BFA
sensitivity of the 1 pM 5-HT-induced 5-HT2AR PLD response and a
concentration-dependent inhibition that was statistically significant
(*,p < 0.05, Wilcoxon test) for BFA concentrations of 50 pM and above
in control and T27N-ARF6-HA samples. Cotransfection of T27N-
ARF6-HA had no discernible effect on BFA sensitivity compared with
control, whereas the PLD response in the presence of T31N-ARF1-HA
was no longer significantly inhibited by BFA.
samples compared with 0.21 ± 0.03% after 5-HT (1 pM, 5 min).
Equivalent values for ARF6-HA were 0.053 ± 0.010%' and
0.067 ± 0.008%, respectively. Although coimmunoprecipitation
of both isoforms of ARF with the receptor seemed to be in¬
creased by addition of 5-HT (mean increase to 1.61- and 1.26-
fold of control, respectively), only the effect on ARF1-HA was
statistically significant (p < 0.05, Wilcoxon test, n = 5 in each
case) These values are useful for relative comparisons but do
not faithfully reflect the fraction of ARF1/6-HA within an indi¬
vidual cell that is associated with sPrC-5-HT2A receptor, be¬
cause we know from dual label confocal immunofluorescence
experiments (data not shown) that a subpopulation of the
COS-7 cells expressing ARF constructs fail to express detect¬
able levels of receptor. When the input level of sPrC-5-HT2AR
was varied by substituting pcDNA3 for part of the receptor
cDNA in the transfection (while keeping the ARF1-HA plasmid
concentration constant), less ARF1-HA was coimmunoprecipi-
tated, in proportion to the level of receptor expression as mon¬
itored by specific [3H]ketanserin binding (Fig. 2B).
An attempt to quantify the amount of ARF1 specifically
coimmunoprecipitating with the receptor was made by co¬
transfection of an ARF1-V5-Hisg construct, the binding of
which was then monitored as anti-V5 tag immunoreactivity.
Densitometric measurements of ARF1-V5-His6 coimmuno-
precipitated with the receptor by PrC tag antibody (or NI IgG
control), as well as input levels of ARF1-V5-His6 in cell ly-
sates, were compared with a coprocessed standard curve of
anti-V5 tag immunoreactivity prepared using ARF1-V5-His6
protein, purified on a Co2+ affinity column. The protein con¬
tent of the purified ARF1-V5-His6 standard was determined,
allowing estimation of the absolute amount of ARF1-V5-His6
that was specifically coimmunoprecipitated in the PrC-tag
antibody pulldown assays. Under basal conditions, this was
calculated as 11.1 ± 1.0 ngofARF1-V5-His6 protein from one
175-cm2 flask. Because essentially all transfected COS-7
cells expressing detectable levels of sPrC-5-HT2AR also ex¬
press ARF constructs, comparison of the amount of coimmu¬
noprecipitated ARF with the Bmax for [3H]ketanserin binding
in equivalent samples allows an estimate of the mean pro¬
portion of sPrC-5-HT2ARs that were bound to ARF1-V5-His6.
Under basal conditions, this was calculated as 23% of the
total; under 5-HT-stimulated conditions, this would be pre¬
dicted to increase to 37% (1.61-fold of basal association).
However, as pointed out above, it is not possible to use this
approach to reliably estimate the proportion of expressed
ARF construct that is associated with receptor.
The effect of 5-HT on coimmunoprecipitation of ARF1-HA
with the sPrC-5-HT2AR was investigated further (Fig. 3).
Nonimmune mouse IgG controls for 5-HT-stimulated sam¬
ples gave results similar to those of unstimulated NI IgG
controls (data not shown). The time course of 1 pM 5-HT-
induced changes in coimmunoprecipitation of ARF1-HA with
sPrC-5-HT2AR showed a clear increase in association from 2
min, a peak around 5 min, and then a gradual decline (al¬
though levels seemed to remain above basal for as long as
2 h) (Fig. 3A). The concentration dependence of the effect of
5-HT (10-min incubation) is shown by the insert in Fig. 3A,
reaching a maximum by approximately 1 pM 5-HT. Figure
3B shows that the 5-HT-induced increase in ARF1-HA coim¬
munoprecipitation with the sPrC-5-HT2AR was reduced to
basal levels by the ARF-GEF inhibitor, BFA (100 pM) (Fig.
3B). As before, the concentration of ARF1-HA present in the
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lysate was very similar between the different conditions (as
shown in Fig. 3B, middle), and the amount of receptor im-
munoprecipitated (Fig. 3B, top) was also even. These obser¬
vations using immunoprecipitation of the sPrC-5-HT2AR in¬
dicate that ARF1, and to a lesser extent ARF6, shows a
physical association with the receptor that can be increased
in the presence of 5-HT, correlating with the functional stud¬
ies on PLD activation.
To examine the receptor-ARF interaction in more detail,
we generated GST fusion protein constructs of the intracel¬
lular loop 3 (i3; Ile258-Gly326) and carboxy-terminal tail (ct;
Asn376-Val471) of the 5-HT2AR, and investigated their abil¬
ity to bind ARF1-HA and ARF6-HA in vitro. Figure 4 is a
schematic representation of the 5-HT2AR showing the amino
acid sequences used for these GST constructs. GST-fusion
protein constructs of the i3 and ct domains of the 5-HT2AR, or
the STREX exon of the BK channel as a control, were at¬
tached to glutathione Sepharose beads and used in in vitro
interaction assays at equivalent input levels [as estimated by
GST immunoreactivity (Fig. 5A)]. The input levels of
ARF1-HA and ARF6-HA or the negative mutant constructs,
deficient in GTP binding, T31N-ARF1-HA and T27N-ARF6-
HA, were also balanced for HA-immunoreactivity (Fig. 5A).
Figure 5B compares ARF1-HA and ARF6-HA interaction
with the constructs. ARF1-HA showed much greater relative
binding to the ct domain of the 5-HT2AR than to the BK
channel construct or the i3 domain of the 5-HT2AR. ARF6-HA
showed a much lower level ofbinding to the 5-HT2Act construct
and little interaction with the S-HT^iS or BK constructs. Fig¬
ure 5C shows the binding profiles for the functionally negative
mutants ofARF1 and ARF6, T31N-ARF1-HA and T27N-ARF6-
HA. The binding of T31N-ARF1-HA to the 5-HT2Act construct
was greatly reduced compared with that of the ARF1-HA wild
type, whereas the low background levels of T31N-ARF1-HA
binding to 5-HT2Ai3 and BK channel constructs were similar to
those seen with wild-type ARF1-HA. T27N-ARF6-HA showed a
low level of binding to the 5-HT2Act construct that seemed to be
similar to that of the ARF6-HA wild type. The apparently
slightly higher levels ofT27N-ARF6-HA binding compared with
the wild type in the experiment displayed correspond to its
somewhat higher input level. GTP-yS facilitated the interaction
of submaximal levels of ARF1-HA with the 5-HT2Act construct
and also seemed to strengthen a weak interaction with the
5-HT2Ai3 construct, which had been minimal in the absence of
added nucleotide (Fig. 5D). GTPyS did not facilitate T31N-
ARF1-HA binding to the receptor constructs. Similar results
were obtained in three different experiments.
Further to this work, a range of concentrations of both
ARF1 and ARF6 were added to the GST-5-HT2Ai3 and GST-
5-HT2Act constructs to assess the concentration-dependence
of binding. Figure 6 shows the relative proportion of ARF
isoform bound to the constructs at increasing ARF concen¬
trations, expressed as a ratio of densitometric values for
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Fig. 2. ARF1-HA and ARF6-HA coimmunoprecipitation with the sPrC-S-HT^ receptor. COS-7 cells were cotransfected with sPrC-5-HT2AR and
ARF1-HA or ARF6-HA. A and B, ARF1-HA and ARF6-HA capture in pulldown assays of the sPrC-5-HT2AR carried out with PrC-tag antibody
compared with a control procedure using NI IgG. In each case, at the top (anti-PrC-tag immunoblot on immunoprecipitates) are shown pulldown
assays of receptor (diffuse bands caused by glycosylation), in which receptor was only detected when immunoprecipitated by PrC-tag antibody, not by
NI IgG. The middle (anti-HA immunoblot on sample input) shows that ARF1-HA and ARF6-HA were expressed at similar levels in the compared
samples. In A, the ARF input level for lane 3 (NI IgG control), designated by *, was the same as that for lane 2 because the same lysate was split
between the two treatments with PrC-tag antibody or nonimmune IgG. The bottom (anti-HA immunoblot on immunoprecipitates) shows specific
coimmunoprecipitation of ARF1-HA (or ARF6-HA) with the receptor. A low level of nonspecific pulldown of ARF can be seen in the NI IgG lane. In
A, cells were challenged with either 5-HT (1 pM) for 5 min or control. Much more ARF1-HA was pulled down compared with ARF6-HA, even though
there was only a small difference in the relative amount of these isoforms expressed in the total lysate. Addition of 5-HT seemed to cause increased
coimmunoprecipitation of both isoforms, but the extent of this increase was greater for ARF1-HA. B, the effect of different levels of sPrC-5-HT2AR
expression on ARF1-HA coimmunoprecipitation. Cells were transfected with different amounts of expression plasmid for the sPrC-5-HT2AR, with
substitution by pcDNA3 vector, thus keeping ARF1-HA expression constant. Cells used for the blot in lane 1 had the standard level of receptor cDNA,
whereas cells in lane 2 received 65% of this level. Densitometric analysis indicated that the amount of receptor immunoprecipitated in lane 2 was 71%
of that in lane 1 and the amount of ARF1-HA coimmunoprecipitated was 62% of that in lane 1, although the ARF1-HA input level was similar in both
samples. In equivalent aliquots of membrane preparations from these cells transfected with the standard or reduced (65%) amount of sPrC-5-HT2AR
plasmid, specific [3H]ketanserin binding represented 627 ± 53 and 344 ± 41 dpm per assay, respectively (means ± S.E.M., n = 4).
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noreactivity in the construct. Increasing the concentration of
ARF1-HA present with each construct caused corresponding
increases in the amount of ARF bound. ARF1-HA bound to
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Fig. 3. Characterization of ARF1-HA association with the sPrC-5-HT2A
receptor. A, incuhat.ion of cells with 5-HT caused a time- and concentra¬
tion-dependent increase in the amount of ARF1-HA coimmunoprecipitat-
ing with the sPrC-5-HT.2AR. The main figure shows that incubation with
5-HT (1 pM) caused a rapid rise in the association of ARF1-HA to 1.81 ±
0.14 of basal at 5 min, reducing thereafter. Values are means ± S.E.M.,
n = 4 to 6 at each point. Inset, a single experiment showing a concentra¬
tion-response curve to 5-HT (10 min) in which a maximal response was
reached by 1 pM. This experiment was repeated twice more with similar
results. B, effects of BFA on the levels of ARF1-HA associating with the
receptor under basal and 5-HT-stimulated conditions. The first lane
shows a control immunoprecipitation procedure with nonimmune mouse
IgG (NI IgG) instead of the PrC-tag antibody, which was used in all other
lanes: nil, no stimulation; nil + BFA, BFA (100 pM, 20 min); 5-HT, 5-HT
(10 pM, 10 min); and 5-HT+ BFA, BFA 10 min, followed by 5-HT plus
BFA for a further 10 min. Pulldown of receptor (reprobed with the
PrC-tag antibody) is shown in the top, input of ARF1-HA in the lysate is
shown in the middle, and coimmunoprecipitation of ARF1-HA in PrC-tag
antibody-directed pulldown assays is shown in the bottom. Because in
these experiments captured proteins were solubilized directly in Laemmli
buffer, nonspecific bands can be seen, reflecting the presence of the
antibody or control immunoglobulin used for pulldown assays.
the GST-5-HT2Act construct to a much greater extent than to
the GST-5-HT2Ai3 construct. ARF6-HA also bound to both
the GST-5-HT2Act and the GST-5-HT2Ai3 constructs, but to a
much lesser extent than the ARF1-HA bound to either con¬
struct, requiring higher levels of added ARF6-HA to obtain
detectable binding. To obtain an estimate of the affinity of
ARF1-V5-His6 (added in cytosolic extracts) for the GST-5-
HT2A ct construct, we quantified the amount of ARF binding
by comparison of densitometric values for V5-immunoreac-
tivity with a coprocessed standard curve ofknown amounts of
ARF1-V5-His6 that had been purified by Co2+ affinity col¬
umn (as above). The ARF-V5-His6 ligand was provided for
the interaction assay as an enriched cytosolic extract rather
than affinity-purified material because binding was more
robust and consistent using this approach. It is not clear
whether this is a result of deleterious effects of the purifica¬
tion on ARF1-V5-Hisfi conformation and function or whether
unknown cytosolic factors are additionally required for opti¬
mal ARF binding. Working within the linear range of the
standard curve for V5-immunoreactive band density against
purified ARF1-V5-His6 concentration, we added a range of
cytosolic ARF1-V5-His6 concentrations (1-25 ng) to interac¬
tion assays and derived values for the amounts of ligand
bound from the corresponding V5-immunoreactive band den¬
sities. Nonlinear curve fitting of the saturation curve gave a
value for affinity (50% saturation) of 1.7 ± 0.4 nM, with
greater than 90% occupancy of available sites by 4 to 5 nM.
The differential signaling properties of the wild-type
5-HT2AR and the N376D mutant 5-HT.2AR (Mitchell et al.,
1998, 2003) suggest that the NPxxY motif, at the junction of
the ct and the 7th transmembrane domain, may participate
in the binding ofARF1 to the receptor. To test this theory, we
carried out signaling experiments, coimmunoprecipitation,
and GST-fusion protein studies with both the wild-type and
N376D mutant form of the receptor. Figure 7A shows that 1
p.M 5-HT-induced PLD activation by the wild-type sPrC-5-
HT2AR was significantly reduced by BFA (100 p.M) or by
coexpression of T31N-ARF1-HA but not T27N-ARF6-HA.
Corresponding responses of the N376D-sPrC-5-HT2AR exam¬
ined in the same experiments showed no significant inhibi-
Fig. 4. Amino acid sequences of the 5-HT2A receptor third intracellular
loop (i3) and carboxy-terminal (ct) tail inserts incorporated into GST-
fusion proteins.
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Fig. 5. Interactions of ARF isoforms with GST fusion proteins of domains from the 5-HT2A receptor. GST-5-HT2Ai3, GST-5-HT2Act, and (control)
GST-BK channel (STREX exon) constructs were incubated with cellular extracts enriched in particular HA-tagged ARF isoforms. A, input levels of
fusion protein constructs and ARF isoforms were balanced in terms of GST immunoreactivity and HA-immunoreactivity, respectively. The fusion
protein construct input levels are shown for GST-5-HT2Ai3 (GST-i3), GST-5-HT2Act (GST-ct), and GST-BK running at apparent molecular masses of
approximately 36, 40, and 34 kDa, respectively. Unconjugated GST ran at approximately 29 kDa. The ARF input levels are shown for ARF1-HA,
AJRF6-HA, T31N-ARF1-HA, and T27N-ARF6-HA. B and C, association of the indicated ARF form with GST-5-HT2Ai3, GST-5-HT2Act, and GST-BK
constructs, respectively. ARF1-HA bound selectively to the GST-5-HT2Act construct, with little binding to the GST-5-HT2Ai3, or GST-BK constructs.
ARF6-HA showed a similar profile but bound to a much lesser extent than ARF1-HA. The T31N mutation in ARF1-HA severely reduced the ability
of the protein to bind to the GST-5-HT2Act construct, but the equivalent mutation in ARF6-HA had no discernible effect. In D, GST-5-HT2Ai3 and
GST-5-HT2Act constructs were incubated with cellular extracts enriched in the indicated HA-tagged ARF isoforms in the presence or absence of GTPyS
(100 nM). GTP-yS increased the binding of wild-type ARF1-HA to both GST-5-HT2Ai3 and GST-5-HT2Act constructs, but did not alter the lack of
binding seen with T31N-ARF1-IIA.
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tion. Figure 7B shows the results of coimmunoprecipitation
experiments in COS-7 cells cotransfected with ARF1-HA and
either the wild-type sPrC-5-HT2AR or its N376D mutant
form. After stimulation with 5-HT (1 pM, 5 min) or control,
solubilized extracts were immunoprecipitated with HA-
tagged antibody, and 5-HT2ARs associated with the immuno-
precipitate were assayed as specific [3H]ketanserin binding.
Low levels of nonspecific [3H]ketanserin binding were
present in each case, and these showed no discernible differ¬
ences between samples. In cells transfected with the wild-
type sPrC-5-HT2AR but not those expressing the N376D mu¬
tant, significant levels of specific [3H]ketanserin binding
became associated with the HA tag immunoprecipitate after
5-HT stimulation. When NI IgG was substituted for the HA
tag antibody during immunoprecipitation, no specific
[3H]ketanserin binding was captured. Using the [3H]ketan-
serin binding protocol there was no evidence for significant
basal association between ARF1-HA and sPrC-5-HT2AR (6 ±
8% of specific binding), unlike the data shown in Figs. 2 and
3. There were a number of methodological differences (such
as shorter time for immunoprecipitation and the addition of
glycerol) between this procedure and that used previously,
which may result in the differences in basal association.
5-HT stimulation clearly caused an increased interaction
between the sPrC-5-HT2AR and ARF1-HA. Comparison of
the amount of specific [3H]ketanserin binding associated
with ARF1-HA immunoprecipitates and the input levels of
binding in solubilized extracts gave an estimate that 30 ± 5%
of sPrC-5-HT2aRs were associated with ARF1-HA after 5-HT
stimulation. This value is in reasonably close agreement with
values estimated from the immunoprecipitation/immunoblot
experiments (above).
Figure 7C shows an experiment to investigate whether the
N376PLVY motif in the 5-HT2AR ct domain may form part of
the binding site for ARF1-HA. GST-fusion protein constructs
of the wild type (Asn376-Val471) 5-HT2Act, the mutant
(N376D-Val471) 5-HT2Act and the truncated (Lys385-
Val471) 5-HT2Act were prepared. Equal amounts of these
constructs (and GST alone) were determined by Coomassie
blue staining and by GST immunoreactivity at the predicted
molecular mass before interaction assays with ARF1-HA.
The ratios of the densitometric values for bound ARF1-HA
immunoreactivity to fusion protein input were then calcu¬
lated on an arbitrary scale relative to that for the wild-type
construct. Both individual images and the mean densitome¬
try ratios for bound ARFl-HA:construct input showed a clear
reduction in binding (to around 40% of wild type) by the
N376D mutation and a further loss (to around 20%) by dele¬
tion of the Asn376-Asn384 sequence (Fig. 7C).
Discussion
Fig. 6. Concentration-dependence of ARF1-HA and ARF6-HA binding to
the GST fusion proteins of domains from the 5-HT2A receptor. GST-5-
HT2Ai3 and GST-5-HT2Act constructs were exposed to increasing
amounts of cellular extracts containing ARF1-HA and ARF6-HA. The
content of HA-immunoreactive ARF per microliter of the ARF1-HA and
ARF6-HA extracts was shown to be equivalent. A, binding of ARF1-HA
and ARF6-HA to the GST-5-HT2Ai3 construct. ARF1-HA bound to the
construct in a concentration-dependent manner, as did ARF6, but to a
much lesser extent. B, binding of ARF1-FIA and ARF6-HA to the GST-5-
HT2Act construct. ARF1-HA bound in a concentration-dependent man¬
ner, whereas the binding ofARF6-HA was minimal and detectable only at
the highest levels of ARF6-IIA input.
The present findings demonstrate that a negative mutant
construct of ARF1, but not ARF6, inhibits the activation of
PLD, but not PLC, by the 5-HT2AR. This indicates a selective
functional role for the ARF1 isoform in the PLD signaling
pathway of the 5-HT2AR. PLD but not PLC responses of the
5-HT2AR were correspondingly reduced in a concentration-
dependent manner by BFA, an inhibitor of the ARF-GEFs,
BIG1/2, which are reported to show selectivity for ARF1
rather than ARF6 (Morinaga et al., 1999). Further evidence
consistent with a functional role for ARF1 in BFA-sensitive
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PLD responses came from experiments assessing the BFA
sensitivity of 5-HT2AR PLD responses in cells coexpressing
negative-mutant ARFs, T31N-ARF1-HA or T27N-ARF6-HA.
The inhibitory effect of the negative-mutant ARF1 construct
pre-empted any further inhibition by BFA, suggesting that
they both acted within the same pathway, whereas negative
mutant ARF6 was without effect. Other GPCRs may show






































Fig. 7. Interactions of ARF isoforms with wild-type and N376D mutant sPrC-5-HT2A receptors. A, 1 /j.M 5-HT-induced PLD signaling responses of
wild-type and N376D mutant sPrC-5-HT2AR. Comparison of their susceptibility to inhibition by BFA (100 /xM) or negative mutant forms of ARF1
(T31N-ARF1) or ARF6 (T27N-ARF6). In control and BFA-treated cells, an amount of empty vector equivalent to that used for the mutant ARFs was
cotransfected with the receptor constructs. Values are means ± S.E.M., n — 6, *p < 0.05 by Wilcoxon test compared with control (5-HT alone). BFA
and T31N-ARF1-HA significantly reduced responses of the wild type, but the T27N-ARF6-HA construct had no detectable effect. B, amount of
PHJketanserin binding to HA-tag directed immunoprecipitates in cells cotransfeeted with ARF1-HA and either wild-type or N376D mutant
sPrC-5-HT,AR. Nonspecific binding of FHJketanserin in the presence of 10 pM mianserin fell in the range of 163 to 241 dpm/assay in all cases and
showed no discernible difference between samples. Control procedures were carried out with an equivalent amount of nonimmune mouse IgG (NI IgG).
Cells were pretreated with 5-HT (1 /rM, 5 min, ■) or control (□). Values are means ± S.E.M., n = 5, *, p < 0.05 by Mann-Whitney U test compared
with corresponding HA-immunoprecipitate without 5-HT prestimulation and to control immunoprecipitation with NI IgG. Significant levels of specific
[3H]ketanserin binding (above nonspecific binding) were recovered only in HA-tag directed immunoprecipitates from cells in which the wild-type
sPrC-5-HT2AR had been prestimulated with 5-HT. The input levels of specific [3H]ketanserin binding in solubilized extracts immediately before
immunoprecipitation were similar for the wild-type and N376D mutant receptors (1166 ± 154 and 1450 ± 125 dpm per sample, respectively). C,
matched levels of GST-fusion proteins incorporating the (Asn376-Val471) wild-type 5-HT2A receptor ct domain, the corresponding N376D mutant, or
a truncated Lys385-Val471 sequence, as well as GST alone, were attached to glutathione-Sepharose beads and incubated with equivalent levels of
ARF 1-IIA. Immunoreactivity for bound ARF1-HA was quantified by densitometry and the ratio to the level of input for each GST-fusion protein
construct was calculated. These ratios were then normalized to that found for the wild-type ct construct. Values are means ± S.E.M., n = 5. A typical
example of ECL film images for HA-immunoreactivity bound to these constructs is shown at bottom.
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ing the M3 muscarinic receptor and in A10 smooth muscle
cells, PLD responses to carbachol and to angiotensin II or
ET-1, respectively were attenuated by T31N-ARF1 and by
T27N-ARF6 (Shome et al., 2000; Mitchell et al„ 2003),
whereas some other GPCRs such as P2u and PAC^,^,! re¬
ceptors may show selectivity for ARF6 over ARF1 (Ronaldson
et al., 2002; Mitchell et al., 2003).
Coimmunoprecipitation experiments demonstrated that the
sPrC-5-HT2AR, under basal conditions, could specifically bind
ARF1-HA and to a lesser extent ARF6-HA. The binding of
ARF1-HA was increased by 5-HT stimulation of the receptor in
a concentration- and time-dependent manner. Only minor in¬
creases in the association of ARF6-HA with the sPrC-5-HT^R
could be seen. The presence of BFA during the stimulation with
5-HT reversed the 5-HT-induced association of ARF1-HA, al¬
though we know from confocal immunofluorescence imaging
that BFA does not prevent agonist-induced translocation of
ARF1-HA to the plasma membrane (data not shown). This
evidence that ARF1 is the isoform predominantly docking to the
receptor in a BFA-sensitive manner is consistent with the data
on PLD activation. Estimates of the proportion of 5-HT2A re¬
ceptors that was associated with ARF1-HA after 5-HT stimu¬
lation ranged between 30 and 37% depending on the approach
taken, with corresponding estimates of basal association be¬
tween 6 and 23%. Interaction of other proteins, such as Gq/11
and perhaps arrestins, with the 5-HT.2AR may well mean that
relevant binding sites were not accessible to ARF1 in part of the
receptor population.
The GST-fusion protein experiments suggested that the ct
domain of the 5-HT2AR provides a binding site for ARFs at
which ARF1 shows a higher affinity than ARF6. Comparison
of the immunoreactivity for ARF1-V5-His,; bound to the GST-
5-HT2Act construct with known amounts of purified ARF1-
V5-His6 allowed an estimate of the affinity of interaction.
This was in the low nanomolar range (1.7 ± 0.4 nM), which
is of lower affinity than that for arrestin interaction with the
M:JR i3 domain (Wu et al., 1997) but higher than the corre¬
sponding interaction of G/3y (Wu et al., 1998). The 5-HT2A
receptor i3 domain shows only low affinity for ARF in vitro
but may still represent an auxiliary binding site in vivo. In
contrast, the i3 domain effectively binds arrestins in similar
experiments (Gelber et al., 1999). The interaction of
ARF1-HA with the ct or i3 domain of the 5-HT2AR seemed to
be facilitated by GTPyS, suggesting that occupancy of its
nucleotide recognition site by GTP rather than GDP pro¬
motes the interaction. Correspondingly, the GTP-binding-
defective mutant ARF1 construct (T31N-ARF1-HA) showed
an almost complete lack of specific binding to the ct or i3
domain GST fusion proteins that was unmodified by GTPyS.
The lower level of ARF6-HA binding seemed to be little
affected by T27N mutation of ARF6-HA, but this was not
investigated further. The means by which agonist induces
increased (BFA-sensitive and GTP status-sensitive) binding
of ARF1 to the 5-HT2AR is not clear. Involvement of BIG1/2
is implicated by the BFA sensitivity, but it is not known
whether agonist activation of the receptor might facilitate
GTP loading ofARF1 by direct protein-protein interaction, by
regulation of BIG1/2, or by other means. However, GTP bind¬
ing operates a conformational switch in ARFs that might
contribute to additional protein-protein interactions (Gold¬
berg, 1998).
Although the tm7 NPxxY motif has been implicated as a
critical determinant of ARF coimmunoprecipitation and ARF-
dependent signaling in rhodopsin family GPCRs, the precise
site of ARF binding to the ct of the 5-HT2AR remains to be
elucidated. Mutation of this motif to DPxxY strongly inhibits
BFA-sensitive, ARF-mediated activation of PLD (Fig. 7A;
Mitchell et al., 1998) and sPrC-5-HT2AR coimmunoprecipita¬
tion with ARF1-HA (Fig. 7B). Using GST-fusion proteins of the
5-HT2aR ct domain, mutation of Asn376 to Asp causes a
marked (60%) reduction in ARF1-HA association and removal
of the Asn376-Asn384 segment reduces association further to
around 20% of the wild-type values. This suggests that the
majority of the key elements involved in 5-HT^R-ARFl inter¬
action, at least under these circumstances, may he within the
Asn376-Asn384 segment. Structural modeling based on rho¬
dopsin and secondary structure predictions (PHD predict;
http://cubic.bioc.columbia.edu/predictprotein/) suggest that the
Pro377 residue is likely to form a pronounced kink in the tm7
helix and that Thr381-Lys385 may form a flexible hinge to an
eighth helical segment that runs in the plane of the membrane
until a palmitoylation anchor at Cys397 (Konvicka et al., 1998;
Palczewski et al., 2000; Yeagle et al., 2000; Visiers et al., 2002).
In the case of rhodopsin, activation of the receptor newly ex¬
poses to the intracellular surface an epitope that includes res¬
idues equivalent to Leu378-Tyr380 here (Abdulaev and Ridge,
1998), consistent with the idea that receptor activation may
reveal residues involved in ARF association. The predicted
fourth intracellular loop of rhodopsin, in particular residues
equivalent to Asn384-Gln386 here, is involved in interaction
with the a and y subunits of transducin (Ernst et al., 2000;
Marin et al., 2000). Interactions between amino acids in the
NPxxY motif and the subsequent seven residues are thought to
influence heterotrimeric G protein activation by both rhodopsin
and the 5-HT2CR (Prioleau et al., 2002; Fritze et al., 2003).
Elements of this surface might also contribute to ARF docking.
The interaction of 5-HT2AR with G«q/1 j, however, is also
thought to involve the carboxyl portion ofthe i3 loop (Roth et al.,
1998).
Additional functional roles have been proposed for the
N/DPxxY motif. The most consistent evidence is for a role
linking the tm2 and tm7 helices (Sealfon et al., 1995). The
NPxxY motif and the Y residue in particular have been
proposed to constitute an internalization motif in some but
by no means all GPCRs (Hunyady et al., 1995). Mutation of
the Asn or Asp residue to Ala generally causes massive
disruption of signaling pathways and of internalization,
whereas reciprocal mutation of Asn or Asp seems to have
relatively minor effects other than on ARF-dependent PLD
activation (Sealfon et al., 1995; Le Gouill et al., 1997; Mitch¬
ell et al., 1998). In the case of the 5-HT2A receptor, we
confirmed that the NPxxY motif, rather than the DPxxY
mutant motif, was necessary for functional BFA-sensitive
and T31N-ARFl-HA-sensitive PLD responses from the re¬
ceptor for 5-HT-induced coimmunoprecipitation of the recep¬
tor with ARF1-HA and for the major part of in vitro binding
of ARF1-HA to the ct domain of the receptor.
There is increasing evidence that particular GPCRs can
interact with diverse scaffolding and signaling proteins other
than their conventional partners, the heterotrimeric G-pro-
teins (Brady and Limbird, 2002; Premont and Hall, 2002).
Receptor ct segments may dock bivalent adapter proteins
containing PDZ or other domains, signaling proteins, and
modulators of signaling functions (Dev et al., 2001; Oakley et
1250 Robertson et al.
al., 2001; Brady and Limbird, 2002). In the 5-HT2 receptor
family, the distal ct residues are targeted by the PDZ-domain
proteins PSD-95 and MUPP-1 (Backstrom et al., 2000; Be-
camel et al., 2001; Xia et al., 2003), interactions that may
modify the signaling function of the receptors. A novel PDZ
domain protein, tamalin, has been shown to bind to both
mGluRl/5 receptors and the ARF-GEF ARNO (Kitano et al.,
2002). It is conceivable that an analogous arrangement might
occur in the case of the 5-HT2A receptor, locating an ARF-
GEF in the proximity of ARF.
ARF may not be the only small G protein that can interact
with GPCRs. We showed that Rho A can be coimmunopre-
cipitated in a complex with NPxxY GPCRs (Mitchell et al.,
1998), and there is evidence that both Ga13 and Gaq may
interact with Rho-GEFs to facilitate Rho function (Sagi et al.,
2001). Other small G proteins of unknown identity have also
been found to associate with the formyl-Met-Leu-Phe recep¬
tor (Polakis et al., 1989).
In summary, these experiments provide intracellular signal¬
ing, coimmunoprecipitation and in vitro domain interaction ev¬
idence for ARF association with the 5-HT2AR, corresponding to
its functional activation of PLD. Furthermore, ARF1 rather
than ARF6 seems to participate in this mechanism through
GTP-dependent interaction with a ct domain of the receptor.
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